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Investigating the molecular causes of inherited thrombocytopenia using
CRISPR-Cas9 gene editing and super-resolution microscopy
Thesis
Abdullah O. Khan
Inherited thrombocytopenias (ITs) are a heterogenous group of disorders characterised by an
abnormal platelet count (<150 x 109/L). Functional investigations into the mechanistic causes
of ITs often suffer from numerous technical limitations, including a lack of patient material
and the absence of platelet producing cell lines. In this thesis, protocols to address these
issues through the application of CRISPR (Clustered Regularly Interspaced Palindromic
Repeats) genome editing and stem cell differentiation are developed and applied to the study
of the platelet and megakaryocyte specific β-tubulin isoform encoded by the TubB1 gene.
First, a novel method of single molecule super-resolution microscopy through the CRISPR
mediated editing of cell lines is devised, and attempts to transfer this approach to stem
cells are currently underway. Secondly existing methods for the differentiation of induced
pluripotent stem cells into megakaryocytes are adapted to generate mature, proplatelet
forming cells for in vitro phenotypic screening. Finally, two families from the UK GAPP
(Genotyping and Phenotyping of Platelets) study with TubB1 mutations affecting C-terminal
function are investigated to determine the role of C-terminal post-translational modifications
(PTMs) on ITs. Two novel PTMs (polyglutamylation and polyglycylation) which regulate
motor protein processivity in both platelet production and function are reported.
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6
GMP Granulocyte Macrophage Progenitor
GMP Guanosine Monophosphate
GPCRs G-Protein Coupled Receptors
GPVI Glycoprotein VI
GTP Guanosine Triphosphate
HDR Homology Directed Repair
HSC Haematopoeitic Stem Cells
IL Interleukin
IMS Invaginated Membrane System
IPF Immature Platelet Fraction
iPSC induced Pluripotent Stem Cell
KI Knock-In
KO Knock-Out
LMPP Lymphoid Primed Multipotent Progenitor
MEP Megakaryocyte-Erythrocyte Progenitor
MK Megakaryocyte
MMEJ Micro-homology Mediated End Joining
MPP Multipotent Progenitor
MPV Mean Platelet Volume
MTSB Microtubule Stabilising Buffer
NFE2 Nuclear Factor Erythroid 2
NHEJ Non-Homologous End Joining
NK Natural Killer Cell
NO Nitrous Oxide
PALM PhotoActivated Localisation Microscopy
PAM Protospacer Adjacent Motif
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SRRF Super Resolution Radial Fluctuations
ssODN single stranded Oligo Donor Nucleotide
STED Stimulated Emission and Depletion Microscopy
TAL Transcription Activator Like
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Platelets are small, anucleated cells which play a vital role in haemostasis amongst other
key physiological roles 1, 2. At the onset of vascular injury, platelets play a central part in
a cascade of biochemical and cellular signals and interactions - ultimately leading to the
formation of a stable platelet aggregate which stems bleeding and allows for wound healing 3.
More recently, platelets have been shown to have extensive roles in diverse biological processes
including inflammation and cancer metastasis4, 5, 6. The study of platelets has classically
been limited by the absence of robust cell lines expressing megakaryocyte (MK) and platelet
specific genes, and thus manipulable in vitro models with which to interrogate the unique
functions of these cells.
This thesis is therefore focussed on the development of robust in vitro protocols for the
study of genes and mutations of interest. The recent development of CRISPR-Cas9 offers a
means by which to introduce highly specific genetic changes in an efficient and cost effective
manner. Alongside recent advances in the generation of platelet producing, mature MKs
from induced pluripotent stem cells, these techniques offer a means by which to bypass the
lack of reliable cell line models and the artefactual effects of over-expression to study novel
genes and mutations. Our particular gene of interest is the MK and platelet specific TubB1,
and the latter part of this thesis looks at the role of novel post-translational modifications on
1
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the function of both MKs and platelets.
In this chapter platelet production and biology are introduced, as well as the development
of their progenitor cells, megakaryocytes (MKs) from haematopoeitic stem cells (HSCs) in
the bone marrow. Inherited thrombocytopenias are introduced, and the role of the national
Genotyping and Phenotyping of Platelets (GAPP) project in identifying novel genes and
mutations is discussed in the context of a need for robust in vitro tools.
1.1 Introduction to Platelet Biology
Typically measuring 2-5 µm in diameter and only 0.5 µm in thickness, platelets are the smallest
cellular component of circulating blood7. Originally identified as effectors of haemostasis and
thrombosis, platelets have more recently been shown to have extensive roles in inflammation,
wound healing, and cancer metastasis8, 9. Circulating platelets typically number between
150-450 109/L in adult human whole blood, and circulate in a discoid, resting state that is
maintained by a distinctive microtubule marginal band7, 10. At the onset of vascular injury,
platelets play a central role in recognising, coordinating, and responding to biochemical
and cellular signals and interactions which ultimately lead to the formation of a stable
platelet aggregate (thrombus) which stems bleeding and allows for wound healing (Figure
1.1A)11, 12, 13.
In an uninjured vessel, platelets are actively inhibited by the endothelium through the
production of Prostacyclin (PGI2), nitric oxide (NO), and ADPase14, 15. Endothelial derived
PGI2 and NO stimulate adenylate and guanyl cyclase activity to increase cAMP and cGMP
production respectively, which in turn activates protein kinase A (PKA) and protein kinase
G (PKG)16. PKA and PKG inhibit activation through a series of phosphorylation events16.
Similarly Endothelial ADPase prevents the binding of ADP to the purinergic receptor P2Y12,
an event which would also lead to the accumulation of calcium and platelet activation17, 18.
Vascular injury results in the exposure of the subendothelial space which platelet surface
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receptors can interact with. These interactions trigger a series of signalling events which
culminate in adhesion, spreading, secretion, and aggregation. Exposed collagen (Type I
and type III) binds circulating multimers of von Willebrand Factor (vWF), resulting in its
elongation and the subsequent exposure of the A1 domain to which GpIbα on the platelet
surface can bind (FIgure 1.1B)19, 20. This is particularly important in smaller blood vessels
which typically feature high shear rates. This initial binding event (also referred to as
rolling and initial adhesion) allows lower affinity platelet surface receptors to interact with
components of the sub-endothelial extracellular matrix (ECM), most crucially collagen.
The Fc-γ-chain associated platelet receptor glycoprotein-VI (GPVI) binds collagen type I
and effects activation of a tyrosine kinase signalling cascade to achieve calcium accumulation
through the activation of PLC-γ2 (Figure 1.1C)21, 22. GPVI signalling triggers a switch
of the integrins αIIbβ3 and α2β1 to high affinity states, events which are critical to firm
adhesion and the subsequent morphological changes resulting in platelet spreading23. Binding
of αIIbβ3 to fibrinogen results in a filamin and α-actinin mediated extension of filopodia and
lamellipodia which both stabilise and strengthen adhesion to the ECM, while also increasing
the surface area available for platelet-platelet interaction (1.1D)23. α2β1 then interacts with
collagen contributing to platelet adhesion. These processes occur alongside a slight expansion
and subsequent retraction of the microtubule marginal band (detailed further in Chapter 4).
Platelet binding, activation, and spreading ultimately leads to the secretion of platelet
granule content. Platelet secretion results in the release of ADP (from dense granules),
fibrinogen, factor V, and vWF (alpha granules) amongst other components, including TxA224.
This release of second messengers (most critically ADP and TxA2) mediates further platelet
activation through GPCRs (G-protein coupled receptors), and further stimulates coagulation
with both pathways potentiating the other to achieve the formation of a stable final clot by
both the amplification of platelet activation and the recruitment of circulating platelets, as
well as providing components critical to the coagulation pathway. Coagulation refers to two
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Figure 1.1: Early stages of platelet activation and thrombus formation.(A) Vascular
injury results in the exposure of the sub-endothelial space and its constituent extracellular
matrix, as well as the loss of the inhibitory effects of endothelial cells on platelet activation.
(B) Exposure of collagen types I and III to circulating vWF results in its binding and
subsequent elongation under shear stress. Multimers of vWF form the first point of contact
with platelets through the GPIb-IX-V complex which triggers initial adhesion and rolling.
(C) The subsequent exposure of platelet surface receptors to collagen results in firm adhesion
through GPVI binding of collagen I. This triggers potent activation signals which ultimately
result in platelet spreading. (D) Platelet spreading involves the extension of filopodia and
formation of lamellopodia as the marginal band contracts for secretion. (E) Platelet secretion
involves the release of the components of alpha and dense granules. These include the second
messengers ADP and TxA2, both of which trigger a potent wave of signalling events involving
gPCRs. Other components like vWF and fibrinogen are released to promote further platelet
activation and spreading as the thrombus forms. (F) Collectively these events result in
platelet aggregation and the formation of a stable thrombus, which undergoes clot retraction
upon completion of the whole process.
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cascades which are critical to haemostasis, the intrinsic (or contact activation) and extrinsic
(tissue factor) pathways, both of which lead to the production of fibrin vital for clotting25.
The final stages of this haemostatic process involve a localised generation of thrombin to
cleave fibrinogen and secure the clot through fibrin formation. A sub-population of platelets
exposed to a large influx of calcium undergo ballooning to expose phosphatidylserine (PS)
on the membrane surface, causing the recruitment of coagulation factors and the cleavage
of prothrombin. The increase in thrombin results in platelet activation through protease
activated receptor-1 (PAR1) and its effects on G-PCRs15, 26.
This is a unique, highly dynamic process which involves an extensive rearrangement
of the platelet cytoskeleton and membrane. These morphological changes are discussed
in the context of the work in this thesis in Chapter 4, and in the context of inherited
thrombocytopenias in section 1.4 of this introduction. For further information, the reader
is referred to an excellent review by Poulter et al.27. Once complete, a thrombus retracts
through the actions of non-muscle myosin II and fibrinogen/fibrin bound αIIbβ3 to restrict
clot size and minimise vessel and flow obstruction.
1.2 Megakaryopoeisis
Platelets are produced by highly specialised progenitor cells known as megakaryocytes (MKs),
which are the largest and rarest of the many cells populating the bone marrow28. Mature
MKs are typically between 50-100µM in size and make up 0.01% of all nucleated cells within
the marrow28. In this section the development of megakaryocytes, their differentiation, and
unique characteristics are discussed in the context of platelet production.
1.2.1 Megakaryocyte differentiation and development
Like most other haematopoeitic cells, megakaryocytes typically develop and mature within
the bone marrow - however these cells can also migrate and as such platelet biogenesis
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has been observed in peripheral blood and the lungs29, 30, 28. The question of the role and
importance of haematopoeisis outside of the bone marrow remains a controversial one, and
as such this section primarily focuses on the more established paradigm of the bone marrow
as a primary site of haematopoeisis.
MKs result from the differentiation of haematopoeitic stem cells (HSCs), pluripotent,
self-renewing cells which, upon the loss of their capacity for long term self-renewal, become
multipotent progenitors (MPPs) which eventually give rise to the diverse subtypes of the
haemotpoeitic lineage (Figure 1.2)31. MPPs diverge into the myeloid and lymphoid arms
of the haematopoeitic lineage tree, and it is under the myeloid arm where the bi-potent
megakaryocyte-erythrocyte progenitor (MEP) is found (Figure 1.2). The MEP goes on to
form either erythroid unipotent or megakaryocyte progenitors.
While classically HSC lineage commitment has been thought of as a step-wise progression
down a defined hierarchy or ’lineage tree’, the exact nature of this model is a subject of
intense debate in the field(Figure 1.2). Alternative models suggest multiple pathways can
lead to the formation of MK precursors, the nature of which are also intensely debated. More
recently alternative approaches suggest that specialised cells arise through a ’continuum of
low primed undifferentiated haematopoeitic stem and progenitor cells’ referred to as CLOUD-
HSPCs(1.3)32, 33, 31. Ultimately the use of single cell transcriptional profiling has contradicted
the paradigm of hierarchical differentiation established by 15 years of flow cytometry 31. This
model has significant implications for the mechanism by which haematological malignancies
arise, as well as significant implications for the process of megakaryo- and thrombo-poeisis in
the context of how the haematopoeitic niche responds to platelet deficiency and inflammation.
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Figure 1.2: Classic hierarchical distribution of haematopoeitic lineages. Until very
recently, the concept of haematopoeitic differentiation and lineages revolved around a hier-
archical distribution whereby cells in a self-renewing, multipotent pool (HSCs of different
longevities including long term (LT-HSC), intermediate (IT-HCS), and short term (ST-HSC))
commit to successively more fate limited progenitors. In later versions of this model, the
HSC pool has expanded to include a range of both differentiation and self-renewal properties
(demonstrated in the above tree as MPP 2, MPP 3, and MPP 4). The lymphoid primed
multipotent progenitor (LMPP) and common myeloid progenitor (CMP) are further down
the hierarchy, with the CMP preceding Erythrocytes and Megakaryocytes via the Multipotent
Erythroid Progenitor (MEP). The GMP (Granulocyte-macrophage progenitor) population
is thought to be more heterogenous, giving rise to monocytes, neutrophils, eosinophils, and
dendritic cells. The Common Lymphoid Progenitor (CLP) gives rise to B cells, T cells, and
Natural Killer cells. (Figure based on material from Laurenti et al.)
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Mature bone marrow megakaryocytes appear anchored to bone marrow endothelial cells
(BMECs) and to project proplatelet extensions into the lumen of bone marrow sinusoids
34, 35, 36, 37. It has been suggested that interactions with BMEC adhesion molecules, stromal
cell-derived factor 1 (SDF-1) and fibroblast growth factor 4 (FGF-4) have been implicated in
an axis thought to induce the expression of very late antigen (VLA-4) on MKs and VCAM-1
on BMECs 38, 39, 40. Recent work investigating the role of Cdc42 and RhoA demonstrates
that the crosstalk of these systems drives transendothelial proplatelet projection41.
Interestingly the paradigm of MK and HSC distribution in the bone marrow has also
recently been challenged. It has been previously thought that HSCs primarily reside within
an osteoblastic niche wherein they expand42. Upon lineage commitment, these cells were
thought to migrate to bone marrow sinusoids, where they subsequently mature as MKs and
eventually produce platelets42. More recently however, an elegant whole bone lightsheet
approach has shown an unbiased distribution of mature and immature MKs throughout the
bone marrow43. This work describes a spatial regulation of MK distribution throughout
the marrow on the basis of an extensively vascularised space which restricts migration and
movement, implying that MKs mature in these tightly defined microenvironments are in
constant proximity to blood vessels 43.
Interestingly, while MKs culture in vitro have been shown to develop proplatelet extensions
(particularly in murine foetal liver cells), the efficiency and scale of this is markedly reduced
when compared to the thousands of platelets produced by MKs in vivo. This remains a
significant obstacle in the in vitro study of platelet production, as well as the burgeoning
field of artificial platelet generation, where even the most sophisticated bioreactors fail to
emulate the thousands of platelets produced by MKs physiologically44, 45, 46, 47, 48, 49. Work
by Stegner et al. and others implies that there is a critical role for proximity to endothelial
sinusoids in both MK maturation and platelet production.
Regardless of the mechanisms by which HSCs commit to the megakaryocytic lineage,
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Figure 1.3: Redefining haematopoeitic hierarchies as a continuum based on single
cell transcriptional profiling. The dogma of a restricted, lineage tree based hierarchy as
defined by years of flow cytometry has been challenged by single cell transcriptomics and
RNA seq. An emerging model suggests that HSCs exhibit a continuum of differentiation,
suggesting a plastic system capable of responding to stress to rapidly produce haematopoeitic
cells as needed. Figure based on material from Laurenti et al.)
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the development and maturation of megakaryocytes is a remarkably specialised process
involving the differential expression of critical genes, proteins, and transcription factors. The
result is the development of large, polyploid cells able to produce and maintain the normal
physiological levels of platelets essential for healthy haemostasis.
In the classic and most well defined hierarchy, a multipotent, committed colony forming
progenitor precedes early megakaryocytes - this cell is the CFU-GEMM, or Colony Forming
Unit Granulocyte Erythroid Macrophage Megakaryocyte capable, as the name suggests,
of differentiating into any one of the three named lineages (erythroid, basophilic, and
erythroid)50, 51, 52. On commitment to the MK lineage, the burst forming unit megakaryocyte
forms (BFU-Meg)52, 53. These early progenitors express a mix of both HSC and MK factors,
including CD34 for the former and CD41a for the latter (Figure 1.4).
Megakaryocytes within the bone marrow present as one of three distinct morphologies.
The first, the promegakaryoblast, varies in size and is dominated by a nucleus up to five times
the size of the surrounding cytoplasm54. The megakaryoblast (or stage I megakaryocyte)
typically features a kidney shaped nucleus, and like its precursor the promegakaryoblast, also
appears basophilic in stained bone marrow preparations54. The stage II megakaryocyte or
promegakaryocyte is typically substantially larger than its precursors (between 20-80µm) and
appears less basophilic with distinctive developing granules54. As megakaryocytes develop,
they accumulate distinctive characteristics which are hallmarks of mature, platelet producing
cells55, 56. These cells begin to lose markers of multipotent stem cells like CD34 and CD45,
and accumulate lineage specific markers (CD41, CD42, CD61), with their differentiation
driven by the presence of critical cytokines like TPO, IL-3, IL-6, and IL-11 (Figure 1.4).
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Figure 1.4: Lineage commitment and maturation of megakaryocytes. From a pool
of self-renewing, multipotent haematopoeitic stem cells a multipotent colony forming unit
(CFU-GEMM) develops before committing to the MK lineage through formation of the
burst-forming unit megakaryocyte (BFU-Meg). These cells express both markers of stem
cells and the MK lineage (CD34+, CD41a+), and their differentiation is driven by SCF,
TPO, IL-3 and IL-6. As the colony forming unit develops into early megakaryoblasts, there
is a loss of stem cell markers like CD34 and an accumulation of MK lineage specific surface
proteins (e.g. CD61, CD42b), and differentiation is increasingly driven by TPO and IL-11.
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1.2.2 Cytokines and the transcriptional regulation of megakary-
opoeisis
As indicated in the previous section, megakaryocyte differentiation is heavily driven by
the cytokine thrombopoeitin (TPO) and its binding to MPL, its receptor57, 58, 59, 60. Upon
binding its ligand, MPL dimerises and induces the autophosphorylation of JAK2 (janus
kinase 2), which subsequently phosphorylates an array of substrates to activate signalling
pathways including PI3K (phosphoinositol-3 kinase) and MAPK (mitogen-activated protein
kinases (Figure 1.5)57, 58, 59, 60. Over the last two decades, a host of downstream effects and
effectors have been discovered, with more mechanistic consequences of TPO activation being
reported61.
Ultimately the effect of TPO is the induction of expression mechanisms which drive the
differentiation and maturation of megakaryocytes. Interestingly, while it is the master regula-
tor of megakarypoeisis and the subsequent maturation and development of megakaryocytes,
TPO is not critical to platelet production - in fact, some evidence suggests that the presence
of TPO may inhibit proplatelet production in vitro 62.
The cloning and purification of TPO led to the development of in vitro methods of MK
culture and proliferation - significantly advancing the field63, 64, 65. Megakaryocytes derived
from human CD34+ cells were shown to mature and form proplatelet extensions when
cultured with TPO63. Interestingly work on TPO-deficient mouse models led to the discovery
of a role for this cytokine in haematopoeitic stem cells. These mice not only demonstrated
the thromboctyopenia that one would expect, but also a reduction in cell number across all
haematopoeitic lineages66, 67, 68. This began work which would go on to establish TPO as a
critical regulator of the haematopoeitic niche, and absolutely vital for the development and
proliferation of megakaryocyte progenitors61.
Other cytokines play a role in megakaryopoeisis - and these include SCF (Stem Cell
Factor), Flt-3, Interleukin-6 (IL-6), and Interleukin-11 (IL-9). Optimising these cytokines
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Figure 1.5: Lineage commitment and maturation of megakaryocytes through TPO
signalling and the actions of key transcription factors. Thrombopoeitin signalling
through its receptor cMPL is critical to the differentiation and maturation of megakarycoytes.
TPO signalling initiates a cascade of downstream signalling events through the autophospho-
rylation of JAK2. These include activation of STAT1, STAT5, PI3K/AKT, and RAS/MAPK.
The expression of key transcription factors is also an essential regulator of gene function
in megakaryopoeisis. GATA1 and RUNX1 are expressed throughout MK development and
maturation, while FLI-1, EV1-1, and TAL-1 are expressed during earlier stages. NF-E2
is expressed during the terminal maturation steps in which megakaryocytes begin to form
proplatelet extensions, driving the expression of key markers of mature MKs e.g. TubB1,
Rab27B, CASP12.
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has been shown to affect the purity of primary MK cultures and the fraction of mature cells.
Recent work by Machlus et al. identified a role of the cytokine chemokine ligand 5 (CCL5)
which, upon binding to its receptor CCR5 triggers signalling through phosphorylation of the
protein BAD. The resulting pro-survival signal may drive increased endomitosis and ploidy69.
Differential gene expression and the resulting changes in protein expression are a key aspect
of differentiation and the development of specialised cell types with specific morphologies. A
number of mechanisms allow for the fine control of which genes are expressed and when -
amongst them is the use of transcription factors (TFs), proteins which bind to specific DNA
sequences to control the rate of transcription and thereby regulate gene expression.
A number of transcription factors have been shown to be critical to haematopoeisis and
megakaryopoeisis - and indeed, the manipulation of these proteins has been used to forward
programme stem cells to generate large numbers of megakaryocyte like cells70. Of these, the
GATA family, RUNX1, Tal-1, EVI-1, and NF-E2 are known to have an important role in
MK development and maturation(Figure 1.5)71. Perhaps unsurprisingly, deficiencies in a
number of these TFs have been associated with inherited thrombocytopenias, and these will
be discussed in section 1.4.
The zinc-finger transcription factors GATA1 and GATA2 are members of the GATA
family of TFs, characterised by their binding of the T/A (GATA) A/G consensus sequence71.
GATA2 has been established as key to the maintenance of HSCs, however it is still expressed
in MKs, and therefore thought to have some overlapping function72. GATA1 is expressed in
MKs (as well as erythroid and mast cells), and the loss of this TF reduces MK maturation
by limiting cytoplasmic maturation and polyploidization. A variant of a form of inherited
thromboctyopenia, Bernard-Soulier syndrome, features a mutation in the GATA-binding
motif of the GP1BB promoter (Discussed further in section 1.4.2).
RUNX1 belongs to the RUNT family of TFs, and is considered a master regulator of
haematopoeisis71. The loss of RUNX1 in MK lineages results in a phenotype similar to
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the one observed where GATA1 is targeted - namely a reduction in polyploidization and
maturation. RUNX1 defects are associated with thrombocytopenias and a predisposition
to malignany (acute myeloid leukaemia)73, 74. Patients with RUNX1 mutations and their
associated familial platelet disorders present with abnormal expressions of MPL and myosin
light chains 9 and 10 (MYL9, 10)75.
FLI-1 (Friend leukemia virus integration-1) works alongside GABPA (GA binding protein
transcription factor alpha subunit), the latter binds genes associated with early MK develop-
ment (GPIIB and MPL), while the former binds to both early and mature genes (GPIBA,
GPIX, and PF4)71. The ratio of FLI-1 to GABPA increases with maturation driving the
expression of genes associated with mature MKs. In patients with an inherited deletion
of the 11Q chromosome and a subsequent hemizygous loss of FLI-1, MK differentiation is
arrested with abnormally small cells (microMKs) observed in bone marrow smears as well as
a thrombocytopenia and bleeding symptoms76.
Depletion of T-cell acute lymphocytic leukemia 1 (TAL-1) in haematopoeitic cells results
in a decrease of erythroid and megakaryocytic cells77. Cyclin-dependent kinase inhibior 1A
(CDKN1A) is a key target of this transcription factor, and is aberrantly over-expressed upon
a decrease of TAL-1 resulting in a reduction in the proliferation, ploidy, and maturation
of MKs78. There is an equivalent reduction in platelet number, but no decrease in platelet
function in this model. To confirm the role of TAL-1 as a regulator of CDKN1A, a knock-down
of this target restores endomitosis in MKs71, 79.
Nuclear factor Erythroid 2 (NF-E2) is a vital regulator of erythroid and megakaryocytic
development (with roles in the myeloid lineage as well)80. Knock-outs of NF-E2 result in a
complete absence of platelets despite an increase in the number of megakaryocytes81. This
work highlights the role of NF-E2 as a terminal regulator of platelet production. Direct targets
of this transcription factor include the TubB1, Rab27b, CASP12, and HSD3B1 genes82, 83, 84.
Each of these targets has an established role in platelet production, with TubB1 for example
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encoding the β-tubulin isoform specific to platelets and megakaryocytes (discussed at length
in this thesis).
While each of these transcription factors are critical in their own right, and so have links
to inherited thrombocytopenia and platelet disorders, they are part of complex regulatory
networks in which they act to regulate one another. These are detailed by Tjissen et al. in
their excellent review on the role of transcription factors in megakaryo- and thrombopoeisis71.
1.2.3 Endomitosis and polyploidization
Mature megakaryocytes undergo a unique process by which they accumulate their hallmark
polyploidy referred to as endomitosis 85, 86, 87. This is a process of repeated, arrested cell
division which results in the unique, lobed nuclei typical of mature megakaryocytes85, 86, 87.
The extent of polyploidization varies extensively, particulary in vitro, ranging in multiples of
a diploid chromosome content (4N, 8N, 16N, 32N, 64N) as a result of two to six endomitotic
cycles. Polyploidization is likely a means by which to achieve gene amplification and a
subsequent increase in mRNA and protein production in preparation for thrombopoeisis88.
An area of significant interest is the method of deregulation which allows megakaryocytes
to undergo an abnormal amplification of DNA and aborted mitosis, processes which are
tightly regulated in other cell types to avoid malignancy. It has been suggested that a
reduction of mitosis promoting factor (MPF) is involved in endomitosis89. In a typical cell,
the synthesis of cyclin B and its subsequent binding to Cdc2 results in an active MPF complex
whose kinase activity is required for mitosis. However, while cell line studies have implicated
inactive Cdc2 or the absence of cyclin B, work in primary megakaryocyte cultures has shown
normal levels of both - and thus active MPF90, 91, 92.
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1.2.4 Invaginated Membrane System (IMS)
Following polyploidization, megakaryocytes also demonstrate a unique processs of cytoplas-
mic maturation which is critical to their role as platelet progenitors. This results in the
accumulation of material which will ultimately be passed on to platelets - including organelles,
platelet surface receptors and other proteins. The development of the invaginated membrane
system (IMS - formerly referred to as the demarcation membrane system or DMS) results in a
characteristic membranous network which was originally thought to form platelet territories93.
More recently, the IMS has been suggested to act as a source of membrane during the process
of proplatelet extension94.
Recent work by Eckley et al. has shown that the plasma membrane folds at specific
points, to generate a peri-nuclear early IMS (pre-IMS) which expands through the addition of
material from the golgi and endoplasmic reticulum95. The IMS is exposed to the extracellular
environment allowing for labelling with a variety of tracers96, 97.
1.2.5 Platelet granules
Secretory granules (α and dense granules) are critical to the vital roles platelets play in
haemostasis and thrombosis. As such, granule generation and their subsequent trafficking
and packaging into platelets is a critical component of megakaryocyte biology and platelet
production. α-granules are typically between 200 and 500 nm in size, and these contain
proteins critical to platelet adhesion and activation in the event of vascular injury98. These
golgi derived secretory vesicles are typically evident in early stage megakaryocytes, and
accumulate their contents both from endogenous production of protein and uptake. Platelet
factor-4 (PF4) and von Willebrand Factor (vWF) are examples of endogenously generated
α-granules proteins, while fibrinogen is a classic example of an endocytosed protein whose
uptake is mediated by αIIbβ399, 100, 101. α-granules also contain a number of platelet surface
receptors including αIIbβ3, P-Selectin (CD62P), and CD36. As multivesicular bodies typically
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contain P-selectin, vWF and other components typical of α-granules, they are thought to be
precursors to these organelles.
Dense granules are typically 250nm in size and are so named due to their typically
electron-dense cores as evidenced by electron microscopy. These are packaged with small
molecules like serotonin, calcium, ATP, ADP and catecholamines98. Italiano et al. proposed
a model of differential granule release based on the observation of non-overlapping granule
proteins (VEGF as a pro-angiogenic factor localised to specific granules)102. Interestingly
this model was contested by Kamykowski et al. in 2011 in a comprehensive super-resolution
study of granule content in which no distinctive, non-overlapping granules were reported103.
However the authors do report sub-clustering of specific proteins within granules, which raises
the possibility of differential release.
Granules are known to be intimately associated with microtubules, as such microtubule
associated motor proteins are likely to be critical for the transport of these organelles down
the length of the proplatelet shaft. This is detailed further in Chapter 4 which discusses the
role of microtubules in platelet production and megakarypoeisis in more detail.
Emerging techniques for rapid, volumetric live cell imaging techniques promise to shed
new light on the biology of granule production, transport, and release. The hope is that these
methods will supplement previous work in the field which has primarily applied electron
microscopy.
1.3 Platelet production
Megakaryocytes have ultimately one terminal function, the generation of platelets in the
numbers needed to maintain haemostasis and effectively respond to vascular injury. The exact
mechanism by which megakaryocytes produce platelets in vivo remains controversial. This is
largely due to the difficulties presented by the bone marrow niche in which megakaryocytes
mature and form platelets, and the differences in the behaviour of these cells when removed
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from this environment and studied in vitro. Classic models of platelet formation and
production include cytoplasmic fragmentation, budding, and proplatelet formation.
The discovery of TPO and its MK specific receptor c-Mpl has been instrumental in
driving MK and platelet research, allowing for the in vitro culture of primary MKs. The
mechanism of MK differentiation, and the subsequent maturation of these cells into platelet
producing, polyploid cells has been intensively studied as a result. in vitro models include
murine megakaryocytes flushed from bone marrow, murine foetal liver MKs, human cord and
peripheral blood derived cells.
Early work looking at electron micrographs of MKs noted surface blebbing of a size
comparable to platelets - leading to the suggestion that platelets are shed from the MK cell
periphery104, 105. This suggestion was quickly undermined by thinner sectioning approaches
which revealed that these structures lacked platelet organelles. Early observations of the
extensive internal membrane system (see section 1.2.4) characteristic of mature MKs led to an
alternative model which described a ’demarcation membrane system’ thought to form defined
platelet territories106. Platelet production was thought to occur as a result of cytoplasmic
fragmentation along these territories107. While these regions are positive for platelet organelles
and proteins, they lack a number of the distinct, defining morphological characteristics of the
archetypal platelet - for example, the microtubule marginal band108, 109.
The proplatelet model of platelet biogenesis remains one of the more convincing models
due to a large number of imaging studies which report the generation of long, beaded
projections both in vitro and in vivo110, 43, 42. This theory suggests that platelets are formed
through the generation of long protrusions into bone marrow sinusoids which, in the presence
of shear, bud off to form preplatelets and platelets. In this model, the IMS acts as a reservoir
of membrane which is extruded during the formation of proplatelet extensions111.
Imaging technologies have generated a large body of evidence supporting the proplatelet
model - most significantly perhaps is intravital imaging work which has shown (albeit
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at relatively low resolutions) the generation of long, thin protrusions through endothelial
junctions43, 42. in vitro proplatelet extensions have been observed in mature MKs derived
from a number of species - including human cells. In thrombocytopenic models a loss of
proplatelet extensions has been reported as causative of low platelet counts.
In its current iteration, the proplatelet theory as studied by live and fixed cell imaging
approaches describes a series of changes which occur over the course of several hours (between
4 and 10)112. This is shown in figure 1.6, a time lapse of murine foetal liver MKs which
sponteneously form proplatet extensions in vitro upon maturation. The process begins with
the polarisation of the cell: a movement of the polyploid, lobed nucleus to one end of the cell
while the IMS and related structures are concentrated to the other28. Pseudopodia develop
and elongate to form long, thin extensions with consistent diameters ranging between 2-4
microns. As evidenced by live cell imaging, these extensions undergo a remarkable and
dynamic series of branching and bending events punctuated by beaded structures which
eventually resolve as platelets. Ultimately, this process leaves the megakaryocyte as little
more than residual nuclear material surrounded by a complex network of beaded proplatelet
extensions28. A rapid retraction followed by the rupture of the extensions between platelet
sized beads is thought to result in the release of platelet like particles. Interestingly these
final stages remain difficult to visualise using classical approaches as the temporal resolution
required over the full observation period is phototoxic in conventional light microscopy.
The dynamic and often dramatic rearrangement of the MK to form proplatelet extensions
is, perhaps unsurprisingly, driven by unique cytoskeletal processes. Both microtubules (MTs)
and actin play a critical role in the significant morphological changes needed to generate
platelets. As this work will primarily focus on microtubules in platelet production, this
particular cytoskeletal protein is discussed in more detail in the following sections - with
actin and its associated proteins touched on briefly.
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Figure 1.6: Proplatelet formation in murine foetal liver megakaryocytes. Foetal
liver megakaryocytes rapidly produce proplatelets in vitro after 4 days in culture. (A) Large,
polyploid cells dominate the culture at the beginning of the acquisition. (B) After 210 minutes
a cell begins to expand, extensively reorganising its cytoskeleton and altering its morphology
(particularly notable when compared to surrounding cells) . (C) At 660 minutes a series
of long protrusions are evident, with distinctive beads along the length of each extension.
Another cell in this field of view begins to re-organise. (D) At 1000 minutes the second cell
has formed a network of long extensions. Images acquired live on a Zeiss Observer 7 system.
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1.3.1 Microtubules in platelet production
Microtubules are a ubiquitous cytoskeletal protein with extensive roles in cell processes
including cell division and vesicle transport. They are comprised of α and β tubulin
heterodimers which assemble into protofilaments, these are further bundled into microtubules
- hollow filaments approximately 25nm in diameter which exhibit uniquely contrary properties
of dynamic stability113, 114. Microtubules are polarised, with bundles of MTs often exhibiting
mixed polarities. The plus (+) end is defined by its exposed β-tubulin subunit, while the
opposite (-) end is typified by an exposed α-tubulin. While MTs can polymerise in both
directions, polymerisation is typically more rapid at the plus end.
Highly specialised cell types exhibiting unique, dynamic processes often achieve these
functions through the regulation of microtubule function in what is referred to as the
’tubulin code’113, 114. This tubulin code is executed through the differential expression of cell
specific tubulin isoforms, and the subsequent recruitment of MIPS (microtubule interacting
proteins) and MAPS (microtubule associated proteins)to unique residues at key sites for
post-translational modification113, 114.
β-1 tubulin is a megakaryocyte and platelet specific isoform of tubulin encoded by the
TubB1 gene115, 116, 84. Expression of this β tubulin variant is specific to mature MKs, and as
such defects in these protein have been linked to defective proplatelet formation and platelet
function84, 43. The specificity and significant divergence of β-1 (20% at the amino acid level
compared to other β-tubulin isoforms) has implicated this cytoskeletal protein as a critical
part of the complex cytoskeletal machinery driving megakaryocyte and platelet function.
Despite this, our understanding of how TubB1 achieves its unique functions in MKs and
platelets remains relatively poor.
TubB1 knock-out mice have shown a substantial reduction in platelet count (approx. 50
percent less in homozygous knock-outs), an increase in mean bleeding time (260s vs. 50s
in wild type), reduced proplatelet formation in vitro, and a loss of the classic discoid shape
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of platelets observed in wild type mice (instead becoming spherical)82, 84. The authors also
observe poorer platelet activation in knock-outs when compared to wild type as evidenced
by P-selectin labelling in response to thrombin. The detailed role of β-1 tubulin in human
thrombocytopenias is discussed in Chapter 4.
Over the course of MK maturation microtubules evidence a substantial change in mor-
phology and organisation. This is likely to correspond with the expression of both β1-tubulin
and a number of other MK specific factors117. In earlier stage MKs microtubule assembly
at centrosomes will stop and MTs move to the periphery of the cell where they form thick
bundles in pseudopodia. As these thick structures begin to extend, MTs rearrange into linear
arrays which are thickest at the portion of the extension nearest to the cell body (and become
progressively thinner along the length of the proplatelet protrusion)117.
Microtubule polymerisation continues throughout the proplatelet structure, however the
rate of polymerization exceeds the rate of extension growth (10.2 µm/min vs a proplatelet
elongation rate of 0.85 µm/min). This coupled with the observation that microtubules
polymerise both towards the end of the proplatelet shaft and the cell body implies that poly-
merisation and proplatelet extension do not necessarily correlate. This is further supported
by work by Bender et al. 112, 118. The authors reported a dynein dependent mechanism of
microtubule sliding analogous to systems observed in flagellated cells and axons 118, 119, 120, 121.
Dynein is one of the two motor proteins associated with MTs (the other being kinesin).
Dynein is a (-) end directed motor protein which has also been reported as a critical player
in the maintenance of the platelet marginal band at rest, and its expansion and coiling on
activation120, 121.
Bender et al. report that while inhibition of microtubule polymerisation does not impair
proplatelet production (consistent with previous reports), the inhibition of cytoplasmic dynein
(EHNA and Ciliobrevin A) significantly impairs proplatelet extension.
Interestingly, recent work has shown that artificial expression of β-tubulin VI in CHO
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cells under the control of a tetracycline inducible promoter has a significant impact on
microtubule assembly and function115. The authors show that an abnormal bundling of
microtubules is observed at the cell periphery mimicking the formation of the marginal band,
and that this is linked to expression level in the stable cell lines generated. Similarly, clones
expressing β-tubulin VI demonstrated aberrant spindle assembly and cell cycle progression
(prometaphase arrest), with an increase in microtubule acetylation. This work implies that
β-tubulin expression is key to driving endomitosis and the unique microtubule localisation
exhibited by megakaryocytes during and after endomitosis.
Platelets require an abundance of specialised proteins packaged in granules to execute their
haemostatic functions - therefore the process of platelet production involves the trafficking of
organelles, granules and their contents along proplatelet extensions and into what will be a
terminal, mature cell122. These components have been shown to be in direct contact with
microtubules and are driven in both directions along proplatelet shafts through the action
MT associated motor proteins28.
Kinesin (a (+) end directed MT associated motor) appears to be related to the distribution
of organelles and granules - and is thus likely to be the motor responsible for transporting
nascent granules along the length of the proplatelet shaft. Recent work by Adam et al.
implicates Kinesin-1 as the motor involved in platelet secretion123. In their study a conditional
Kif5b knock-out was used to assay the effects of the loss of the major kinesin-1 heavy chain in
the MK lineage - the authors report no change in the morphology of platelets, their number,
or the distribution and number of granules123. They do however report a reduction in platelet
aggregation in vitro inconsistent with the lack of phenotype otherwise observed.
The role of MTs and their motors in the context of platelet activation and the broader
literature are discussed in more detail in the introduction to Chapter 4.
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1.3.2 Actin in platelet production
Globular actin is assembled into filamentous structures (microfilaments) which are critical
in cell motility and division amongst a host of other functions. In megakaryocytes, actin
branching drives proplatelet bending and facilities the generation of force through interactions
with its motor, non-muscle Myosin. MKs treated with actin inhibitors (e.g. latrunculin,
cytochalasin) form long proplatelet extensions which lack their characteristic branched
appearance112. Mutations in the heavy chain-of non-muscle myosin (MYH9) results in
May-Hegglin anomaly, a condition which presents with a macrothrombocytopenia124, 125.
Actin is regulated by a host of interacting proteins which help this ubiquitous cytoskeletal
protein to achieve cell specific functions. In platelets and megakaryocytes these include WASp
(Wiskott-Aldrich Syndrome protein), Profilin1A, Arp 2/3, and Cofilin. Wiscott-Aldrich
syndome proteins are autoinhibited and activated by Cdc42 and PIP2 to allow for the binding
and activation of the Arp2/3 complex (which nucleates actin). Human patients and WASp
knock-out mice both demonstrate low platelet counts as a result of increased clearance with
evidence of ectopic platelet release - although platelet function in these instances has been
reported as normal126, 127.
Profilin is an ADP binding protein which interacts with the ends of actin filaments. Mouse
models deficient in profilin 1 exhibit a significant microthrombocytopenia128, 129. The Arp2/3
complex drives actin nucleation, with the ARPC1B subunit highly expressed in cells with a
haematopoeitic lineage. A recent study by Kahr et al. reported that the loss of the ARPC1B
isoform caused a complex condition featuring inflammatory disease, vasculitis, thrombocy-
topenia, and platelet dysfunction. In ArpC2 knock out mice a microthrombocytopenia is
observed typified by an ectopic release of platelets within the bone marrow130.
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1.3.3 Spectrin in platelet production
While the majority of current and previous research into the cytoskeletal mechanisms driving
platelet production focus on actin, microtubules, and their myriad interacting and regulating
proteins, other components are likely to play a key role in the dynamic and extensive
shape changes evident in platelet production131, 132. The membrane skeleton has been
recently reported as important for elements of MK development. Proplatelets have been
reported to feature a spectrin membrane skeleton, with non-erythroid subunits alpha-II and
beta-II spectrin highly expressed in MKs (erythroid isoforms are expressed albeit at lower
levels)131, 132.
Treatment of MKs with a tetramer-disrupting peptide inhibits the formation of the IMS or
proplatelets. When the same peptide is applied to detergent permeabilized MKs, proplatelet
morphology is disturbed131, 132. This remains a nascent field, however the evidence to date
suggests an important role for the spectrin tetramer in platelet production.
1.3.4 Platelet production and apoptosis
In many ways MK maturation and the process of platelet production resemble a directed
form of cell death. Both pro- and anti-apoptotic factors have been described in MKs. Bcl-2
and Bcl-XL are anti-apoptotic factors found in early MKs, and when these factors are
overexpressed in these cells the result is an inhibition of proplatelet formation133, 134. Work
by Debili et al. investigating apoptotic caspases in cord blood derived MKs report a loss of
proplatelet formation when these factors are inhibited 135. In contrast however, knock-out
mice deficient in Caspase-8, Caspase-9, and the pro-apoptotic factors BAK, and BAX report
no reduction in platelet counts.
It is suggested that MK maturation is a product of the inhibition of the intrinsic pathway
of apoptosis - with key survival proteins involved in the repression of intrinsic apoptosis.
MCL-1 knock-out mice demonstrate no defects in platelet production, while treatment with
Chapter 1. Introduction 27
an inhibitor of Bcl-XL and Bcl-2 result in MK cell death. This evidence suggests that
repression of apoptosis is required for platelet production133, 134.
1.3.5 Platelet release
The production of platelets ultimately terminates in the release of platelets into the blood-
stream - the observation that the anucleate fragments launched into the vasculature are
typically larger than mature platelets implies that an intermediate stage precedes the final
product136, 137. These ’preplatelets’ are thought to precede the final stages of platelet forma-
tion which occur in circulation. ’Preplatelets’ are reported as discoid cells up to 10µm in
diameter which form a characteristic barbell-shape prior to fission into platelets. This final
step is likely driven by MT associated motors - and indeed the macrothrombocytopenias
discussed in Chapter 4 are thought to occur as a result of a loss of this key MT mediated
behaviour136, 137.
Intravital microscopy has provided a remarkable insight into the release of platelets in
vivo, with a number of excellent works documenting the generation of proplatelet extensions
into the lumen of bone marrow sinusoids42, 43. Recent advances in imaging technologies are
likely to improve on the resolution of previous works and provide further insights into this
process.
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1.4 The molecular basis of inherited thrombocytope-
nias (ITs)
Inherited thrombocytopenias (IT) are a class of hereditary diseases characterized by abnor-
mally low platelet counts (below the normal range of 150-450 x109/L), often manifesting
as bleeding diathesis 138, 139, 140. With the advent of improved, high throughput sequencing
technologies, ITs have been revealed to be complex inherited disorders resulting from a diverse
range of novel mutations (Figure 1.7). Moreover, these often unique variants have, upon
further investigation, yielded novel insights into platelet and megakaryocyte (MK) biology on
a molecular level 141, 139, 140.
ITs are often difficult to diagnose, firstly as rare diseases which, due to variation in their
molecular causes, can present with a range of symptoms141. The classic hallmark of ITs, an
abnormally depleted platelet count, is one which is often only diagnosed after a patient has
been sufficiently challenged 141. Interestingly Morowski et al. show that mice can tolerate
significant decreases in platelet count before presenting with a bleeding phenotype142. The
authors systematically deplete platelet counts using antibodies and subject treated mice to a
number of challenges, showing a surprising tolerance of reduced platelet counts in terms of
functional assays 142. This work highlights the need for human, in vitro based assays when
interrogating human mutations.
Similarly unique patient mutations can have markedly different effects on protein function,
ranging from a complete loss to truncations with functional consequences, with possible
species dependent variations. These can cause thrombocytopenias due to defective platelet
production, clearance, or MK maturation. Unpicking the mechanistic effects of mutations
can be quite complex, as in many instances there are further characteristics of particular
thrombocytopenias which compound the initial mutation. For example, as detailed later in
this chapter, particular thrombocytopenias are associated with enlarged platelets or defects
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in granule content and release.
The last decade has seen the discovery of an unprecedented number of novel genes
implicated in ITs due to the emergence of Next Generation Sequencing (NGS) technologies,
most notably the Whole Exome Sequencing (WES) approach 139. To date, 31 genes responsible
for 27 distinct inherited thrombocytopenias have been reported 141, 139, 140. These molecular
approaches have linked mechanistic causes with patient phenotypes, prominent examples of
which include myosin heavy chain 9 (MYH9)-related and Bernard-Soulier disease143, 144, 145, 146.
Future challenges are in identifying novel genes and patients whose diathesis are a
result of different variants working in combination to affect megakaryopoeisis and platelet
production145. Typically, defects implicated in ITs can be grouped according to their effects
on the differentiation of platelet progenitors, MKs, the maturation of MKs, and platelet
formation, or in a minority of cases, in genes and proteins not directly involved in the process
of generating platelets139, 140.
This section will briefly discuss a range of inherited thrombocytopenias and their respective
molecular causes. TubB1 and previous reports of thrombocytopenias which arise as a
consequence of its mutation are excluded from this section for a more comprehensive discussion
in Chapter 4.
1.4.1 Grey Platelet Syndrome
The loss of α-granules results in the classic gray appearance of platelets on blood smears of
patients affected by Grey Platelet Syndrome (GPS) 147, 148. Patients diagnosed with GPS
will typically present with macrothombocytopenia, bleeding diathesis, splenomegaly, and
bleeding diathesis149.
Both platelets and megakaryocytes in GPS present with a loss of α-granules, while dense
granules and lysosomal compartments appear unaffected. As secretory vesicles carrying
an abundance of factors promoting adhesion and wound healing upon platelet activation,
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Figure 1.7: Megakaryocyte differentiation is a stepwise process over which MKs
accrue hallmark features. Arising from the haematopoeitic stem cell (HSC), the
promegakaryoblast is a larger cell with a low nucleus to cytoplasm ratio. As the cell
develops becoming a megakaryoblast, it forms a distinctive kidney shaped nucleus. Further
differentiation results in the formation of the promegakaryocyte, a cell type which begins to
accumulate granules and the loss of the previously basophilic appearance of the cell. A mature
megakaryocyte is the final result of this differentiation process. This cell type demonstrates
the characteristic polyploidy which occurs as a result of endomitosis and can go on to form
platelets. This maturation process is defined by the expression of a series of transcription
factors implicated in thrombocytopenias. Genes associated with inherited thrombocytopenias
can be broadly split into two key groups - genes affecting MK development, differentiation,
and maturation, and those resulting in defective proplatelet formation or release. (Figure
adapted from Johnson et al. 140.)
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GPS patients will as a result present with bleeding149. Interestingly proteins synthesised
by MKs are particularly deficient in these cases (e.g. PF4, β-thromboglobulin), while other
components of these vesicles are less reduced.
GPS is caused by variations in the gene Nbeal2 (Neurobeachin-like 2) which encodes a
protein of the same name which is found in the platelet endoplasmic reticulum150, 151. Nbeal2
null mice demonstrate the same macrothrombocytopenia with a loss of α-granules, as well as
a delayed maturation of MKs and a reduction in their ploidy152.
1.4.2 Bernard-Soulier Syndrome
Bernard-Soulier Syndrome (BSS) is a rare inherited bleeding condition which presents with
defects of the GP1b-IX-V complex153. Typical symptoms include reduced platelet numbers,
giant platelets, and bleeding tendency153. Loss of function in this receptor results in poor
binding with von Willebrand Factor, an event critical for a healthy haemostatic response154.
The GP1b-IV-V complex is formed from the expression of four genes (GP1BA, GP1BB,
GP9, and GP5 ) as MKs mature in the bone marrow. Mutations causing BSS are spread over
these four genes, with the exception of GP5 (in which no mutations causing BSS have been
reported thus far)154. Due to the range of possible causative mutations, BSS can present
with varying degrees of severity and a host of symptoms154.
1.4.3 MYH9-Related disease
MYH9 encodes Myosin 9, the heavy chain of a key non-muscle myosin IIA heavily involved in
platelet production139, 140. Interestingly mutations in this gene have been shown to increase
the production of proplatelet extensions, suggesting a role for this protein in the terminal
phase of platelet fission - the loss of which causes thrombocytopenia155, 156.
MYH9-Related diseases include the May-Hegglin anomaly, Sebastian, Epstein and Fechtner
syndromes. Each condition shares key clinical features, namely the formation of a small
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number of enlarged platelets (macrothrombocytopenia) and leukocyte inclusions known as
Dohle bodies157.
1.4.4 Paris Trousseau type thrombocytopenia
Paris-Trousseau thrombocytopenia is a bleeding diathesis demonstrated by individuals with a
terminal deletion of chromosome 11, a rare condition referred to as Jacobsen syndrome158. In
these patients, a reduced platelet count is accompanied by platelets with giant α-granules and
abnormal responses to thrombin 159, 160, 161. These individuals will also feature two distinct
subsets of megakaryocytes, one normal and the other abnormally small 158, 159, 160, 161.
Amongst the genes lost by the Jacobson deletion is the transcription factor FLI-1, a key
regulator of megakaryocyte development described in a previous section 158, 159, 160, 161. The
loss of FLI-1 has been modelled in mice and human stem cells and is likely to be causative of
Paris-Trousseau thrombocytopenia in Jacobsen patients.
1.4.5 Wiskott-Aldrich Syndrome
Actin polymerisation is a key component of the morphological changes associated with both
platelet production and function. The actin nucleation promoting factor WASp, encoded by
the WAS gene and expressed in haematopoeitic cells, has a critical role in platelet production
and function (discussed in more detail in section 1.3.2)162. Abnormal WAS expression is
associated with Wiskott-Aldrich Syndrome, a rare X-linked condition which includes a low
platelet count (X-linked thrombocytopenia) amongst other symptoms (e.g. micro platelets,
eczema, immune deficiency)162.
Interestingly the microthrombocytopenia observed in Wiskott-Aldrich syndrome is also
evident in the recently reported ARPC1B disorder, supporting the role of actin nucleation
(and subsequent branching) in the production of healthy platelets163.
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1.4.6 von Willebrand disease
von Willebrand Factor (vWF) is a vital mediator of platelet function in haemostasis and
thrombosis, the loss of this protein results in a series of conditions known as von Willebrand
Diseases (VWD) 164, 165, 166, 167. vWF binds to the N-terminus of glycoprotein Ibα through
its A1 domain when the protein is exposed in the subendothelium 164, 165, 166, 167.
In types 1 and 3 of VWD, a deficiency or complete lack of the protein cause the bleed-
ing condition, however in type 2B a functional deficiency is responsible for the resulting
diathesis164, 165, 166, 167. In VWD type 2B, mutations in the A1 domain of the protein result
in a gain of function phenotype, wherein circulating vWF spontaneously binds to platelet
GP1bα.
Interestingly a dysfunction in megakaryopoeisis has been reported in VWD type 2B by
Nurden et al.. 168. A family with a substitution mutation in the A1 domain of the protein
show poorly differentiated megakaryocytes from peripheral blood cultures168.
1.4.7 The UK Genotyping and Phenotyping of Platlets (GAPP)
project and challenges in the study of inherited thrombocy-
topenias
With the importance of defining novel mutations responsible for ITs in mind, the Genotyping
and Phenotyping of Platelets (GAPP) study was created with the intention of cataloguing
and investigating platelet phenotypes and genotypes169, 170. With samples from patients with
suspected thrombocytopenia and functional defects across the UK, whole exome sequencing
(WES) has identified numerous novel defects in patients139, 140. A recent example is the
identification of schlafen 14 (SLFN14 ) in patients with a history of thrombocytopenia,
excessive bleeding, and platelet secretion defects171.
12 patients from 3 unrelated families with similar phenotypes, namely a dominant
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inheritance pattern, enlarged platelets, thrombocytopenia, and decreased ATP secretion, were
found to harbour missense mutations within the GTP/ATP-binding region of SLFN14 171. In
this instance, not only has the underlying molecular cause of the patient phenotype been
discovered, but the importance of this particular protein in platelet production has been
highlighted. The identification of SLFN14 is a prime example of how investigating patient
mutations through the GAPP project can lead to an improved understanding of ITs and
platelet biology, and current work is focussing on dissecting the role of SLFN14 in platelet
formation.
The work performed thus far on SLFN14 also highlights a significant obstacle in the study
of platelet disorders, namely the need for enough patient sample for the characterisation and
study of novel defects. The advent of CRISPR-Cas gene editing has created a previously
unprecedented opportunity for the generation of cells harbouring specific mutations of interest.
Applying this gene editing tool to cell lines and stem cell derived MKs can overcome the
historical limitations applied to such studies by the finite amounts of patient sample available.
1.4.8 Aims
The primary focus of this PhD has been the development of methodologies to apply these
technologies to the study of novel variants and genes revealed by the GAPP project. In
the absence of patient material and cell lines which mimic platelet production, there is a
need for the development of reliable iPSC differentiation models to yield mature, proplatelet
producing cells for phenotypic screening.
In the following chapters the use of CRISPR for the endogenous labelling of genes of
interest is reported, and the development of a method of single molecule imaging through
CRISPR is validated. Attempts to adapt these knock-in methods for CRISPR in iPSC are
discussed, alongside the adaptation of protocols for the generation of mature, proplatelet
forming MKs from induced pluripotent stem cells.
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Finally, investigations into the role of post-translational modifications of TubB1 are
reported with a number of novel insights into how the expression of the MK and platelet
specific isoform of β-tubulin drives the unique morphologies and functions of these cells.
Chapter 2
Development of CRISPR-PALM
In this chapter the development of a method of single molecule imaging through the endogenous
expression of fluorescent proteins is reported. One of the aims of this project is to establish
protocols for CRISPR mediated knock-in of donor DNA. Applying CRISPR-Cas9 editing to
insert fluorescent tags offers an easy-to-assay means of developing these protocols. Extending
this approach to insert photoswitchable tags offers a novel application of this gene editing
approach to address a number of long standing issues in the field of single molecule localisation
microscopy. Finally, the protocols developed through these experiments should translate to
the introduction of patient SNPs through CRISPR as both single base pair and reporter
knock-in rely on the same homology directed repair (HDR) pathway.
CRISPR mediated knock-in also offers a number of distinct advantages in the study
of novel genes implicated in inherited thrombocytopenia. Where good antibodies are not
available, endogenously expressed labelled protein offers a convenient and robust method
of studying the distribution and function of genes of interest. Combined with stem cell
approaches discussed in chapter 3, these methods offer a potential means by which candidate
genes can be modelled and studied in vitro.
In this introductory section, super-resolution techniques are introduced with a particular
emphasis on single molecule localisation microscopy (SMLM). The application of CRISPR-
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Cas9 in the context of imaging techniques is discussed, and finally data pertaining to
a novel method of single molecule imaging through knock-in, CRISPR-PALM (CRISPR-
PhotoActivated Localisation Microscopy), is discussed.
2.1 Introduction: Sub-Diffraction or Super-Resolution
Microscopy
Light microscopy has been a powerful tool in cell biology since its inception, and because of
the continuous development of fluorescent reporters and immunofluorescence techniques, has
become a mainstay of modern cell biology. Modern microscopes are virtually indistinguishable
from their ancestors as ever advancing optical configurations, cameras, and illumination path-
ways allow for improved resolution, signal to noise ratio (SNR), and phototoxicity. Arguably
the most significant advance in modern imaging technologies has been the development of
super-resolution techniques - methods which overcome the classic resolution limit of light
microscopes to provide nanoscopic insights into the workings of the cell.
Defined by Ernst Abbe as a function of the numerical aperture of an optical system and
the wavelength of light, the diffraction limit has classically kept cellular imaging above a
resolution limit of approximately 200-300 nm (Figure 2.1), restricting the detailed structural
study of nanoscopic elements of the cell172. In light microscopy, resolution refers to the
maximum distance at which two distinct objects or point spread functions can be resolved
as individual components. In recent years, a number of approaches have been developed
which circumvent the diffraction limit, allowing for sub-diffraction or super-resolution (SR)
nanoscopy of living and fixed cells 172. Super-resolved fluorescence microscopy techniques
were awarded the Nobel prize in Chemistry in 2014 (the prize was awarded to William E.
Moerner, Eric Betzig, and Stefan Hell, though these are by no means the only individuals
responsible for the development of these techniques), and have since become widely spread
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methods of interrogating biological samples on the scale of nanometers.
A number of approaches can be applied to ’break’ the diffraction limit, each with its
own benefits and drawbacks. In this introduction the most widely used super-resolution
techniques are discussed with a particular emphasis on SMLM.
2.1.1 Structured Illumination Microscopy (SIM)
Structured Illumination Microscopy (SIM or SR-SIM) refers to imaging modalities which
apply an interference pattern to samples during acquisition, this can be used to computation-
ally extract high-frequency information from the sample which is typically discarded, and
reconstruct images with a doubling of the lateral resolution limit and an axial improvement
ranging between 150-300nm (depending on the implementation used)173, 174, 175. SIM offers
relative simplicity compared to other SR techniques, no specialised reporters or sample
preparation is needed, and so multiplexing (imaging multiple reporters) is straightforward
when compared to methods like single molecule localisation microscopy (SMLM).
However, classical limitations of SIM have included slow acquisition speed and recon-
struction artifacts173. In the early SIM systems reported by Gustaffson et al. a diffraction
grating was iteratively rotated to achieve a modified excitation pattern - and so achieve the
variations in phase needed for SR-SIM. This unfortunately, was a time consuming method as
the grating would need be mechanically moved for each acquisition, often between as many
as 9 to 15 times - ultimately limiting the applicability of the approach for live cell imaging176.
Since this early implementation, an array of alternative methods have been developed to
achieve the variations in angle and phase needed to generate SIM images - including spatial
light modulators, digital mirrors, and electro- and acousto-optic devices. These approaches
have led to progressively faster SIM, and as a result, live cell applications which benefit from
the efficient use of photons in modern cameras177.
As reconstruction is needed to extract the relevant information needed from SIM ac-
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Figure 2.1: The diffraction limit and super-resolution imaging modalities. While
whole cells are typically described on the scale of microns, most sub-cellular structures
measure on a nanoscopic scale and receptors and other proteins are spatially organised in the
tens of nanometers. ’Standard’ imaging modalities like widefield or confocal microscopes are
limited to the diffraction limit (200-250nm laterally), however an array of super-resolution
techniques can provide insights on a scale of nanometers, which is much more appropriate for
describing sub-cellular organisation and distribution. Cytoskeletal structures are an excellent
example of cellular components which exist on a scale an order of magnitude beneath the
classical diffraction limit. Microtubules and actin filaments have diameters of approximately
25nm and 9nm respectively, substantially lower than the resolution limit of conventional light
microscopy. While techniques like SIM and STED can offer substantial improvements in
resolution, only SMLM techniques allow for resolution on the scale needed to describe spatial
relationships in the tens of nanometers.
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quisitions, reconstruction artefacts have been a concern. Acquiring an experimental point
spread function (PSF) substantially reduces the likelihood of artefacts, as does the reduction
of sample drift and chromatic aberrations173. Artefacts become more likely as a sample
photobleaches and the signal-to-noise ratio (SNR) deteriorates - this is an important consid-
eration in live cell imaging experiments where later acquisitions are likely to suffer from this.
Similarly sample depth and restricting interference from out of focus light are critical to high
quality SIM imaging173.
Recent advances in the application of non-linear SIM have improved on the technique’s
2-fold increase in lateral resolution. Non-linearity is easily introduced in samples with
photoswitchable fluorophores and dyes, as well as simply through applying high illumination
intensities to drive singlet state saturation178, 179. The development of photoswitchable
fluorophores with high brightness and the ability to undergo a high number of switching
cycles is extremely promising - particularly in the context of non-linear 3D SIM in lightsheet
imaging (discussed in section 2.1.4)180.
The relative ease of application and live cell utility of SIM have driven its popularity in
recent years, particularly in the field of megakaryocyte and platelet biology. SIM has recently
been proposed as a method of diagnosing platelet granule disorders by Westmoreland et al.
as the two fold improvement in resolution allows for the accurate quantification of granule
number 181. Poulter et al. applied SIM to investigate the distribution and architecture of
actin nodules in spreading platelets. Finally, Kahr et al. utilise SIM to investigate the effects
of an ARPC1A knock-out in an immortalised megakaryocyte cell line163.
2.1.2 STimulated Emission and Depletion Microscopy (STED)
Stimulated Emission and Depletion Microscopy (STED) refers to one of the original methods
of SR imaging. STED is similar to confocal in that a pinhole is used to restrict illumination to
a single image plane and achieve pixel by pixel excitation, however to achieve super-resolution,
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the effective PSF is improved by applying a second laser (a depletion beam) with a red-shifted
wavelength182, 183, 184.This depletion laser is described as a doughnut-shape with 0 intensity
at the centre to selectively suppress excitation around the centre of the imaging laser’s PSF,
thereby improving the effective resolution of the system182.
An extension of this approach is Reversible Saturable Optical Fluorescence Transitions
(RESOLFT) microscopy, where the spatial manipulation of both organic fluorophores and
photoswitchable fluorophores into their respective on-off states can achieve improvements in
lateral resolution185.
Like SIM, STED can be performed on conventional fluorophores, and therefore offers
relative ease of use in terms of sample preparation and in the absence of post-acquisition
processing. As in any imaging modality, the quality of fluorescent labels is key to sample
quality. Criteria like molecular brightness and photostability for example, will determine the
quality of imaging. Critically, fluorophores with excitation/emission spectra and singlet states
favourable for this modality must be chosen. Most of the complexity in STED arises from
the illumination of the sample, in particular selecting appropriate excitation and depletion
wavelengths. The magnitude of the depletion laser also restricts the application of STED
based techniques to live cell imaging. Although RESOLFT in particular has been reported
in the live cell format, ultimately this approach depends on significant intensities which will
undoubtedly have phototoxic effects on cells.
A very recent and exciting application of STED has been the combination of expansion
microscopy and STED imaging. This method, referred to as ExSTED, reportedly achieves a
30 fold increase in lateral (to below 10nm), and 50nm isotropic resolution186.
2.1.3 Computational methods of super-resolution
In the last decade methods of widefield deconvolution have also offered a means of sub-
diffraction limited imaging. Prominent examples include SOFI (Super-Resolution Fluctuation
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Imaging), an approach which relies on the statistical analysis of fluctuations in fluorescent
signal over time to achieve up to a five-fold improvement in resolution 187. A Bayesian
localisation approach developed by Cox et al. in 2011 achieved lateral resolutions of 50nm by
modelling blinking and bleaching events in an entire dataset as opposed to the frame by frame
approach typically applied in localisation microscopy188. These approaches can successfully
extract super-resolution data from non-linear data sets, without the need for specialist optics
(although they benefit substantially from high quality cameras and objectives).
Most recently, the SRRF method has offered a means of super-resolution through sub-
pixel radial fluctuations, without the traditional computational cost associated with high
density analysis189. This approach has substantial benefits in live cell imaging, as the authors
demonstrate that low levels of illumination can be used to generate super-resolved images at
sub-second temporal resolutions.
2.1.4 Super-resolution in lightsheet imaging
Selective plane illumination microscopy (SPIM), also known as lightsheet imaging, has become
one of the most popular live cell imaging approaches in recent years. It is also used extensively
in imaging larger fixed samples, including cleared bone and brain samples190, 191. The main
advantages of SPIM are superior optical sectioning (due to the illumination of a single plane
through the orthogonal arrangement of both illumination and detection pathways) and speed,
both of which are critical in live cell imaging, where selective illumination substantially
reduces the phototoxic effect of repeated illumination190, 191. As the focus of this chapter is
super-resolution imaging, this section will focus primarily on lightsheet applications which
have achieved sub-diffraction limited imaging.
The high SNR and rapid volumetric imaging offered by SPIM systems makes them ideal
modalities for super-resolved imaging. This is particularly significant for live cell imaging due
to the substantial reduction in phototoxicity achieved through selective plane illumination. A
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number of approaches combining structured illumination with SPIM have successfully achieved
live cell super-resolution imaging. Most notably, Li et al. demonstrate remarkable live cell sub-
diffraction imaging through non-linear excitation in a lattice lightsheet set up192, 193. Chang
et al. used two counter-propagating sheets to produce structural illumination (a method
described as coherent structured illumination light sheet based fluorescence microscopy -
csiLSFM)180.
More recently single molecule localisation microscopy has been performed in lightsheet
modalities. Galland et al. apply a method of SPIM referred to as soSPIM to perform single
molecule localisation microscopy in 3D samples (cells and Drosophila), performing remarkably
effective single molecule imaging at unprecedented depths in large samples. The use of tilted
lightsheets to overcome the geometrical limitations of orthogonal excitation has allowed
high numerical objectives to be used in SPIM set ups, with significant consequences for the
application of SPIM for super-resolved imaging194, 195. Gustavsson et al. have demonstrated
high quality 3D single molecule localisation microscopy using a tilted sytem. A recent
application of the lattice lightsheet demonstrated 3D single molecule imaging at depth in
Drosophila 196. A particularly recent use of the lightsheet approach compared a traditional
TIRF single molecule live cell acquisition on coverglass with lightsheet imaging of suspended
T-cells196. The authors found that while the two imaging modalities were comparable in
performance, receptor diffusion was profoundly affected by the presence of glass, and that
contact with a surface resulted in calcium influx. These findings suggest that by removing the
restriction of imaging at a coverslip, lightsheet imaging can also remove biological artefacts
which arise as a result of technological limitations.
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2.1.5 Single Molecule Localisation Microscopy (SMLM)
Of the many sub-diffraction limited techniques available, photoactivated localisation mi-
croscopy (PALM), and stochastic optical reconstruction microscopy (STORM) allow for
the highest spatial resolutions197, 198, 199, 200, 184. These technologies can achieve localisation
precisions up to 10nm, effective spatial resolutions of 20nm and below, and have also been
shown to offer 3 dimensional, multi-colour, and live cell imaging options, all with distinctive
benefits and drawbacks197.
PALM and STORM are single molecule localisation microscopy (SMLM) techniques,
reliant on the stochastic activation of subsets of molecules within a sample to allow for precise
localisation and rendering post-acquisition198, 199. The key difference between these two
approaches lies in the nature of the reporters used to generate ’blinking’ events as a result of the
stochastic activation of fluorophores (Figure 2.2). While in STORM paired dyes (nSTORM)
or organic fluorophores capable of switching within an appropriate redox buffer (dSTORM)
are used, PALM relies on fluorescent proteins with photoswitching capabilites which occur as a
consequence of cis-trans isomerism when irradiated at particular wavelengths197, 198, 199, 200, 184.
Each technique offers its own distinct disadvantages, dSTORM is limited to fixed samples
and is dependent on the use of high quality antibodies, as well as the optimisation of imaging
buffers. PALM suffers from a limited palette of photoswitchable tags, decreased photon
counts and increased localisation uncertainties, as well as the artefacts associated with
over-expression as tags often must be transfected into cells. Quantitatvely, dSTORM is often
confounded by unknown labelling stoichiometries and the undefined on-off cycling of organic
fluorophores.
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Figure 2.2: Single molecule localisation microscopy (SMLM). SMLM approaches
involve generating a data set comprised of consecutively acquired frames capturing the
activation of subsets of fluorophores. Provided sufficient temporal separation is achieved
by these acquisitions, each individual emission can be fitted to a Gaussian to determine its
centroid, and therefore reconstruct a super-resolved image from the detection and recording
of potentially millions of single localisation events as samples progressively bleach.
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Both dSTORM and PALM have been applied successfully in a number of studies demon-
strating not only the utility of nanoscopic resolution, but the potential of quantitative single
molecule microscopy. In a recent review by Miklosi et al., the role of single molecule imaging
in dissecting the function and distribution of neurotransmitters and other molecules of interest
at synapses is discussed in the context of quantitative proteomics 201. The authors discuss
the utility of dSTORM as a quantitative and spatial tool in neurobiology and explore studies
where the application of single molecule imaging allows for the mapping and quantification
of vesicles and neurotransmitters in synapses.
In platelet biology recent work by Mayr et al. demonstrate super-resolution of the platelet
cytoskeleton 202. Poulter et al. applied dSTORM as a quantitative tool to interrogate integrin
distribution at actin nodules and show a distinct absence of integrin clustering at nodules - a
finding which would not have been possible without the use of single molecule localisation
microscopy27.
Both PALM and dSTORM are potentially potent quantitative tools, however single
molecule imaging and quantification have important caveats which are critical for accurate
image acquisition, reconstruction, and quantification. First and foremost is the correct
identification of single molecules, which is often confounded by frame to frame persistence.
The phenomenon of ’blinking’ involves repeated cycling between on-off states, and persistence
across multiple frames such that ’single’ molecules are more often collections of peaks
203, 204, 205. This is a significant caveat in single molecule quantification, and a considerable
focus of the field is accurately detecting individual emitters and modelling fluorophore
behaviour.
A significant advance in the field would be the development of systems with an established
labelling stoichiometry and known photoswitching kinetics. While PALM addresses both to
an extent by introducing photoswitchable tags with a known 1:1 labelling ratio, the variability
and artefacts introduced by over-expression are one of a number of problems inherent to
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this approach. As the following section will discuss, the use of CRISPR to knock-in tags to
ameliorate the negative effects of PALM has the potential to substantially advance single
molecule imaging.
2.1.6 Development of CRISPR-PALM
While there have been reports of successful CRISPR mediated knock-in of fluorescent proteins
since the development of the tool, the generation of endogenously expressed fusion proteins
remains a relatively new field with limited applications. To date, only one study has reported
the use of knock-in reverse switchable mEGFP to generate super-resolution data through
the RESOLFT method206. A recent study used a SMLM approach to investigate RNA
Polymerase function through knock-in of the photoswitchable tag Dendra - however the
authors do not adequately report super-resolution or investigate the effect of knock-in on
protein expression and function. Perhaps most significantly, this study does not compare the
resulting data with any other methods of super-resolution, raising doubts as to the efficacy
of their super-resolution method207.
The use of endogenously expressed fluorescent proteins would address a number of
long standing issues in single molecule imaging. Most significantly, a known, defined ratio
of labelled protein would substantially improve the quality of single molecule imaging.
By avoiding over-expression transfection artefacts like the artificial clustering of proteins,
would be prevented. Finally in the age of SPIM and long term fluorescence imaging at low
phototoxicities, endogenous expression offers the opportunity to observe cells over significantly
longer periods than those typically defined by transfection.
The work reported in this chapter describes efforts to develop CRISPR-PALM and address
some of the obstacles presented by endogenous expression. While CRISPR knock-in provides
a means by which to avoid over-expression and its associated issues, a key question is whether
endogenous expression can achieve the labelling density required to satisfy the Nyquist-
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Shannon criteria. Key aims of this section include first establishing methods by which to
introduce fluorescent tags to target loci through CRISPR knock-in, and to establish whether
the resulting expression levels are sufficient for single molecule imaging.
The work in this chapter focusses on the α-tubulin isoform expressed by the gene TubA1B.
Firstly, tubulin is in many ways a perfect target for single molecule imaging as microtubules
are found well beneath the diffraction limit, with an average diameter of approximately 25nm.
With monomers 4nm apart from one another, resolving these fine sub-cellular structures will
require an even distribution of reporter fluorophore at a high enough density to satisfy the
sampling criteria. Secondly, this gene is ubiquitously expressed and as such will allow us to
interrogate any cell line specific effects (as different lines will express different amounts of this
specific isoform), and so establish where the labelling criteria for SMLM are met. Finally, as
this gene is expressed, single cell sorting to isolate clones and to measure knock-in efficiency
will be valuable tools in establishing CRISPR-knock in methodologies in this project.
As our long term interest is to study the molecular causes of inherited thrombocytopenia,
we will adapt these methods to study the megakaryocyte and platelet specific β-tubulin
(detailed in Chapter 4), the work performed in this section is relevant to adapting CRISPR-
knock in to iPSCs as discussed in chapter 3.
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2.2 Materials and Methods
2.2.1 Cell culture and transfection
Human Alveolar Basal Carcinoma (A549) and Embryonic Kidney 293T (HEK293T) cell
lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
Penicillin/Streptomycin (1%), 2mM L-Glutamine, and 10% Foetal Bovine Serum (FBS).
Human Erythroleukaemia 92.1.7 cells (Hel 92.1.7) were maintained in identically supplemented
Roswell Park Memorial Institute (RPMI) 1640 medium. All cells were cultured at 37◦C
and 5% CO2. Adherent cells were passaged by washing T75 cell culture flasks (Corning)
twice with sterile Phosphate Buffered Saline (PBS) without calcium or magnesium, before
incubation with Trypsin-EDTA (Thermo Scientific) for 5 minutes at 37◦C. Cells were then
re-suspended in complete DMEM before passaging at an appropriate dilution in a fresh flask.
Suspension cells (Hel 92.1.7) were passaged by spinning cells at 1200 RPM for five minutes
before re-suspension in fresh complete RPMI, dilution in fresh media, and incubation.
Adherent cells were transfected with Lipofectamine 3000 (Thermo Scientific) as per
manufacturer guidelines. Briefly, cells were plated at a density of 1x105 in 12 well plates
(Thermo Scientific) 18 hours before transfection. Immediately preceding transfection, cells
were washed twice with sterile PBS before incubation in Optimem. For Dronpa experiments,
the BPK1520 guide expressing vector (Addgene Plasmid #65777 BPK1520 was a gift from
Keith Joung), Cas9-RFP (Sigma), and Dronpa donor vectors were transfected at equimolar
ratios to a total of 1µg DNA per well. For mEGFP and mEos experiments, the px459 guide
and Cas9-puro expressing plasmid was used (Addgene plasmid #62988 was a gift from Feng
Zheng).
Suspension cells were transfected using the Neon electroporation system (Thermo). Briefly,
cells were resuspended in a final total volume of 10µl buffer R with 1µg of total DNA (equimolar
guide C px459 and donor) and a total of 1 x 105 cells. 10 µL tips were used with 2x pulses at
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20ms pulse width and 1450V.
2.2.2 Guide vector cloning
The MIT CRISPR database (http://crispr.mit.edu/) was used to design guide sequences, each
of which were ordered as complementary oligos and suspended at 10µM before incubation
in the presence of T4 PNK (New England Biolabs) to generate phosphorylated oligos.
Annealing was performed using a thermal cycler (Sense Quest) programmed to a 5 minute
95◦C denaturing cycle, followed by a gradual cooling to room temperature at - 0.1◦C per
second. The BPK150 vector was digested with the BsmBI restriction enzyme (New England
Biolabs) and treated with T4 Calf Intestinal Phosphatase (CIP) (New England Biolabs) to
generate linearised, dephosphorylated backbones with overhanging sequence complementary
to the annealed oligo duplex.
Finally, both digested vector and oligo duplex were ligated using T4 DNA ligase (New
England Biolabs) at room temperature for 10 minutes. 2µl of the resulting ligated DNA was
then transformed into competent cells (Bioline - Alpha Select Silver Efficiency E. Coli) by
heat shock at 42◦C for 30 seconds, incubation on ice for 2 minutes, and incubation in SOC
medium (Thermo) for 1 hour. Transformed cells were plated on penicillin agar plates over
night before colony selection and screening.
Colony PCRs were used to validate guide vectors. 2µL of each bacterial inoculation
was amplified using an OS280 primer and RedTaq ReadyMix PCR Reaction mix. Thermal
cycling was performed according to manufacturers instructions, and the resulting product
run on a 1.5% agarose gel with ethidium bromide for 25 minutes at 120V.
2.2.3 Donor vector cloning
Donor plasmids were generated by ordering gBlock synthetic DNA (Integrated DNA Tech-
nologies) for both left and right homology arms and each of the inserts tested (Dronpa, mEos
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3.2, mEos 3.2 codon optimised, mEos 4b, mEos 4b codon optimised, and mEGFP). Each
fragment was designed with a 20bp segment overlapping the adjacent arm. Homology arms
and inserts were cloned into an empty pGem-T-Easy backbone using a HiFi Gibson Assembly
kit (New England Biolabs).
2µL of each 10µL reaction volume was transformed into competent cells as described in
the previous section. Individual colonies were selected after overnight growth on ampicillin
plates, miniprepped (using manufacturer instructions included in the GeneJet kit - Thermo
Fisher), and subject to an EcoRI test digest to verify the presence of an insert. Clones
carrying an insert of the correct size were further verified by Sanger sequencing.
2.2.4 Flow cytometry
Validation and verification of knock-ins was performed using an Accuri C6 Flow Cytometer
(BD Technologies). Samples were gated according to forward and side scatter, with positive
fluorescence for these experiments detected in the FL-1 channel.
2.2.5 Single cell sorting
Single cell sorting was very generously performed by Matt MacKenzie (TechHub) on a BD
FACSAria Fusion cell sorter with a 100µm nozzle at 20 psi. Gates were set on the brightest
population of cells to ensure that both highly expressing and correctly editing clones were
selected.
2.2.6 Western Blotting
Clonal populations were expanded in 6-well plates (Thermo Scientific) before lysis in NP-40
buffer with proteolysis inhibitor (Sigma). Lysates were prepared by 30 minutes incubation
on ice in NP-40 with inhibitors before a final 10 minute spin at 14000 rcf. The supernatant
was then added to 2x reducing sample buffer and boiled for 5 minutes.
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Western Blots were prepared through SDS-PAGE on 4-12% gradient Bolt gels (Thermo
Scientific). Gels were run for 15 minute at 70 V, and 45 minutes at 125 V. Once run, each gel
was transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad) using a Turbo
transfer system (Bio-Rad).
After transfer, membranes were blocked with 4% BSA in 0.1% Tween-20 Tris buffered
saline (TBST) and probed with the relevant primary antibodies. Antibodies to α-tubulin
(Sigma - T9026), GAPDH (Abcam) and GFP (Thermo Scientific) were predominantly used
in this chapter. To determine cell line variability in the expression of TubA1B, a TubA1B
specific antibody (Abcam) was used. Values were normalized to loading controls (GAPDH).
Secondary incubations were performed using fluorescent antibodies (LiCor Instruments) in
TBST. Anti-mouse 680 and anti-rabbit 800 fluorescent antibodies were used for detection
using an Odyssey Fc (LiCor Instruments). Finally, Image Studio was used to quantify western
blots.
2.2.7 Imaging (PALM, dSTORM, and SRRF)
Clones of interest were imaged on 35mm MatTek Dishes (MatTek Corporation) on a Nikon
N-STORM system (Andor iXon Ultra DU897U EMCCD, Ti-E stand, Perfect Focus, Agilent
MLC400 laser bed). A 100x 1.49 NA TIRF Objective was used for each acquisition, which was
then reconstructed using ThunderSTORM 208 (Maximum Likelihood, Integrated Gaussian
PSF fitting). Live cell SRRF images were reconstructed from 100 frame acquisitions using
NanoJ-SRRF189.
Hel 92.1.7 cells were treated with phorbol 12-myristate 13-acetate (PMA) (Sigma) and
thrombopoeitin (TPO - a generous gift from Ian Hitchcock) overnight to drive spreading and
differentiation prior to imaging. Once seeded on MatTek dishes, cells were washed twice with
PBS before treatment with microtubule stabilising buffer (MTSB - 80mM PIPES pH 6.8,
1mM MgCL2, 4mM EGTA) and 0.5% Triton-X100 for 30 seconds before fixation with ice
Chapter 2. Development of CRISPR-PALM 53
cold Methanol at -20◦C for 3 minutes. Samples were then washed with TBST and imaged in
PBS for CRISPR-PALM. dSTORM samples were blocked (2% goat serum,1% BSA) before
staining with α-tubulin primary, and anti-mouse Alexa-647 secondary. Finally, these samples
were imaged in blinking buffer (100mM mercaptoehylamine-HCL, 1g/mL catalase, 50g/mL
glucose oxidase, PBS).
2.2.8 Statistical Analysis
Statistical analysis was performed using GraphPad PRISM 6, with statistical tests as indicated
in figure legends. Briefly, significance was determined using a 2-way ANOVA with multiple
comparisons (Tukeys). n = 3 across samples, and error bars represent standard deviation of
the mean.
Full Width Half Maxima (FWHM) were measured across microtubules by drawing a 5µm
line on ThunderSTORM reconstructed normalised Gaussian images. Each plot profile was
uploaded to Igor Pro (6.37) for multi-peak fitting. Fourier Ring Correlation for mEos 3.2
and dSTORM data was performed using the BIOP FRC plug-in. For mEos 4b data this was
performed using the recently published NanoJ-SQUIRREL plug-in209, 210.
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2.3 Results
To date, no other attempts at generating super-resolution single molecule data sets through
CRISPR knock-in have been reported. The closest study describes the insertion of Dendra
into RNA Polymerase II, but the authors do not evaluate the effects of the knock-in on
expression, nor on the resolution of the final image. The stringent sampling requirements
of imaging at 10-20nm resolution is critical in experiments where label density will be
determined by genomic expression. In classical PALM the use of over-expression, while
biologically problematic (particularly in receptor quantification), is helpful in that it provides
an abundance of labelled protein - and so satisfies this otherwise strict sampling criteria.
To that end the results that follow work to first establish the validity of using photo-
switchable tags for SMLM through endogenously expressed reporters.
2.3.1 CRISPR-Cas9 mediated knock-in of the photoswitchable
tag Dronpa into the TubA1B locus
While our long term goal is to study the effects of patient mutations on TubB1 and platelet
production, the absence of proplatelet forming cell lines means that the only viable method of
phenotypically screening the effect of mutations would be the use of iPSC differentiated MKs.
Unfortunately the literature to date shows that HDR efficiency is extremely low in iPSC,
making genome editing in iPSC a poor choice for developing and validating a methodology.
Similarly, at the beginning of this project we had no protocols for the differentiation of
iPSCs into mature, proplatelet forming MKs. As TubB1 is only expressed in terminally
differentiated megakaryocytes, this would hinder our efforts to investigate the feasibility of
using genomically introduced tags for our imaging.
With this in mind, our initial experiments targeted a ubiquitously expressed tubulin gene,
TubA1B in Hek293T. These cells have been extensively used in the literature to date as they
demonstrate a reasonably high rate of HDR and knock-out. We selected the photoswtichable
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tag Dronpa for our pilot experiments, Dronpa is a monomeric fluorescent protein with high
brightness and has been favourably reported in its applications in PALM211, 212.
4 guide sequences were designed using MIT’s Zhang lab guide tool (described in methods),
each targeting the N-terminus of the TubA1B gene (Figure 2.3A). Oligonucleotides for each
guide were synthesised, annealed, and cloned into BPK1520 empty vectors to form TubA1B
targeting guide vectors. These were validated first using a colony PCR, and finally by
sequencing (Figure 2.3B).
An HDR template was generated by designing homology arms flanking the N-terminus of
TubA1B, between which a Dronpa sequence was inserted. Each segment was ordered as a
gBlock from IDT and assembled into a pGem-T-Easy backbone (Figure 2.3C). While the
original homology arms were designed to be approximately 600bp each, issues in the synthesis
of the left (5’) arm resulted in a final design of 220bp for the left homology arm, 690bp for
the Dronpa insert, and 626bp for the right homology arm (Figure 2.3D). The presence of an
insert was first verified with an EcoRI restriction digest, with successfully cloned plasmids
appearing 1536bp in size compared to the 3000bp of the empty pGem-T-Easy backbone
(Figure 2.3E).
Representative control transfection FACS plots are demonstrated in figure 2.4A, where no
fluorescence is observed in the FL-1 channel in both untreated and Cas9-RFP only controls.
Conversely, 90% of cells transfected with a Dronpa α-tubulin over-expression vector are
positive in this channel. In cells treated with a mix of Cas9-RFP, donor vector, and the
relevant guide a small percentage of cells become positive in the FL-1 channel (Figure 2.4B)
suggesting successful HDR and integration of the donor repair template.
A comparison of all 4 guide sequences shows that guide C is the most efficient at facilitating
the insertion of the Dronpa tag at the target sequence (Figure 2.5). No significant difference
in median fluorescence intensity (MFI) is evident across any of the guides, consistent with
the fact that the introduction of the sequence for endogenous expression is unlikely to yield
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Figure 2.3: Generation of guide and donor plasmids for CRISPR knock-in tar-
geting the TubA1B locus. (A) Guide RNAs targeting the N-terminus of TubA1B were
cloned into a BsmBI stuffer cassette in a BPK1520 backbone. (B) Successful cloning was
validated using a colony PCR which successfully amplified the relevant sequence in each cloned
plasmid. (C) To introduce the Dronpa tag into the targeted locus, an HDR template with the
fluorescent protein flanked by homology arms was designed and cloned into a p-Gem-T-Easy
backbone. (D) This donor plamid featured 3000 base pairs (bp) of backbone, a 690bp Dronpa
sequence, and left and right homology arms (220 and 626bp respectively). (E) Successfully
cloned donor plasmids were validated by restriction digest before sequencing. Control pGem
appeared as a linearised 3000bp sequence, while successfully cloned HDR template plasmids
appeared as approximately 1500bp heavier.
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Figure 2.4: Successful integration of fluorescent donor template in cells transfected
with guide RNA and donor plasmid. Hek293T were co-transfected with Cas9-RFP,
guide, and donor plasmids. (A) Untreated and Cas9-RFP only controls show no fluorescence
in the FL1 channel, while over-expressed Dronpa α-tubulin results in a strong shift. (B) In
cells co-transfected with Cas9, guide, and donor plasmids a percentage of cells becomes FL-1
positive, indicative of successful HDR.
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any variation. Interestingly however, the MFI of each population is dramatically lower than
the over-expression control.
The highest efficiency guide (guide C) was taken forward to generate clonal populations
expressing tagged TubA1B. After single cell sorting, clones were expanded before DNA
extraction and subsequent genotyping. Primers designed as indicated in Figure 2.6 amplified
a 324bp wild type sequence, and where the Dronpa tag had been successfully inserted, a
1018bp fragment. The clones selected demonstrate a mix of different genotypes including
hetero- and homo-zygous cells. This result shows a successful insertion, and so the brightest
of these cells as determined by FACS were taken forward for further evaluation.
Dronpa clones 1, 4, 6, 7, and 11 were taken forward for further evaluation. Firstly,
cells were tested by flow cytometry after PCR validation to ensure fluorescent protein (as a
genomically expressed TubA1B fusion) was expressed. As shown in figure 2.7, each clone
was notably fluorescent in the FL-1 channel when compared to wild type. Lysates were
then collected for each clone and western blotting was performed to determine whether this
fluorescence was due to the expression of a Dronpa tagged α-tubulin.
Lysates were prepared for wild type Hek293T, validated Dronpa positive CRISPR clones,
and Hek293T transfected with Cas9-RFP and donor only. In WT, Cas9, and donor transfected
samples a mouse monoclonal antibody to α-tubulin detects a single band at the predicted
molecular weight of approximately 50 kDa (Figure 2.8A) cells transfected with 100ng and
500ng of the Dronpa over-expression plasmid, a second band at a molecular weight of 80 kDa
is observed. This is consistent with the predicted molecular weight of an α-tubulin fusion
with Dronpa. Each of our CRISPR clones are positive for a band at this weight, indicating
that a fusion protein of the correct molecular weight is expressed by each of the cells (Figure
2.8A). This was further confirmed by probing with a Dronpa specific monoclonal antibody
which recognises this 80kDa band(Figure 2.8B).
Surprisingly there is no difference in expression between heterozygous (clones 1, 4, 11) and
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Figure 2.5: Efficient knock-in using TubA1B targeting guide C. Hek293T cells were
co-transfected with Cas9-RFP, donor, and guide plasmids. Compared to untreated and Cas9
only controls, cells transfected with all 3 plasmids demonstrate a percentage of FL-1 positive
cells. Of the 4 guides tested, guide C presents the highest rate of HDR integration of the
Dronpa tag (6.82% ±1.2). No significant difference in median fluorescence intensity is evident
across any of the guides. One-way ANOVA with multiple-comparisons performed. n = 3.
Figure 2.6: PCR validation shows successful knock-in at target locus. After generat-
ing knock-in TubA1B Hek293T cells, individual clones were isolated using fluorescence assisted
cell sorting (FACS). Each clone was expanded before DNA extraction and genotyping by
PCR. Primers designed to flank the insert site generate a 324bp band for wild type sequence,
and a 1018bp band for successfully inserted alleles. Compared to WT cells, individual clones
demonstrate a mix of heterozygous and homozygous insertions of the Dronpa sequence.
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Figure 2.7: FACS of individual clones shows the presence of a fluorescent popula-
tion. Hek293T TubA1B -Dronpa clones validated by PCR were screened by flow cytometry to
ensure that a fluorescent protein was expressed. All 5 clones are positive in the FL-1 channel
when compared to wild type Hek293T, indicating that a functional fluorescent protein is
expressed in these cells.
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Figure 2.8: Western blotting of Dronpa tagged TubA1B Hek293T indicates ex-
pression of tagged tubulin. CRISPR tagged Hek293T were single cell sorted and expanded
for western blot analysis. (A) Negative control cells include wild type, untreated Hek293T,
as well as cells transfected with Cas9 vector (no guide or donor), and a donor only control.
In these samples, α-tubulin appears as a single band at approximately 50 kDa. As a positive
control, Hek293T were transfected with two concentrations of an over-expression Dronpa
tubulin vector, and in these samples a second band appears at approximately 80 kDa, the
predicted weight of a Dronpa α-tubulin fusion protein. In each of the PCR verified CRISPR
clones (1, 4, 6, 7, and 11) this heavier band is evident. (B) Lysates were probed with a
Dronpa specific antibody, and this detects the same band confirming the presence of a Dronpa
labelled α-tubulin in each CRISPR clone.
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homozygous clones (6 and 7). The loss of wild type TubA1B would in theory result in a loss
of the wild type protein, and as a result an increase in the expression of the Dronpa tagged
protein when compared to heterozygous clones. The fact that this is not observed suggests
that there may be a regulatory mechanism which silences a tagged gene if there is a negative
or deleterious effect on protein folding or function. Finally, there is no significant loss of
wild-type α-tubulin in homozogous clones suggesting that expression of the tagged allele is
regulated by compensatory mechanisms potentially increasing the expression of other WT
α-tubulin isoforms. Alternative explanations include the potential presence of an additional
copy of the wild type protein, as well as potential translocations or deletions in one of the
targeted alleles which results in an erroneous insertion at one of the targeted alleles.
2.3.2 Evaluation of endogenously expressed Dronpa tagged α-tubulin
as a method of single molecule imaging.
To investigate whether the Dronpa fusion maintains the photoswitchable characteristics of the
fluorophore, PALM imaging was performed on clone 7 and compared to dSTORM imaging of
α-tubulin in Hek293T (Figure 2.9). Unfortunately the resulting Dronpa image appears poor
both in widefield and as a super-resolved image, with indistinct microtubules when compared
to the dSTORM equivalent. This was verified by comparing the full width half maxima
(FWHM) of dSTORM with that of the Dronpa images (Figure 2.10). While distinctive peaks
with FWHM ranging as low as 41.96nm are apparent in dSTORM image plots, the line profile
from the Dronpa-PALM image is poor with FWHM as high as 232.06nm.
SMLM data sets can be compared quantitatively by looking at the total number of
detections or localisations as in Figure 2.11A, which shows a significantly reduced number
of detections in Dronpa Clone 7 when compared to the dSTORM image (** p =0.0016).
Similarly, the mean xy uncertainty of the Dronpa cell is substantially higher than that of
the dSTORM image, though this is unsurprising considering the dramatically higher photon
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Figure 2.9: Comparison of dSTORM and CRISPR-PALM Dronpa images shows
poor quality SMLM in Dronpa knock-ins. In Hek293T wild type cells labelled with an
α-tubulin antibody, dSTORM imaging shows consistent microtubules. In comparison Dronpa
PALM imaging of a CRISPR knock-in clone shows an uneven distribution of the labelled
protein.
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count of organic fluorophores (** p = 0.0191). Finally, as demonstrated by Figure 2.11B, the
number of detections per frame rapidly tails off in the Dronpa clone, while it is sustained
over the 20,000 frames observed in the dSTORM image.
Together this data shows that while a successful insertion of Dronpa at the target TubA1B
locus successfully results in the genomic expression of a photoswitchable tag, there are a
number of considerations which appear to impact the quality of the resulting SMLM image.
The above comparisons to dSTORM, the gold standard of SMLM in terms of resolution,
show that Dronpa tagging of the TubA1B gene does not produce high quality single molecule
images. This is likely due to the low expression of the tagged protein across all Dronpa
clones, regardless of whether they are hetero- or homo-zygous for insertion, as well as the
poor performance of Dronpa as a SMLM reporter in the context of endogenous expression,
despite previous applications in the literature in standard PALM.
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Figure 2.10: Comparison of full width half maxima (FWHM) in dSTORM and
CRISPR-PALM Dronpa images shows poor resolution of microtubules in Dronpa
knock-in clones. FWHM are a classical means of comparing effective resolution in super-
resolved images. In these cropped images, there are substantial qualitative and quantitative
differences in the performance of CRISPR-PALM when compared to dSTORM. While
dSTORM shows continuous microtubules and bundles, the Dronpa image shows poor label
distribution, and as a result poorer FWHM. Red lines indicate raw peak values as determined
by line profiles in ImageJ, while red lines indicate the ’fit’ and resulting FWHM as measured
by automated peak fitting in IgorPro.
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Figure 2.11: Quantitative comparisons between dSTORM and CRISPR-PALM
through Dronpa insertion support poor performance of Dronpa knock-in as a
single molecule system. Hek293T wild type cells imaged with dSTORM were compared
to Dronpa tagged CRISPR clones. (A) Compared to dSTORM, Dronpa tagged clone 7 shows
a significantly reduced number of localisations, consistent with the poor resolution in the
images previously shown (** p =0.0016). Similarly Dronpa images show a significantly higher
mean XY uncertainty indicative of poor SMLM imaging (** p = 0.0191). (B) A comparison
of detections per frame shows that the Dronpa sample quickly tails off, while dSTORM
imaged cells continue to detect molecules over the 20,000 frames observed. n = 3, S.D.,
Student’s T-Test performed.
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2.3.3 mEGFP and mEos 3.2 tagged TubA1B
The work presented thus far in this chapter demonstrates the successful insertion of a
photoswitchable fluorescent tag in a targeted genomic locus through CRISPR-Cas9. However,
these results show that the process of generating a robust method of single molecule imaging
through genomic knock-in will have its own complications. Firstly, the expression level of
the tagged allele observed is lower than expected, the fact that even homozygous knock-ins
do not appear to surpass a particular level of expression suggests that there is a regulatory
mechanism which maintains cell function and morphology at the cost of the expression of a
targeted allele. This could be due to the tag used and the properties of both its sequence
and encoded protein (monomericity, maturity, etc.), or due to the cell line used.
To address where and why Dronpa-TubA1B performed poorly as a method of CRISPR-
PALM, donor vectors were redesigned to include mEGFP and mEos 3.2 sequences, flanked by
homology arms and a linker identical to the Dronpa donor. mEGFP is a highly monomeric,
rapidly maturing, codon optimised, bright fluorescent protein. mEos 3.2 is a photoconvertible
fluorescent protein which shifts its emission spectra upon excitation with ultraviolet light213, 214.
This photoconversion from an emission maxima of approximately 460 to 560 combined with
subsequent bleaching at the 560 wavelength allows for the generation of stochastically activated
fluorophores ideal for PALM. mEos 3.2 offers distinct advantages over other photoconvertible
fluorophores - perhaps most significantly a higher photon count which is critical to high
quality PALM214. While the fluorophore does not retain the brightness of Dronpa, nor its
capacity for reversible photoswitching, it offers an important alternative in this work. Namely
photoswitching kinetics which can improve the poor quality of CRISPR-PALM reported thus
far.
Donor vectors were designed and cloned according to the same criteria as the previously
reported Dronpa donor (Figure 2.12). Identical gBlocks for left and right homology arms
were cloned into a pGem-T-Easy vector with either an mEos 3.2 or mEGFP donor (Figure
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Figure 2.12: Design and cloning of TubA1B mEGFP and mEos 3.2 donor vectors.
(A) mEos 3.2 and mEGFP inserts were designed using the same approach as the Dronpa
approach, with the candidate insert flanked by homology arms and a short linker. (B) gBlocks
for an mEos 3.2 insert were ordered with overlapping arms flanking the fluorophore for cloning
into a pGem-T-Easy backbone. (C) A similar gBlock was synthesised to generate an mEGFP
donor vector. (D) Inserts were cloned in using Gibson Assembly, with individual clones
validated using an EcoRI digest. An EcoRI digested empty pGem-T-easy control vector runs
at 3000bp, while a correct insert will result in two bands, one at 3000bp and the other at
approximately 1500bp.
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2.12A, B, C). Clones were subject to a test EcoRI digest and compared to a blank donor
vector (Figure 2.12D). Clones positive for the correct insert presented with both a 3000bp
and 1500bp band. Positive clones were sequenced to verify correct assemblies and taken
forward for transfection experiments.
Hel 92.1.7, A549, and Hek293T cells were co-transfected with a px459 guide RNA
expressing vector carrying the previously reported guide C and either the successfully cloned
mEGFP or mEos 3.2 donor vectors. Cells were then single cell sorted and surviving clones
expanded before DNA extraction and PCR to validate the presence of an insertion at the
TubA1B locus (Figure 2.13). Genotyping of these cells by PCR showed primarily heterozygous
insertion of both mEGFP and mEos 3.2, with the exception being two mEos 3.2 clones
(Clones 13 and 15) in Hel 92.1.7 cells.
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Figure 2.13: Genotyping of single cell sorted TubA1B knock-in clones shows suc-
cessful insertion of both fluorophores. After single cell sorting and clonal expansion,
DNA was extracted for mEGFP and mEos 3.2 clones for each of the three target cell lines
(Hel 92.1.7, Hek293T, A549). As with the Dronpa clones previously reported, successfully
targeted clones will feature a band at approximately 1000bp. Most clones are heterozygous
for insertion, with the exception of two Hel 92.1.7 mEos 3.2 clones which demonstrate a
homozygous knock-in and as a result the loss of a wild type band (Clones 13, 15).
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Figure 2.14: Western blot analysis of TubA1B knock-in clones reveals a tag and
cell line dependent expression of tagged tubulin. PCR validated clones were expanded
and lysates prepared for western blotting. (A) Western blot analysis of Hel 92.1.7, A549, and
Hek293T clones tagged with mEGFP and mEos 3.2 reveals a successful genomic expression
of the tagged protein, however with an obvious variation in tag expression across all three
cell lines. (B) Quantification of these gels reveals both a tag and cell line dependent level
of tagged TubA1B expression. Hel 92.1.7 consistently expresses the highest level of tagged
α-tubulin, however there is a statistically significant difference in expression between tags
(**** p < 0.0004). A549 and Hek293T cells show a markedly lower expression of tagged
TubA1B, with mEos tagged cells from both lines showing a significant down regulation when
compared to mEGFP equivalents (** p < 0.0014 and *** p < 0.001) respectively. n = 3,
S.D., Two-Way ANOVA with multiple comparisons.
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Figure 2.15: Cell line specific expression of TubA1B impacts label distribution for
SMLM imaging through endgenous expression. Western blotting of wild type Hel
92.1.7, A549, and Hek293T lysate shows with a TubA1B specific antibody shows that Hel
92.1.7 cells express TubA1B higher than A549 and Hek293T.
Chapter 2. Development of CRISPR-PALM 73
Positive cells were taken forward for western blot analysis to quantify the expression level
of tagged TubA1B. Interestingly, both a cell line and tag-dependent regulation of expression
was observed (Figure 2.14A). Across all three cell lines, mEGFP tagged tubulin is well
expressed, conversely mEos 3.2 tagged TubA1B is consistently down-regulated. A cell line
dependent relationship is also observed, which is likely attributable to varying expression of
this specific α-tubulin isoform in the cell lines studied (Figure 2.15).
Out of the three cell lines tested here, Hel 92.1.7 tagged clones most highly express tagged
α-tubulin at approximately 20% for mEGFP and 15% in mEos 3.2 labelled clones. A549 cells
express mEGFP tagged α tubulin at approximately 10% compared to 3% mEos 3.2, and
finally Hek293T express mEGFP-TubA1B at between 8 and 15 compared to 2% for mEos 3.2.
These findings are surprising as no previous work has demonstrated a sequence dependent
downregulation of endogenously expressed fusion proteins.
Expression level is likely to have a significant effect on SMLM due to the stringent
labelling requirements inherent to nanoscopic resolution. As demonstrated in figure 2.16,
TubA1B -mEGFP folds correctly and assembles into distinct microtubules which co-stain
with α-tubulin antibody. These cells are potentially powerful tools for long term live cell
imaging using lightsheet modalities, where the high SNR can compensate for the relatively
low brightness compared to over-expressed cells.
As expected however, the variation in expression has a substantial impact on the quality
of CRISPR-PALM images as demonstrated in figure 2.17. Here CRISPR-PALM images are
compared to dSTORM, and while Hel 92.1.7 cells demonstrate clearly resolved microtubules
which compare favourably with dSTORM, the other two cell lines studied show punctate,
incomplete structures when compared to the antibody based technique.
SMLM images can be compared through quantitative means to determine the quality of
the data sets acquired. When comparing mean and mode localisation precisions, CRISPR-
PALM in Hel 92.1.7 cells does not significantly differ from dSTORM data, however both A549
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Figure 2.16: TubA1B-mEGFP knock-in cell lines express correctly folded tubulin
at sufficient brightness for diffraction limited imaging. mEGFP TubA1B knock-in
cells all show correct folding and expression of α-tubulin which co-stains well with an α-
tubulin antibody. Despite the lower expression of the tagged protein in A549 and Hek293T,
there is sufficient label density for diffraction limited imaging.
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Figure 2.17: Comparison of mEos 3.2 knock-in cells and dSTORM α-tubulin shows
SMLM imaging dependent on cell line specific expression. CRISPR-PALM (mEos
3.2 knock-in) imaging was performed in A549, Hek293T, and Hel 92.1.7 cells and compared
to dSTORM images of α-tubulin labelled wild type cells. In A549 and Hek293T dSTORM
imaging shows clearly resolved microtubules, while the respective CRISPR-PALM image
suffers from a lack of sufficient labelling evidenced by poor, incomplete MTs. Interestingly,
Hel 92.1.7 cells express enough mEos 3.2 labelled α-tubulin to achieve comparable SMLM
images.
Figure 2.18: Quantitative comparison of CRISPR-PALM and dSTORM confirms
cell line specific quality of SMLM imaging. A quantitative comparison of CRISPR-
PALM through knock-in of mEos 3.2 with dSTORM images shows that the expression level
has a substantial effect on the quality of subsequent single molecule imaging. Two key metrics
are compared here, localisation precision (mean and mode) and total number of localisations.
Across all three measurements, a significant variation is observed across cell lines (**** p ¡
0.0001). In Hel 92.1.7 cells, which highly express the mEos 3.2 tagged tubulin, mean and
mode localisation precision and total number of localisations are not significantly different
when comparison to dSTORM. In A549 and Hek293T however, a statistically significant
difference in all measurements is evident. This is consistent with poor quality SMLM as a
result of the down regulation of the mEos 3.2 tagged allele. n = 3, S.D. Statistical testing
performed using a 2-Way ANOVA with multiple comparisons.
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and Hek293T cells are significantly poorer compared to dSTORM (**, * for mean and modal
precision respectively according to multiple comparisons). While the higher photon budget
of organic fluorophores does naturally improve the localisation precision of subsequent fits,
the precision measured in ThunderSTORM reconstructions is also affected by background
and out of focus detections which are likely to be significant in antibody labelled samples.
Similarly the total number of localisations is significantly reduced in CRISPR-PALM A549
and Hek293T cells when compared to dSTORM, while there is no significant difference
between the number of localisations in Hel 92.1.7 samples.
Finally measures of effective resolution can be applied to compare the quality of CRISPR-
PALM to dSTORM. A collection of full width half maxima (FWHM) of microtubules across
all cells observed shows no significant difference in FWHM between dSTORM and CRISPR-
PALM in Hel 92.1.7 cells (Figure 2.19) (p = 0.086). Using a relatively recent measure of
effective resolution called the Fourier Ring Correlation method a slight improvement in
Fourier Image Resolution (FIRE) can be observed in CRISPR-PALM cells (p = 0.0447)215.
This is most likely due to the more even labelling density observed in CRISPR-PALM cells
(as FIRE calculation takes sampling density into account).
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Figure 2.19: Effective resolution in CRISPR tagged Hel 92.1.7 TubA1B is com-
parable to dSTORM. CRISPR-PALM images of Hel 92.1.7 were further evaluated to
determine how effective resolution of this modality compares to dSTORM. (A) (i) a represen-
tative line profile shows (ii) clearly resolved peaks. When these are compared to dSTORM
images across multiple replicates, no significant difference is observed between the two modali-
ties. (p = 0.086) (C) A comparison of Fourier ring correlation (FRC) as a measure of effective
resolution shows a significant improvement in CRISPR-PALM when compared to dSTORM,
presumably due to the consistent labelling density in the genomic expression of tagged protein
(p = 0.0447). n = 3, S.D. Statistical testing performed using unpaired t-test.
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2.3.4 Applications of CRISPR-PALM cells
Multiplexing has been a significant issue in the field of SMLM due to the substantial difference
in fluorophore performance - both in PALM (between photoswitchable fluorophores) and
dSTORM (between organic fluorophores). A CRISPR-PALM approach offers a relatively
simple method of combining high performing dSTORM fluorophores (e.g. Alexa647) with
well characterised PALM tags (mEos 3.2), without the loss of performance in particular
blinking buffers. In figure 2.20 Alexa-647 labelled TTLL10, a tubulin ligase, is imaged in a
Hel 92.1.7 clone edited to express TubA1B -mEos 3.2. The result is high quality SMLM where
spatial relationships between tubulin and its accessory protein are revealed at nanoscale
resolutions.
Another significant advantage of CRISPR-PALM is the option of live cell imaging,
particularly over periods of time which would exceed those allowed by transient transfection
(48-72 hours). Significant concerns in live localisation microscopy include phototoxicity and
temporal resolution - while classical PALM would require millions of localisation events
to be recorded within each acquisition, more recent advances which utilise non-linearity
in photoswitching data sets can super-resolve without over exposure to light (and hence
toxicity), or a loss of temporal resolution. Most significant of these is the recent development
of SRRF (Sub-pixel radial fluctuations), an approach which uses sub-pixel radial symmetry
to super-resolve at sub-second temporal resolutions and low light intensities (Figure 2.21).
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Figure 2.20: Multiplexing CRISPR-PALM and dSTORM for convenient two-
colour SMLM. Multiplexing SMLM tags has classically been a challenge due to the diverse
photochemistry and blinking kinetics of organic fluorophores. The use of a CRISPR-PALM
approach compliments the use of high performance dSTORM antibodies for high quality
two-colour imaging without the need to compromise on one of the two reporters used. Here
two-colour imaging is used to achieve nanoscopic resolution of both TubA1B (green) and
TTLL10, a tubulin ligase (magenta).
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Figure 2.21: CRISPR tagged mEos 3.2-TubA1B Hel 92.1.7 cells allow for super-
resolved live cell imaging. An endogenous expression system offers many other benefits,
including the capacity for live cell imaging. (A) A recent publication applied the use of
sub-pixel fluctuations to super-resolve at low laser intensities. This approach, called SRRF,
can be used on mEos 3.2 knock-in Hel 92.1.7 cells to image the endogenously labelled TubA1B
gene at sub-second temporal resolutions. (B) FWHM from a sample frame show effective
super-resolution in the SRRF image compared to an equivalent averaged widefield frame.
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2.3.5 Fluorophore properties directly impact protein expression
after CRISPR-Knock-in
The sequence specific downregulation of tagged TubA1B observed in our knock-in cells is a
surprising finding with significant consequences for the field of CRISPR mediated knock-in.
To determine whether fundamental properties of the fluorophore and its sequence drive this
effect, three mEos variants were designed and cloned into the donor plasmid (Figure 2.22A).
A codon optimised mEos 3.2 variant, as well as the recently reported mEos 4b and a codon
optimised variant of the original sequence. mEos 4b has been reported as a truly monomeric
variant of mEos216. Each of these fluorophore sequences were cloned as previously described
using Gibson assembly, and after clonal isolation and expansion, digested with EcoRI to
validate the presence of an insert (Figure 2.22B). Sequence alignments as shown in figure
2.22 indicate variations in the 4b sequence from the original 3.2 insert, and that codon
optimisation does not alter the protein sequence of these inserts.
Sequence validated donors were then co-transfected in Hel 92.1.7 cells with a px459
TubA1B -guide C plasmid and single cell sorting (Figure 2.23A). As Hel 92.1.7 cells best
express TubA1B, they provide a good sample in which to try and reverse the downregulation
of mEos observed. As shown in figure 2.23A, wild type cells are negative for signal in the
FITC channel, while validated mEos 3.2 expressing clone 13 is positive for signal in this
channel. Blots for mEos 4b and its codon optimised variant show a higher rate of insertion
compared to the codon optimised mEos 3.2 (5.31% and 5.70% respectively compared to
1.9%).
After single cell isolation and expansion, individual clones were genotyped and validated
by PCR amplifying the targeted region (Figure 2.23B). Once again positive clones are
predominantly heterozygous (with one exception - mEos 4b clone F8), demonstrating a band
approximately 700bp heavier than wild type as expected.
Validated clones were then subjected to western blot analysis to determine whether
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Figure 2.22: Generation of TubA1B donor plasmids with mEos variants. (A) Donor
plasmids with identical linkers and homology arms harbouring mEos variants were designed.
These include a codon optimised mEos 3.2 sequence, as well as a truly monomeric version of
the protein reported as mEos 4b, and a respective codon optimised variant. (B) gBlocks were
cloned into pGem-T-Easy backbones and validated through EcoRI digest. Negative controls
are 3000bp in length, while successfully cloned vectors demonstrate an insertion which runs
at approximagely 1600bp. Finally sequence alignments show differences in the 3.2 and 4b
protein sequence, and that codon optimisation does not alter the reading frame or coding
sequence reported. Amino acids marked in red are where the mEos 4b protein differs from
its predecessor mEos 3.2.
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Figure 2.23: Single cell sorting and PCR based genotyping of Hel 92.1.7 clones
carrying mEos variants to determine successful integration. (A) Hel 92.1.7 cells
co-transfected with a guide targeting TubA1B and donor templates carrying codon optimised
mEos 3.2, mEos 4b, and codon optimised mEos 4b were single cell sorted into a 96 well
plate. Cells were compared to previously generated mEos 3.2 clone 13 which stably expresses
TubA1B -mEos 3.2 fusion as a knock-in, and is therefore a completely fluorescent population
and a useful positive control. (B) Clones were expanded and validated by PCR. The
amplification of wild type DNA results in a 300bp band, while heterozygous clones positive
for fluorophore insertion at the TubA1B locus also feature a second band at approximately
1000bp.
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varying the properties of mEos and its sequence impact the expression of tagged α-tubulin
(Figure 2.24A). Quantification of these western blots shows that while there is no significant
difference between codon optimised mEos 3.2 and the parent sequence, there are significant
differences between the mEos 3.2 clone and both mEos 4b and mEos 4b codon optimised.
Surprisingly, expression of mEos 4b is significantly reduced across all three clones (*** p =
0.0016, p = 0.0015, p = 0.0023 for each clone respectively), but elevated in 2 of the three
codon optimised mEos 4b knock-in cells (** p = 0.0084, ns p = 0.1, * p = 0.011 respectively).
The improved expression of the codon optimised mEos 4b knock-in suggests that a
highly monomeric, codon optimised of mEos is better suited to SMLM due to the improved
abundance and distribution of labelled protein. PALM performed on codon optimised mEos
4b clone C4 results in high quality super-resolution imaging (Figure 2.24C), with significantly
more localisations observed in total and across each frame when compared to mEos 3.2
knock-ins (* p = 0.0230) (Figure 2.24C,D). There is no significant difference in FRC or XY
uncertainty, consistent with the fact that despite the improved expression, mEos variants still
demonstrate the same fundamental fluorophore properties (molecular brightness, quantum
yield, switching kinetics etc.) (p = 0.3844 and p = 0.0861 respectively) (Figure 2.24E, F).
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Figure 2.24: Improved expression of a codon optimised, monomeric mEos variant
results in high quality CRISPR-PALM. Hel 92.1.7 cells expressing mEos variants are
compared to mEos 3.2 knock-ins by western blot and imaging. (A) Western blotting shows a
substantial improvement in tagged tubulin expression in cells labelled with codon optimised
mEos 4b when compared to other mEos variants. (B) Quantification of western blotting
shows no significant difference in expression when comparing codon optimised mEos 3.2 and
the original mEos 3.2 knock-in. mEos 4b demonstrates a significant reduction in expression
(** p = 0.0016, p = 0.0015, p = 0.0023 for each clone respectively), while codon optimised
mEos 4b shows significantly improved expression when compared to mEos 3.2 (** p = 0.0084,
ns p = 0.1, * p = 0.011 respectively). (C) The improved expression of mEos 4b CO results in a
higher number of detections reported per frame compared to mEos 3.2. (D) Codon optimised
mEos 4b demonstrates a significantly higher number of localisations when compared to mEos
3.2 knock-in clones (* p = 0.0230). (E) No significant difference in fourier ring correlation is
observed (p = 0.3844). (F) Similarly no difference in xy uncertainty is observed as expected
from mEos variants (p = 0.0861). (n = 3. S.D., Two-Way ANOVA with multiple comparisons
for western blot experiments. Unpaired t-tests performed for uncertainty and number of
localisations.)
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2.3.6 Towards a two-colour CRISPR-PALM approach
Finally to begin developing CRISPR-PALM as a two colour approach, TubA1B donors
carrying a HaloTag™insert were generated. HaloTag™refers to a modified bacterial enzyme
(a haloalkane dehalogenase) is capable of hydrolysing choloroalkane linkers on synthetic
ligands or organic fluorophores 217, 218. The enzyme can be expressed instead of a fluorescent
protein, and is therefore not fluorescent in its native state. However, on incubation with a
label conjugated to an appropriate chloroalkane linker, the enzyme hydrolyses the linker to
effectively bind the reporter.
This approach allows for genomic expression, and thus the control of labelling stoichiometry,
as well as a a range of different choices in terms of fluorophores and the advantageous photon
counts typical of organic fluorophores217, 218. Cell impermeable labels (e.g. Alexa Fluor,
Atto-488) can be used to label membrane bound elements and image their internalisation,
while permeable fluorophores (e.g. TMRs, Janelia Fluor) can be used to label intracellular
components. Such an approach offers a great deal of experimental flexibility and the benefits
of both expression mediated labelling and the brightness and photostability of organic
fluorophores217.
As previously described, a codon optimised HaloTag™sequence was cloned into a TubA1B
donor plasmid and validated (Figure 2.25A,B) before co-transfection into Hel 92.1.7 cells
with TubA1B targeting guide C. HaloTag™cells were single cell sorted after incubation with
Janelia Fluor 546 (which appears positive in the PE channel) (Figure 2.25C).
Single cell clones were imaged with JF546 and evaluated for expression using western blot.
While the cells demonstrate tagged α-tubulin comparable to mEGFP (Figure 2.26A), western
blot based quantification of tagged protein shows low levels of expression (approximately
5%), substantially lower than both mEGFP and any mEos variant.
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Figure 2.25: Generation of donor plasmid carrying codon optimised HaloTag™and
subsequent single cell sorting post-transfection. (A) A donor vector carrying a codon
optimised HaloTag insert flanked by TubA1B specific homology arms was designed and
cloned into a pGem-T-Easy backbone. (B) Clones were validated by EcoRI digest before
sequencing to confirm correct assembly. (C) Validated TubA1B HaloTag™donors were then
co-transfected with a guide and Cas9 expressing plasmid before single cell sorting.
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Figure 2.26: Knock-in of HaloTag™at the TubA1B locus in Hel 92.1.7 cells results
in a substantial down-regulation of the tagged allele. (A) TubA1B HaloTag™knock-
in clones fold correctly and are comparable to mEGFP clones after incubation with Janelia
Fluor 646. (B) Expression of HaloTag™was evaluated by western blot and found to be low
(approximately 5%) compared to previously reported expression levels of other tags.
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2.4 Discussion
The use of CRISPR-PALM as a means by which to generate SMLM data sets has the potential
to address a number of long standing issues in the field of single molecule imaging. Most
significantly perhaps, a known stoichiometry promises accurate quantification, particularly
when combined with the known switching kinetics of a photoswitchable tag. The use of
endogenous expression would overcome the issues associated with transfection inherent to
PALM, and allow for super-resolution imaging of novel genes for which quality antibodies
would likely be unavailable.
However the caveat to endogenous expression will be the loss of labelled protein in
the sample - previous attempts at PALM have always benefited from saturating cells with
labelled protein to satisfy the strict labelling/sampling criteria of single molecule localisation
microscopy. A challenge in developing a single molecule system based on endogenous expressed
will be expressing enough labelled protein to achieve nanoscopic resolutions - in the work
reported thus far, this is further complicated by an apparent sequence dependent down
regulation of tagged tubulin.
This work presents an efficient method of cloning donor sequences to generate CRISPR
tagged knock-in lines. The use of gBlocks (synthetic DNA) and Gibson assembly has allowed
for the generation of multiple donor sequences with relative ease. A host of other donor
plasmids carrying alternative tags not presented here have been produced for future work -
including rsKame, rsFastLime, mApple, PAmCherry, and rsTagRFP. Future work will involve
comparing knock-ins of these to determine which fluorophores are best expressed and what
properties determine this.
The work presented in this chapter demonstrates the first attempt to establish a CRISPR
based method of single molecule imaging. Microtubules are an ideal test subject as they
present a number of challenges which, if overcome, can yield high quality images. As
structures well beneath the diffraction limit (25nm diameter) they are ideally suited for
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SMLM, however to achieve resolution in the tens of nanometers sufficient labelling of these
cytoskeletal structures needs to be achieved.
The lack of homozoygous knock-ins across all three cell lines has been surprising - we
reason that this is likely to affect microtubule formation, and hence cell viability. At the
time of the publication of this work, no discussion of the potentially deleterious effects of
bi-allelic insertion was found in the literature. Since then, work by the Allen Institute in the
generation of stem cell libraries independently confirmed that it was not possible to produce
bi-allelic TubA1B CRISPR knock-ins219. Roberts et al. report a generally low incidence of
bi-allelic insertions across a number of genes. Interestingly in one of the only other approaches
designed to apply knock-ins for super resolution microscopy (RESOLFT), Ratz et al. report
bi-allelic insertions for two of their genes (ZYX and HMGA), but only mono-allelic knock-in
for their cytoskeletal target, Vimentin. While the authors do not quantify their knock-in of
rsEGFP2, their data suggests that they too are restricted to mono-allelic insertions for this
target.
This finding has important implications for the application of CRISPR-Cas9 for HDR
mediated fluorophore insertion, particularly in the context of the sequence and fluorophore
dependent down regulation of tagged alleles reported in this chapter. To our knowledge, no
work to date has reported this phenomenon - however it stands to reason that there are
cellular mechanisms which maintain morphology and function at the cost of the translation of
a potentially detrimental gene. In this work, it would appear that monomericity (mEGFP and
mEos 4b are highly monomeric) and codon optimisation (mEGFP and codon optimised mEos
4b) are important factors in determining the expression of tagged alleles220, 216. Interestingly,
codon optimisation of mEos 3.2 is insufficient to achieve high levels of expression, suggesting
that in this instance the monomericity of the protein restricts expression.
Comparisons between transfected and knock-in cells show that knock-ins maintain a cells
native morphology and function221, 206. In work by Uemura et al., endogenous expression of
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an EGFP β-actin fusion does not alter dendritic spine morphology or function - in contrast,
over-expressing the equivalent fusion protein results in aberrant morphology and growth.
Similarly Ratz et al. demonstrate an alteration of morphology and protein distribution in
over-expression cells when compared to equivalent knock-ins. In the context of the work
presented in this chapter, it is likely that knock-in cell lines down-regulate protein to maintain
morphology and function. To our knowledge, this has not been explicitly reported in the
literature. Similarly the sequence dependent effect observed here has not, to our knowledge,
been reported, with significant implications for the wider application of CRISPR knock-in.
On one hand, the preservation of function at the cost of expression is biologically ad-
vantageous. A long standing criticism of transfection has been the aberrant expression of
fusion proteins, and hence, biological artefacts as a result. In quantitative SMLM, which has
particular applications in receptor biology, this can lead to clustering artefacts dependent on
expression level. CRISPR knock-in offers a means by which to ameliorate this by allowing
cells to regulate the genomic expression of fusion proteins in the interest of biological integrity.
Unfortunately, a caveat to this will be the loss of signal which is critical to high quality live
cell imaging. It is also likely that some genes will not tolerate genomically expressed fusion
proteins, and that some fluorescent proteins will have a detrimental effect on expression as
we have observed in this work.
While we have observed that high quality SMLM comparable to dSTORM can be achieved
through CRISPR-PALM, the sequence dependent down-regulation of tagged alleles is an
extremely important observation. While this work establishes a role for monomericity and
codon optimisation in altering endogenous expression, a host of other important fluorophore
parameters have yet to be explored. It is likely that maturation rates, size, and linker design
may play a role in regulating expression level. Future work in this and other labs should aim
to develop fluorophores optimised for CRISPR knock-in. Similarly the careful quantification
of protein expression after knock-in should become best practice after CRISPR knock-in.
Chapter 3
Development of iPSC Protocols
The lack of platelet producing cell lines has been a significant obstacle in the field of
megakaryocyte and platelet biology. The absence of a reliable, high throughput in vitro
approach has restricted much of the work in MK and platelet biology to mouse models,
patient samples, and relatively poor leukaemic cell lines. In the context of the study of
inherited thrombocytopenias, and in particular the GAPP study, this is a significant obstacle
when studying novel genes and/or mutations.
In this chapter two key technologies are discussed in the context of their applications in this
field, namely induced pluripotent stem cell (iPSC) differentiation and Clustered Repeating
Interspaced Palindromic Repeat (CRISPR) gene editing. After a brief introduction, efforts
to generate differentiation models and to introduce CRISPR knock-ins to stem cells are
reported.
3.1 Chapter Introduction
While a number of cell lines exist which express a range of MK markers, no existing
immortalised cell line produces proplatelet extensions or platelets in vitro222. As such murine
bone marrow and foetal liver derived megakaryocytes have been a staple tool in interrogating
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platelet production223, 224, 110. That being said, the generation of mouse models is an expensive
and time consuming business which as such, is by its nature, low throughput.
Human cord and peripheral blood derived megakaryocytes have been one of the main
methods of obtaining functional, human megakaryocytes to study. Once isolated from CD34+
cells, mature megakaryocytes can be generated after approximately 12 days of culture. These
cells can then proceed to form proplatelet structures in vitro in a substrate and time dependent
manner 225.
However the yield of proplatelet forming MKs has always been very low in these human
derived cells, and while they can be virally manipulated to introduce reporter proteins and
mutant phenotypes this process is often detrimental to cell viability226. In cultures where the
number of cells derived is usually quite low, the effect of viral manipulation on sample size
can have a significant effect on the quality and throughput of experiments.
With these limitations in mind, stem cell technologies offer a solution to the problem of a
robust, high throughput in vitro assay to screen mutations and proteins of interest in mature,
stem cell derived MKs. The key question is whether current methods of iPSC differentiation
can yield the numbers of proplatelet producing cells needed for the quantitative phenotypic
study of mutations of interest.
3.1.1 Methods of iPSC derived megakaryocyte differentiation
In one of the most significant works of modern regenerative medicine, Takahashi et al.
published the successful reprogramming of adult mouse fibroblasts to form colonies with stem
cell like pluripotency, later dubbed induced pluripotent stem cells (iPSCs)227.
Plasticity in somatic cells had been previously shown, first in the 1960s where the injection
of a nucleus from an adult somatic cell into an enucleated oocyte results in the development
of a healthy frog228, 229. These findings were later corroborated by the successful cloning
of ’Dolly’ the sheep as a phenomenon reproducible in mammals230. These somatic cell
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nuclear transfer (SCNT) approaches challenged the dogma of terminal differentiation, and
demonstrated the presence of re-programming factors with the capacity to introduce the
epigenetic changes needed for pluripotency. Takahashi et al.’s seminal work resulted in a
significant leap forward as reprogrammed adult stem cells overcome many of the ethical and
logistical issues inherent for the use of embryonic human stem cells231.
In the field of megakaryocyte and platelet biology iPSC differentiation presents an
opportunity to develop human, mature, proplatelet producing cells in vitro232. The driving
force behind the development of mature iPSC MKs is the potential for the generation of
large numbers of potentially transfusable platelets232. As anucleate cells in constant demand
in blood banks globally, stem cell derived platelets are a viable option for the first ex vivo
cell type generated for transfusion233.
Directed differentiation is one of the key methods by which iPSCs can be driven towards a
particular cell lineage. These approaches typically depend on the use of a substrate to support
differentiation and the introduction of an array of cytokines designed to drive differentiation
towards a germ layer. To generate MKs, this method is based on the induction of medodermal
differentiation through BMP4 (Bone Morphogenic Protein-4) and Wnt signalling234. This
mesoderm like layer is further driven towards haematopoeitic differentiation by the formation
of haemogenic endothelium (or a haematoendothelial mesoderm). Early work applied this
method to the production of MKs and platelets from human Embryonic Stem Cells and
on feeder layers235. While effective, these approaches are limited in their applicability in
transfusion medicine (where animal derived culture components are strictly forbidden and
large scale stem cell culture and production are needed), and as such later work has focussed
on applying these techniques to induced pluripotent stem cells235, 236, 237.
Feng et al. applied directed differentiation to generate a large population of mature iPSC
derived MKs in a feeder free format, however these cells generate an extremely small number
of platelets (approximately 6 per MK) compared to the several thousand produced in vivo238.
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The authors drive pluripotent cells towards a mesoderm lineage by plating on Collagen IV
and incubating cells in a phase I medium containing VEGF, FGF, and BMP-4 at 5% oxygen.
After 6 days of culture, the authors incubate their haemogenic endothelium in a second
cocktail of cytokines including factors critical for the expansion of haematopoeitic progenitors.
The authors report a population which is approximately 60% positive for CD31 and 35%
positive for CD34, both key markers of haemogenic endothelium.
The cytokine cocktail includes SCF, TPO, IL-3, IL-6, and Flt-3, and results in the
generation of haematopoeitic progenitors (CD34+ cells), which the authors freeze and
terminally differentiate to produce a population of CD41/CD42+ MKs (approximately 40%).
These cells then go on to produce proplatelet extensions and platelet like particles which
appear to respond to Thrombin (albeit an impaired response compared to ex vivo human
platelets even at high doses (1U)), spread on glass, and perhaps most importantly, are
recruited to thrombi in vivo when injected into a mouse injury model238.
Forward programming iPSC can be used to generate large numbers of mature megakary-
ocytes through the virally mediated transduction of key MK transcription factors. The
benefits of forward programming approaches is that they typically yield significantly larger
numbers of progenitors by overcoming the asynchronous nature of cell differentiation as
driven by directed cytokine treatment239. In 2014 Nakamura et al. reported the generation of
an immortalised megakaryocyte progenitor cell line (imMKCL) through the introduction of a
doxycycline inducible cassette regulating the expression of BCL-XL, C-MYC, and BMI1240.
The resulting cells express markers of mature MKs and are sustainable in culture for 5 months.
Upon the removal of doxycyline, and the subsequent loss of expression in these transgenes,
imMKCLs undergo terminal maturation and release mature platelets which respond to a host
of agonists240. Critically however, these functional responses are substantially lower than
those evidenced by platelets isolated from human blood.
Similarly Moreau et al. over expressed FLI1, GATA1, and TAL1 to generate iPSC-MKs
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in large numbers. These cells remain viable in culture while expressing key markers (e.g.
CD41, CD42) for up to 90 days, and are capable of producing small numbers of platelets.
The authors report the generation of 2x1011 from 106 input iPSC, releasing a total of 1x1012
platelets - averaging just over half a platelet per cell 70.
These approaches all share similar shortcomings in that none of the cells generated
closely resemble human bone marrow megakaryocytes. Regardless of the means of generation,
the MKs produced are typically substantially smaller than adult, mature MKs in human
bone marrow, and produce nowhere near the vast number of platelets needed to maintain
haemostasis in a human. Similarly, the platelets produced resemble human circulating
platelets in size and morphology, but respond poorly to agonists. While the authors of these
various studies demonstrate recruitment of their artificially generated platelets to thrombi in
vivo using mouse models, typically this will be substantially less than the level of recruitment
evidenced by platelets derived from peripheral blood.
The development of bioreactors as a means by which to drive improved platelet production
in these cells is one of a number of routes by which iPSC-MKs can be improved in terms of
their platelet production capacity, however as of yet no bioreactor has successfully yielded the
number of platelets per input MK demonstrated by bone marrow cells241, 233. A significant
concern when using forward programmed cells is the potential impact of over-expressing
tumuorogenic genes - of which C-MYC and FLI1 are prime examples.
The applications of iPSC derived MKs in disease modelling and functional, phenotypic
screening hinges on their ability to produce proplatelets in vitro. Unfortunately to date only
a handful of studies apply these methods as a means by which to interrogate the effects of,
for example, particular patient mutations. This particular aspect of the field is discussed in
section 3.1.3
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3.1.2 Genome editing through CRISPR-Cas9
The discovery of an adaptive prokaryotic immune system referred to as CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats)- Cas (CRISPR associated) has led to
what is arguably one of the most significant advances in modern biology. In 2012 this
bacterial immune system was shown by Jinek et al. to be programmable for site specific DNA
cleavage in vitro, a finding which was shortly followed by the application of this technique
for genome editing in human cell culture242, 243, 244. While previous nuclease based gene
editing approaches, most notably Zinc Fingers and TALENs (Transcription Activator-Like
Effector Nuclease), brought the possibility of site-specific genome editing to the study of
gene function, issues with complexity and cost have always hampered efforts to make either
technique widespread and readily available245. CRISPR-Cas allows for inexpensive, efficient,
and relatively simple site specific genome editing both in vitro and in vivo.
The key components of CRISPR-Cas systems in mammalian genome editing are an
endonuclease (most often the Cas9 protein from S. pyogenes) and a single guide RNA
(sgRNA) which targets the protein to a sequence of interest (Figure 3.1)242, 243, 244. Cas
endonucleases must bind an sgRNA targeting a region of genomic DNA immediately adjacent
to a Protospacer Adjacent Motif (PAM) site (Figure 3.1)246. This is specific to the species
from which the Cas endonuclease is derived. In the most commonly used protein, Cas9 from
S. pyogenes, the PAM sequence is NGG246. Due to the frequency at which this particular
PAM sequence is found in the mammalian genome, the S. pyogenes Cas9 based system has
become extremely popular.
Upon the introduction of a Cas endonuclease and an sgRNA to which it can bind, whether
through plasmid expression or transfection of an RNP (Ribonucleoprotein) complex, site
specific double stranded breaks are induced immediately 3-4 base pairs 5’ of the PAM246, 247.
A number of Cas9 mutants have been developed, each of which feature mutations which alter
the binding or cutting ability of the endonuclease. These include ’nickase’ enzymes which
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Figure 3.1: Components of a CRISPR-Cas9 editing system. Programmable CRISPR
systems designed for mammalian gene editing rely on relatively basic components. A Cas
endonuclease, most often the S. pyogenes Cas9 is expressed alongside a single guide RNA
(sgRNA) targeting a specific genomic sequence immediately adjacent to a PAM site. sgRNAs
are comprised of a CRISPR-RNA (crRNA) which is specific to the genomic target, and a
tracrRNA which acts as a scaffold through which the Cas9 endonuclease binds the crRNA.
On binding to an sgRNA, the Cas9 protein is able to bind to its adjacent PAM site and
induce a double stranded break 3-4 base pairs immediately 5’ of the PAM.
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inactivate one of the two active sites of the enzymes to generate single stranded breaks (the
D10A mutant for example), as well as inactivated or ’dead’ Cas9s (dCas9) which retain their
targeting ability but are unable to cleave DNA246, 247, 248.
Nuclease directed genome editing ultimately depends on exploiting endogenous repair
mechanisms following DNA damage, in this instance, a double stranded break. Once Cas9 has
performed its cutting function, it falls to the cell to pursue either non-homologous end joining
(NHEJ) or homology directed repair (HDR), the two key pathways for DNA damage repair
(Figure 3.2). NHEJ is an error-prone pathway which will often result in indel mutations
causing a premature stop codon which, if placed sufficiently towards the N-terminal coding
region of the protein, can knock-out protein expression in the treated cell (Figure 3.2). HDR
is a higher fidelity pathway which relies on the presence of a repair template (Figure 3.2).
Its incidence is comparatively lower than NHEJ, however this particular mechanism can
be exploited by co-transfecting with single stranded oligonucleotide or plasmid donors with
sufficient homology to the target region for HDR. This hijacking of the DNA repair system is
where the true potential of CRISPR-Cas lies, allowing for highly specific, targeted changes to
the genome both in vitro and in vivo.
Microhomology mediated end joining (MMEJ) is another repair mechanism with poten-
tially important implications for CRISPR-Cas9 experiments (Figure 3.2)249. This repair
pathway occurs at frequencies higher than HDR, but lower than NHEJ, and can allow for
targeted deletions as well as the insertion of larger sequences (e.g. fluorophores or resistance
cassettes)249.
The application of CRISPR-Cas 9 to achieve either targeted knock-outs or insertions in
a relatively high throughput manner has had an undeniably significant impact on modern
biology. In just 5 years the technology has developed in leaps and bounds, with a huge range
of applications both in vitro and in vivo. In the following section, the relevance of these
approaches to the study of inherited thrombocytopenias are discussed.
Chapter 3. Development of iPSC Protocols 100
Figure 3.2: Resolution of Cas9 induced double stranded breaks through endoge-
nous repair mechanisms. The CRISPR Cas system causes double stranded breaks which
are resolved through endogenous repair mechanisms to introduce changes. In the absence of
a designed repair template, NHEJ will constitute a large percentage of double strand break
repairs. This is an error prone mechanism by which indels, and as a result, frameshifts and
stop codons can be obtained. To introduce single base pair changes or large insertions like
fluorophores, the high fidelity HDR route is often used. In this instance, a repair template
(often a single stranded oligonucleotide for SNPs and a plasmid for large insertions) with
significant regions of homology are introduced alongside the CRISPR-Cas9 components. HDR
allows for the incorporation of these donor sequence in a relatively error-free manner. Finally
microhomology mediated end joining is another means by which DSBs are resolved. This
repair mechanism requires donors with regions of microhomology (5-25 bps) with the target
strand. The donor DNA is resected until the region of microhomology is reached, at which
point this is incorporated into the target DNA, most often resulting in the formation of large
deletions.
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3.1.3 Applying CRISPR-Cas9 genome editing and iPSC technolo-
gies to the study of inherited thrombocytopenia
Both technologies introduced in this chapter offer the potential to address long standing
issues in the field of MK and platelet biology. In the absence of proplatelet producing cell
lines, or an ability to culture large enough numbers of primary human MKs, iPSC derived
megakaryocytes offer a potentially robust platform for in vitro experiments. Similarly, the
development of CRISPR-Cas9 as a relatively simple method of gene editing allows for a
means by which to edit genes of interest without the issues associated with over-expression
(and practical issues associated with transfection in iPSC).
To date only a handful of studies apply these methods to the study of platelet production
defects. This is at least partly due to the fact that iPSC-MK generation methods thus
far have only demonstrated a limited capacity for proplatelet formation in vitro. A key
criticism of many of the methods discussed in this chapter is the lack of quality imaging
or immunofluorescence in iPSC derived MKs, and as such there is no indication from the
literature that the use of iPSC-MKs is a viable means by which to assay platelet production
in vitro.
The bulk of current iPSC-MK based studies to date use patient derived tissue to generate
stem cell lines for phenotypic study. Notable examples include studies by multiple groups
which reprogram cells from patients with a familial platelet disorder. In these works a loss of
MK differentiation is reported recapitulating the thrombocytopenia reported in the patients
involved250, 251, 252. Similar work has been performed in stem cells derived from patients
with Paris-Trousseau syndrome and Glanzmann thrombasthenia253, 239. Critically proplatelet
formation is not assayed in any of these works, nor are images of the iPSC-MKs reported.
Kahr et al. recently published an investigation into the loss of a haematopoeitic specific
component of the Arp2/3 complex - ARPC1B. In this elegant study, two unrelated patients
with a loss of function in ArRPC1B present with similar haematopoeitic deficiencies, including
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eosinophilia, inflammatory disease and microthrombocytopenia163. The authors establish
the phenotype observed using samples obtained from both patients, but also go on to use
CRISPR-Cas9 to delete the ARPC1B complex in the imMKCL line from Namakura et al..
They proceed to report a reduction in proplatelet formation in edited cells versus wild type
using quantitative SIM.
A substantial criticism of this latter part of the work is the appearance of the ’proplatelet
forming’ imMKCLs reported. Both cells are approximately 10µm in size, with no polyploidy
evident in either of the cells shown. The proplatelet extensions reported do not resemble the
beaded structures evidenced by foetal liver MKs, with no clearly defined tubulin rings which
are considered hallmarks of proplatelet structures163.
Reprogramming patient material is one of two methods of stem cell based disease modelling.
Stem cell lines derived from patient tissue can successfully recapitulate the disease phenotype
observed, and provide a powerful means by which to interrogate mechanistic questions -
however, such an approach is less useful when dissecting the cause of a particular disease
phenotype. Where multiple confounding mutations may be causative, or where patient
sample is unavailable, being able to introduce particular mutations of interest into a genomic
’blank canvas’ is a powerful method by which to specifically interrogate the effects of a novel
mutation. CRISPR-Cas9 makes the latter method of disease modelling a viable option, as is
discussed in the following section.
3.2 Aims
This chapter introduction has described significant advances in both genome editing ,and
the application of stem cell technologies in the study of MK and platelet defects. To date,
the utility of both these techniques to functionally characterise mutations has only been
demonstrated by Kahr et al. in their study of the ARPC1B subunit. As detailed above,
this study suffers from the same issues currently plaguing the application of iPSC-MK
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differentiation for phenotypic screening - namely the lack of a method by which to generate
large numbers of proplatelet forming cells in vitro.
This work aims to develop protocols by which to develop mature, proplatelet forming MKs
from iPSC cultures, and to apply CRISPR-Cas9 genome editing to stem cells to replicate
patient mutations and tag proteins of interest for microscopic study and analysis. The aim
is to achieve a work flow demonstrated in figure 3.3, whereby candidate mutations can be
efficiently modelled in an iPSC-MK model to evaluate the effects of said mutation on platelet
production. This would be a substantial advance in the field, and offers a powerful in vitro
tool in a field which has suffered from the lack of such an approach.
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Figure 3.3: Design of work flow aiming to apply CRISPR to the study of inherited
thrombocytopenia.Example of workflow based on output from the Genotyping and Pheno-
typing of Platelets (GAPP) study. Unique patient mutations are first identified by the GAPP
project, and proteins of interest identified in this manner are placed in a CRISPR-Cas pipeline
to first generate fluorescently tagged fusion proteins expressed at near endogenous levels.
Patient specific mutations are then introduced to generate clonal populations expressing
both wild type fusion proteins as controls, and mutant proteins for investigation into novel
molecular causes of thrombocytopenia.
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3.3 Materials and Methods
3.3.1 Stem Cell Culture
Gibco human episomal induced pluripotent stem cell line was purchased from Thermo Scientific
and cultured on Geltrex basement membrane in StemFlex medium (Thermo Scientific).
Routine passaging was performed using EDTA (Sigma), with single cell seeding performed
for transfection and attempted clonal isolation through the use of TryplE (Thermo Scientific).
Briefly, cells were washed twice with PBS and once with either EDTA (for clump passaging)
or TrypLE (for single cell) before incubation in 1mL relevant detachment media for 3 minutes
at 37◦C.
For clump passaging, EDTA was removed and 1mL of StemFlex added. Cells were
detached by triurtating media onto the bottom of the well and subsequently adding the
required volume to fresh media (in a new, GelTrex coated plate).
For single cell seeding, TrypLE was diluted in 2mL StemFlex and the solution added
to a 15mL falcon tube for centrifugation at 200g for 4 minutes. The supernatant was then
discarded and the cell pellet resuspended in the required volume.
3.3.2 iPSC MK differentiation
iPSC differentiation to mature, proplatelet forming megakaryocytes is discussed in the results
section of this chapter, and is modified based on an original protocol published by Feng et
al.238.
To summarise, cells were detached by the clump passaging protocol described in section
3.3.1 and seeded on dishes coated with Collagen Type IV (Advanced Biomatrix) at 5µg/cm2.
Cells were seeded overnight with RevitaCell to support survival on the new basement substrate.
To begin the protocol cells were washed twice and incubated in phase I medium comprised
of APELII medium (Stem Cell Technologies) supplemented with BMP-4 (Thermo Scientific),
Chapter 3. Development of iPSC Protocols 106
FGF-β, and VEGF (Stem Cell Technologies) at 50ng/mL each. Cells were incubated at 5%
oxygen for the first four days of the protocol before being placed in a standard cell culture
incubator for a further two days in freshly made phase I medium.
At day 6 of the protocol cells were incubated in phase II media comprised of StemSpan II,
TPO (25 ng/mL), SCF (25ng/mL), Flt-3 (25ng/mL), Interleukin-3 (10ng/mL), Interleukin-6
(10ng/mL) and Heparin (5 U/mL) (all supplied by Stem Cell Technologies).
Each day in phase II media suspension cells were spun down at 400g for 5 minutes and
frozen in 10% FBS/DMSO. After 5 days of collection, all frozen cells were thawed for terminal
differentiation.
Terminal differentiation was performed by incubating cells in StemSpan II with heparin
(5U/mL) and Stem Cell Technologies Megakaryocyte Expansion supplement on low attachment
dishes (Corning).
3.3.3 FACS antibodies
Validation of surface marker expression was performed on an Accuri B6 as described in
previous chapters. Cells were labelled by either first detaching (if cells were adherent) with
TrypLE (Thermo Scientific) before centrifugation at 400 x g for 5 minutes. The pellet was
then re-suspended in FACS buffer, comprised of PBS, 2mM EDTA, and 2% FBS. The relevant
conjugated antibodies were added at a dilution of 2:50 and samples were incubated on ice for
20 minutes before the addition of 1mL PBS, and 2 subsequent washing and spinning steps.
Finally, cells were re-suspended in 100µL FACS buffer before analysis. Undifferentiated iPSC
were similarly treated to generate control samples.
The following antibodies were used to determine iPSC differentiation in this chapter:
CD31 Alexa 488 conjugate (Thermo Scientific), CD42b APC conjugate (BD Pharmingen),
CD34 Alexa Fluor 488 conjugate (Thermo Scientific), CD41 Alexa Fluor 488 conjugate
(Thermo Scientific), and CD144 APC conjugate (BD Pharmingen).
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3.3.4 RNP Complexes
The IDT Alt-R®RNP system was used for the relevant experiments in this chapter. crRNAs
were ordered at 2nmol (following the design of TubA1B targeting guide C reported in Chapter
2) and resuspended in 20µL TE buffer (IDT) for a final concentration of 100µM. Atto-555
labelled tracrRNAs were ordered at 5nmol and resuspended in a volume of 50µL for a final
concentration of 100µM.
To prepare small guide RNAs (sgRNA), equimolar ratios of both crRNA and tracrRNA
were mixed with Nuclease Free Duplex Buffer (IDT). This mix was then incubated at 95◦C
for 5 minutes before allowing the reaction mix to cool at -1◦C/second to 25◦C. This mix was
then spun down and complexed with either HiFi Cas9 V3 (1081058 - IDT) or Cas9 R10A
nickase (1081063 - IDT) purified Alt-R®.
Cas9 protein was diluted to 6µg per transfection and incubated with an equal volume of
annealed sgRNA. This mix was left for 30 minutes at room temperature to form complete
and stable RNP complexes.
3.3.5 Stem Cell Transfection
iPSC transfection was performed using Lipofectamine Stem according to manufacturer
instructions. Briefly, iPSC were seeded on 24 well dishes coated with Geltrex at 50,000 cells
per well. After an overnight incubation in StemFlex with RevitaCell, cells were washed twice
with PBS and once with OptiMem before incubation in OptiMem with RevitaCell.
RNP complexes were prepared as described in section 3.3.4 and resuspended in 25µL
OptiMem per reaction. A Lipofectamine Stem master mix was prepared using 25µL OptiMem
and 2µL Lipofectamine STEM per reaction (4µL if a donor template is included). Equal
volumes of both Lipofectamine and RNP mix were incubated to form lipofection complexes
over a 10 minute incubation at room temperature. The final transfection mix was added
to cells in OptiMem and left for 4 hours before the addition of StemFlex medium (and any
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relevant small molecules).
Measurement of iPSC transfection efficiency after treatment with Lipofectamine STEM
and IDT RNP complexes was performed using manual cell counting in Evos acquired images
(Phase contrast and fluorescence).
3.3.6 Small molecule targeting of the HDR pathway
Small molecules were purchased and resuspended in DMSO before dilution to the required
concentrations. SCR-7, RS-1, (Sigma), NU7026 (Sigma), Trichostatin A (Sigma), MLN4924
(Adooq BioScience), NSC 15520 (ChemBridge).
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3.4 Results
3.4.1 Establishment of an iPSC Culture System
A plethora of iPSC culture systems are currently available, usually comprised of different
basement membranes or feeder layers, cytokines, or nutritional supplements. The choice of
system ultimately has a significant impact on downstream applications. For our purposes,
a culture system which supports cells when ’challenged’ through transfection or single cell
cloning, without detrimental effects on potency, survival, or karyotype, would be key for
successful genome editing and differentiation.
To that end a range of different feeder free basement membranes and media were trialled,
including matrigel and vitronectin for the former, Essential 8 and NutriStem for the latter
(data not shown). Ultimately however, we found that growing our iPSCs on GelTrex
basement membrane and StemFlex media supported growth with virtually no differentiation
and minimal cell death. As shown in Figure 3.4A, even after defrosting, cultures show
minimal cell death with tight, clearly defined colonies lacking the spread differentiated cells
typical of iPSC post thaw.
Despite freezing and subsequent thaw and culture, cells maintain a normal, healthy
karyotype (Figure 3.4(B)). In our hands this culture system is ideal for our subsequent
treatment of the cells.
3.4.2 Electroporation of iPSC with Cas9 and guide expressing
plasmid
iPSC transfection was, at the start of this project, extremely difficult in the absence of viral
transduction. Initial work trialled a number of lipofection agents (Lipofectamine 3000, Fugene
HD, TransIT) and electroporation methods (Neon electroporation, Amaxa Nucleofection) to
introduce the px459 guide C expressing plasmid and mEGFP TubA1B donor described in
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Figure 3.4: Establishment of a routine iPSC culture system with a stable kary-
otype. (A) After trialling a range of basement membranes and culture media, Gibco iPSC
StemFlex media and GelTrex were found to allow for routine culture of iPSC without un-
wanted differentiation around colony edges. Images of a culture after defrosting, an event
which usually drives differentiation and cell death, show a stable culture with no notable
differentiation around colony edges at both 4x and 10x magnification. Clean colony edges are
observed (indicated by red arrows). (B) Cells maintain a normal, healthy female karyotype
as indicated by two representative images. (Fixed samples were sent to Birmingham Womens
Hospital for karyotyping).
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chapter 2 of this thesis. The aim of this was to trial an established method of using CRISPR
to evaluate the efficiency of HDR and fluorophore integration in iPSC.
Of these early attempts at replicating the cell line data, Neon electroporation was the
only successful method (Figure 3.5), generating mEGFP positive cells at 0.1% efficiency
(compared to as much as 10% in cell lines) in cells electroporated at 1200V and with a 30ms
pulse width. Other settings were not successful in introducing the mEGFP tag.
Unfortunately this efficiency, while consistent with the HDR rates observed in the literature,
is extremely low. When targeting MK and platelet specific genes which are not expressed in
undifferentiated iPSC it would be almost impossible to isolate the 0.1% of the population
carrying an insertion.
3.4.3 Transfection with Lipofectamine STEM and RNP complexes
Thus far while small molecule treatment does have a positive effect on tag integration in both
cell lines and iPSC, the effects observed have not achieved the level of integration needed to
make routine gene tagging in stem cells a viable option. While this is consistent with much
of the literature, it remains a substantial obstacle to this work.
With this in mind both the method of transfection and Cas9 delivery were altered as per
recently published work which shows an increase in cleavage efficiency and HDR through the
delivery of ribonucleoprotein complexes (RNPs)254. Jacobi et al. demonstrate an improvement
in CRISPR efficiencies when purified Cas9 protein is complexed with a synthetic sgRNA and
subsequently electroporated or lipofected into cells.
Firstly the method of transfection was altered as a sample of the newly developed
Lipofectamine STEM was kindly provided by Thermo Scientific. As demonstrated in figure
3.6, the use of Lipofectamine STEM with IDT’s RNP complex allows for efficient transfection
into iPSC. The IDT Alt-R®system is comprised of a user designed guide element which is
annealed to a fluorescently labelled tracrRNA before complexing with purified Cas9 protein.
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Figure 3.5: Electroporation of Cas9 and guide expressing plasmid targeting
TubA1B does not achieve efficient integration of donor sequence. iPSC were
electroporated using the Neon electroporation system and an optimised protocoll provided
by the manufacturer for Gibco iPSC. Cells were mixed with the px459 plasmid containing
theTubA1B targeting guide C used in Chapter with and without the relevant mEGFP donor.
3 different electroporation conditions were used as recommended by the manufacturer, with
only one achieving an extremely low efficiency of integration (0.1% at 1200V and a pulse
width of 30ms).
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Figure 3.6: Efficient iPSC transfection using Lipofectamine Stem. A test batch of
Lipofectamine STEM was provided for test transfections. We performed lipofections using
this kit and IDT RNP complexes which include a tracrRNA labelled with Atto555. (A)
iPSC were plated over night in ROCK inhibitor before lipofection in OptiMem. Cells were
transfected with IDT RNP complexes and incubated in OptiMem with ROCK inhibitor
for 4 hours before the addition of StemFlex culture medium. Untreated and Cas9 control
only cells show no fluorescence using illumination through a 555 cube on an Evos-FL (10x
objective, 400m scale bar), in contrast cells treated with an RNP complex and tracr show a
high number of cells positive for signal, as do cells treated with both the guide complex and
an mEGFP donor. (B) Analysis of transfected images show a transfection efficiency of 71.08
% (±1.28). n =3, S.D.
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The fluorescent RNP complex is transfected and is easily visualised using a bench top Evos
system for a convenient assessment of transfection efficiency.
Transfection efficiencies as high as 71.08% (±1.28)have not been reported through lipofec-
tion in iPSC, but perhaps more critically, cell survival and health as demonstrated in figure
3.6A remains excellent, while electroporation is notoriously harsh and causes significant cell
death. In karyotypically sensitive cells like iPSC, this is vital to generating and maintaining
healthy CRISPR edited lines.
With an efficient method of introducing a Cas9-guide complex, iPSC were then treated
with the Alt-R®RNP complex carrying TubA1B targeting guide C and either double stranded
or plasmid donor DNA. While plasmid donors worked extremely well for the cell line work
reported in chapter 2, there is some debate as to whether it is the appropriate format for
knock-in donor sequences in HDR focussed CRISPR experiments247.
3.4.4 Testing small molecule enhancers of HDR
In 2016 a number of papers reported that small molecule inhibitors of NHEJ could increase
the rate of fluorophore integration through HDR in CRISPR targeted cells. Of these,
the most often published small molecule was the DNA Ligase IV inhibitor SCR7, with
reports of increased HDR in cell lines, primary cells, and iPSC for both small and large
insertions255, 256, 257. Of the many other small molecules reported, RS-1 showed a substantial
improvement in HDR in cell lines and on insertion into mouse embryos - interestingly, the
authors show a negligible effect of SCR7 in comparable experiments258. RS-1 has been
previously reported as a stimulator of RAD51, a member of the RecA family mediating
homology directed repair259.
Based on these works, RS-1 and SCR7 were used at a range of concentrations recommended
by the literature to determine the effects of these small molecules on the integration of TubA1B
mEGFP in Hek293T. As shown in figure 3.7, treatment with both RS-1 and SCR-7 improves
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the rate of HDR, with significant increases at an RS-1 dose of 7.5µM, and SCR-7 doses
of 0.5µM and 1µM, both consistent with reports in the literature. Interestingly we do not
observe a clear dose dependent increase in integration, though this is likely due to the
deleterious effects of homozygous knock-in at the TubA1B locus.
As SCR7 at 1µM achieves the most substantial fold increase in HDR (1.763 fold ±0.15), this
concentration was taken forward for iPSC experiments. iPSC were transfected in an identical
experiment and treated with either DMSO or SCR7. SCR7 treated cells demonstrated an
increase in integration, however the rate of HDR remains extremely low (Figure 3.8). In
SCR7 treated cells a total of 47 positive cells were found out of a total of 65,253. In the
DMSO control 44 positive cells were found in a total of 172,922 (Figure 3.8B) (0.2%).
While the treatment reproduced a rate of HDR in iPSC consistent with the literature,
the overall rate of fluorophore integration remains too low for our purposes. With SCR7
treatment we would still need to screen 1,388 individual stem cell cultures to find a single
positive clone.
3.4.5 Testing Cas9 nickase and CRISPY inhibition
A recent publication described the rational inhibition of key components of NHEJ machinery,
reporting up to 7.20 fold increases in integration in treated cells with approximately 20% of
targeted chromosomes successfully edited260. These are the highest rates of HDR reported
in the literature thus far, and so we acquired components of the CRISPY mix to determine
whether CRISPY could improve our editing rates260.
The CRISPY mix described by Riesenberg et al. refers to a cocktail of small molecules
targeting specific components of the cellular repair machinery to inhibit NHEJ and improve
HDR. NU7026 is a small molecule inhibitor of Ku 70/80, while other components of the mix
are enhancers of particular components of the HDR machinery. MLN4924 and Trichostatin
A are enhancers of CtiP and ATM, while NSC 15520 (which we were not able to procure) is
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Figure 3.7: Effect of Small Molecule Inhibitors of NHEJ On Knock-In Efficiency.
Hek293T cells were treated with Cas9 and the TubA1B targeting guide C described in (insert
where here) in the presence and absence of an mEGFP donor and two NHEJ inhibitors.
KI indicates knock-in controls, samples treated with the complete combination of vectors
but no additional small molecules. (A) RS-1 and SCR-7. Treatment with these inhibitors
increased the percentage of cells positive for an mEGFP insertion in all treated samples. (B)
Normalisation to fold change in insertion reveals significant increases at 7.5µM of RS-1, and
0.5µM and 1µM of SCR-7, with the largest fold change observed in SCR-7 treated samples
at 1µM with a 1.763 fold increase in insertion (SD 0.3198). (Data tested with a One Way
ANOVA and multiple comparisons with no corrections n = 4).
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Figure 3.8: Treatment with SCR7 increases rate of HDR. To determine whether the
increase in HDR observed through SCR7 treatment in Hek293T achieved a similar result in
iPSC, stem cells were electroporated with an mEGFP donor, Cas9 and TubA1B targeting
guide C in the presence of 2µM SCR7 or DMSO. (A) In untreated iPSC, no integration of the
mEGFP tag is observed. (B) In DMSO treated cells 0.1% population is positive for mEGFP,
while 0.2% of the SCR7 treated population is positive. This doubling of HDR is consistent
with a similar treatment in Hek293T, however the overall rate of HDR is extremely low. (B)
Samples were run to completion and a total of 44 positive cells are observed in the DMSO
treated sample out of 172,922 - while 47 positive cells are observed in the SCR7 treated
sample (out of 65,253).
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thought to block p53 binding to RPA and RAD9. The authors show significant increases in
iPSC editing through the introduction of both large cassettes (a BFP sequence) and single
nucleotide changes260. This work demonstrates the highest reported improvement in HDR,
with as many as 50% of chromosomes edited in particular targets.
The authors report a significant improvement when used in an iPSC line with an inducible
Cas9 nickase cassette, and as such we adapted our RNP complex to include purified Cas9
D10A nickase protein. Cells were transfected with an mEGFP donor in either a dsDNA
format (generated by PCR), or as a plasmid as in chapter 2. Unfortunately we found, as
demonstrated in figure 3.9, that CRISPY treatment did not alter the rate of mEGFP insertion
when targeting the TubA1B gene.
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Figure 3.9: Use of paired Cas9 nickase guides and CRISPY inhibition does not
significantly increase HDR at TubA1B. iPSC transfected with RNP complexes com-
prised of a Cas9 D10A mutant and two paired guide RNAs and an TubA1B mEGFP donor
(either plasmid or dsDNA) were screened for HDR with FACS after 48 hours in the presence
of either DMSO or CRISPY small molecule mix. (A) Untreated, negative iPSC were negative
for any cells in the FL-1 channel. DMSO treated cells with either a dsDNA or plasmid
donor both demonstrate extremely low rates of integration (0.1%), which are not significantly
improved on treatment with CRISPY.
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3.4.6 Directed differentiation of iPSC megakaryocytes
One of the key aims of this project is the development of a method of phenotypic screening
through the differentiation of iPSC into mature, proplatelet producing MKs. While significant
advances have been made in the generation of MKs from iPSC in recent years, the application
of these methods for mechanistic studies has been limited. Developing a robust assay of
proplatelet formation in human, stem cell derived MKs would be a substantial advance in
the field, particularly in conjunction with modern gene editing techniques.
To that end, with a robust iPSC culture system in place, the Feng et al. 2014 method
of directed differentiation was adapted to produce large cultures of mature cells. Briefly,
this method involves the generation of haemogenic endothelial progenitors by seeding iPSC
on collagen IV in the presence of cytokines that drive pluripotent cells towards a primitive
mesoderm. To encourage, this cells are incubated in hypoxic (5% oxygen) conditions for the
first phase of differentiation. After 6 days the culture medium is changed to one carrying
cytokines known to favour haematopoeitic differentiation. For the following week cells are
harvested each day and frozen in 10% DMSO before thawing and further culture in a terminal
differentiation step.
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Figure 3.10: Variation in confluence results in markedly different cultures. Cells
seeded on collagen IV at a low, medium, and high cell density demonstrate substantially
different differentiated cultures on day 6 of this directed differentiation protocol. The low
confluence sample demonstrates less outgrowth than its counter parts, while the higher
confluence seems to result in increased cell death. The medium density results in a confluent
monolayer with raised ridges in which cells appear to overlap with one another.
Chapter 3. Development of iPSC Protocols 122
Early attempts to reproduce this protocol on a number of basement membranes and in
different culture media proved ineffective. On matrigel and geltrex cells differentiate, but do
not successfully generate haematopoeitc cells (data not shown). Similarly the formulation
of the media originally used in the publication has since been altered, and we found that
using these media similarly reduced the efficiency of haematopoeitic differentiation (data not
shown). As such the original protocol has been altered as described in this results section.
Feng et al. do not report a seeding density in the original publication, and early experiments
quickly revealed a significant impact of cell density on culture growth and architecture (Figure
3.10). We found cell survival on Collagen IV to be poor on single cell seeding, and as such
proceeded with clump passaging to better preserve cell viability. Cells were seeded at a low
(1/20 dilution), medium (1/10 dilution) and high (1/5) confluence of a routine passage (grown
to approximately 75% confluence) and imaged as demonstrated in figure 3.10. The resulting
population of haemogenic endothelium is dramatically different across cultures, with low
seeding densities resulting in poorer out growth and more spread cells, while the higher cell
density can achieve detrimental effects on cell health. At a ’medium’ confluence, cells form a
monolayer with distinctive ridges in which cells appear to overlap (Figure 3.10).
As the role of confluence had not been reported in the original paper, day 6 differentiated
populations from each seeding density were screened by FACS to determine the expression
of markers of haemogenic endothelium, and so which seeding density is best suited to the
efficient generation of haematopoeitic progenitors. In this first phase of the differentiation
protocol, we found APELII to be an optimal medium as suggested by a consultation with the
manufacturer (Stem Cell Technologies). This base media was supplemented with 50ng/mL
of BMP-4, FGF, and VEGF. Compared to unstained and undifferentiated iPSC controls,
there is a substantial increase in key markers (CD31, CD34, and CD144) as shown in figure
3.11A. Cells seeded at a medium confluence demonstrate a substantial increase in both the
percentage of CD34 and CD144 cells, with an increase in median fluorescence intensity in
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Figure 3.11: Seeding density impacts the quality and number of haematopoeitic
progenitors developed through directed differentiation. iPSC differentiated following
the first phase of the Feng protocol demonstrate a confluence dependent change in surface
marker expression. Cells were stained with key markers of haemogenic endothelium, namely
CD31, CD34 (both of which are detected in the FL-1 channel), CD144 and CD43 (which
are detected in the FL-4 channel). (A) A notable increase in expression is observed in
differentiated samples when compared to wild type and unstained cells. (B) More confluent
cells appear to better express CD34, the key marker of haematopoeitic progenitors. While
a lower confluence appears to favour the expression of CD31, a classic endothelial marker.
Cells seeded at a higher density demonstrated more variance consistent with the higher cell
death observed in these samples.
Chapter 3. Development of iPSC Protocols 124
Figure 3.12: Addition of haematopoeitic cytokines drives the development of MK
progenitors. The addition of phase II differentiation media results in the formation of
progenitors and blast like cells (indicated by red arrows). APELII media supplemented
with Flt-3, SCF, TPO (50ng/mL), IL-3, IL-6 (10ng/mL), and Heparin (5U/mL) drives the
formation of these cells, which become evident at day 6+1 and day 6+2, albeit in substantially
lower numbers. As the culture matures more progenitors form on day 6+4 and 6 +5.
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CD34 also observed.
Interestingly, cells seeded at a lower density demonstrate an increase CD31 positive
cells (figure 3.11B), suggesting that the lower density is better suited to the generation of
endothelial like cells than haematopoeitic precursors. The variation evident in the high
density seeded samples is likely due to the cell death observed as cells overgrow.
This data suggests a role for cell-cell signalling in generating a population of robust
haematopoeitic progenitors. Interestingly as the images of the culture shows in figure 3.10,
there are regions of overgrowth where cells appear to be self-organising into structures almost
like embryoid bodies. Future work will interrogate these samples with immunfluorescence to
determine which parts of this complex culture become haematopoeitic precursors.
With an optimal configuration for the first phase of this differentiation in hand, cultures
were taken forward to the second phase in which haematopoeitic cytokines are introduced
to induce the generation of haematopoeitic precursors and megakaryoblasts. As shown
in figure 3.12, incubation in phase II media (comprised of APELII, 25ng each of Flt-3,
SCF, TPO, 10ng each of IL-3, IL-6, and 5 units of heparin) results in the development
of haematopoeitic precursors which resemble megakaryoblasts. The number of these cells
increases each subsequent day, and to maintain the population at a rougly equal stage of
maturation cells are harvested and frozen each day, with fresh media preparations added at
days 3 and 6 of phase II.
Upon completion of the second phase of differentiation, frozen cells are thawed and
resuspended in StemSpan II medium supplemented with StemCell Technology’s Megakary-
ocyte Expansion Supplement and heparin at 5 U/mL. This MK supplement is comprised
of TPO, SCF, IL-6, and IL-9, and has been shown by Feng et al. to facilitate the terminal
differentiation of MK progenitors into mature megakaryocytes. Cells are grown on ultra-low
attachment plates and imaged on day 1 and day 5 of terminal differentiation (Figure 3.13).
At day 1 of the terminal differentiation, the cells observed are approximately 10µm in size
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(Figure 3.13A). After 5 days of growth cells are notably larger at approximately 25µm in size,
with some appearing substantially larger (Figure 3.13B).
Most methods of iPSC differentiation to the megakaryocytic lineage successfully generate
blasts and mature MKs positive for CD41 and CD42. However the major impediment in the
field has been moving these cells forward into a state of active platelet production both for
the purposes of phenotypic screening and platelet generation for transfusion medicine.
This culture system yields cells which generate complex networks of proplatelet extensions
very similar to those observed in murine foetal liver cells, the current gold-standard of in
vitro platelet production (Figure 3.14). The appearance of this particular morphology is
one of the key aims of this project, and to our knowledge is thus far the best example of
iPSC-MK proplatelet formation reported.
Validation of this culture system is still underway, however early work shows that the
consistent with markers and phenotypic features of mature iPSC-derived MKs (Figure 3.15).
60% of the terminally differentiated day 5 population are double positive for CD41 and
CD42, compared to no such population in the undifferentiated iPSC control (Figure 3.15A).
Immunofluorescence reveals polyploidy in analysed cells, with the characteristic lobed multiple
nuclei of a mature megakaryocyte (Figure 3.15). Finally cells produce long, beaded extensions
which, on tubulin staining, reveal beaded structures not dissimilar to those observed in
proplatelet forming murine foetal liver cells.
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Figure 3.13: Terminal differentiation of iPSC derived MKs. On thawing and culturing
in Megakaryocyte Expansion supplement, iPSC derived MKs demonstrate a marked increase
in size preceeding proplatelet formation. (A) As indicated by representative images acquired
on separate differentiations, on day one of the terminal differentiation protocol cells appear
approximately 10µm in size. (B) By day 5 of the culture cells are substantially larger,
typically 25µm in size. This increase in size is a hallmark of cultured MKs, and is consistent
across experiments.
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Proplatelet forming iPSC MK samples are also positive for platelet like particles (Figure
3.16A). These are small cells with a distinctive marginal band, no nucleus, and about 3µm
in size. While the focus of the current protocol is the development of a proplatelet assay,
the presence of these platelet like particles suggest that future work could study genetically
altered platelets generated ex vivo through this experiment.
Figure 3.17 summarises the current version of the revised Feng protocol which has been
developed in the last few months. The protocol differs in some ways from the original,
primarily in the choice of media, density of cells, and preparation of samples in the final
stages.
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Figure 3.14: Terminal differentiation of iPSC MKs results in the formation pro-
platelet forming cells. Between day 4 and day 6 of the terminal differentiation of iPSC
generated MKs cells demonstrate proplatelet production in vitro. Proplatelets appear as
long, beaded extensions (indicated by red arrows) often covering up to 100µm fields of view,
consistent with those observed in foetal liver murine cells.
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Figure 3.15: Initial validation of iPSC MK cultures. Initial validation of iPSC MKs
through FACS and immunfluorescence confirms characteristic hall marks of megakaryocytes.
(A) CD41/CD42 staining, the archetypal markers of mature MKs, reveals a substantial
population of iPSC MKs (60%) at day 5 of the terminal differentiation. When spun down
and imaged on Poly-L-Lysine, round healthy cells double positive for both markers are
observed. (B) Immunofluorescence further reveals the presence of large, lobed nuclei. These
polyploid cells are typical of megakaryocytes. vWF, a platelet granule protein, can also be
seen accumulating in the cell. (C) Finally immunofluorescence of platelet extensions in this
tubulin stained image shows a fine network of beaded proplatelet extensions.
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Figure 3.16: Platelet production in iPSC-MKs. (A) Platelet like particles are observed
in cultures as iPSC MKs mature and develop proplatelet extensions. (B) These cells are
discoid with a distinctive marginal band, and appear approximately 3µm in size.
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Figure 3.17: Summary of revised directed differentiation protocol.] The refined iPSC
MK differentiation protocol developed in this chapter is summarised as a three phase process
to yield mature, proplatelet forming cells. First, iPSC are seeded on Collagen IV with
ROCK inhibitor in StemFlex medium. Cells are then placed in phase I medium comprised of
APELII with VEGF, BMP4, bFGF (at 50ng/mL). Phase II involves altering the cytokine
culture to favour haematopoeitic differentiation. This cocktail includes IL-3 and IL-6 at
10ng/mL, heparin at 5U/mL, and TPO, SCF, and Flt-3 at 25ng/mL. Progenitor cells are
harvested and frozen in 10% DMSO on each day of phase II, before defrosting for the final,
terminal differentiation. At this stage cells are cultured in StemSpan II with a megakaryocyte
expansion supplement for 5-6 days, at which point platelet production can be observed in
days 4-6.
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3.5 Discussion and Conclusions
This chapter has reported on attempts to develop protocols for the CRISPR mediated
editing of iPSC through HDR and for the differentiation of iPSC to mature MKs suitable
for phenotypic screening. While much of the work targeting TubA1B has failed to yield a
practical level of integration, the method of iPSC differentiation based on work by Feng et al.
has produced a means by which to study platelet production in vitro.
3.5.1 Adapting CRISPR methods to iPSC
At the start of the project the literature primarily suggested that methods used to target
cell lines could be conveniently transferred to iPSC - albeit at significantly lower efficiencies
due to the poor transfection of these cells and other technical challenges246. In our work we
have found that the relatively high level of knock-in we observe at the TubA1B locus in cell
lines is not effectively reproduced in iPSC, even after adapting our methods to produce high
transfection rates of RNPs reported to significantly increase editing efficiency.
While the use of Lipofectamine STEM and RNP complexes allows for high transfection
efficiency, this has not translated to an improved efficiency of knock-in. The use of SCR-7, a
small molecule inhibitor of NHEJ, only marginally improved HDR efficiency, while the use of
CRISPY unfortunately had no effect on targeting at this site.
A notable paradigm shift is evident in more recent research, with more recent publications
describing the need to optimise knock-in for specific cell systems. The CRISPY system is an
excellent example of this, where the authors detail a method which substantially enhances
HDR in iPSC, while having no effect on cell lines at all. This is supported to an extent in
our work where we see a substantial increase in HDR in Hek293T on SCR7 treatment, but
do not observe this in iPSC under the same conditions.
There are notable differences in our system which may account for the lack of improvement
in HDR observed. The authors use an inducible Cas9 nickase system which ameliorates the
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need for transfection, and will result in the expression of large amounts of Cas9 protein. As
we achieve high rates of transfection, this is unlikely to exclusively account for the poor
effects observed. The authors use a large single stranded oligonucleotide donor rather than
double stranded DNA or a plasmid donor260. There is some evidence to suggest that editing
efficiency is dramatically improved where single stranded DNA is used, and current efforts
are focussed on generating ssDNA templates to trial insertion efficiencies.
Finally gene target is a key consideration when evaluating editing efficiency. In these
optimisations we specifically target TubA1B, however it has been well established that editing
efficiency is also dependent on the availability of target DNA in particular cell types261. Work
in chapter 4 describes efforts to target the TubB1 gene, but to effectively develop iPSC
specific methods of gene tagging we would need to trial various editing strategies across
multiple gene targets.
3.5.2 Adapting methods of iPSC differentiation to MKs
Substantial advances have been made in the development of protocols to generate mature
megakaryocytes from iPSC. Both forward programming and directed differentiation ap-
proaches have advanced significantly, driven largely by the potential for transfusable clinical
grade platelets. However, key limitations remain the relatively minimal production of platelets
from these cells, particularly in the absence of a bioreactor. In terms of using iPSC-MKs for
disease modelling, the lack of platelet production in these cells corresponds to poor proplatelet
formation which limits the applicability of these cells for phenotypic screening.
Our initial attempts at reproducing the Feng et al. protocol would yield granular cells
which, while positive for CD41 and CD42, would not produce proplatelets or become signifi-
cantly larger over the course of a terminal differentiation (data not shown). Experimenting
with different media quickly showed that APELII sustains substantially healthier cells which
rapidly grow larger and form proplatelets in culture at the end of the terminal differentiation
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phase. Feng et al. reported this, but do not show quality imaging to support the method as
a means of generating a large sample of proplatelet forming cells.
Our CD41/CD42 double positive fraction appears larger than that which is reported by
Feng et al. (60.3% compared to 37%), though this may be a consequence of preferential
differentiation towards this lineage in our specific iPSC line. Epigenetic memory is known to
influence the efficiency of terminal differentiations in iPSC and is dependent on their tissue
of origin262.
Significant work remains to be done to finalise this protocol. Further FACS and im-
munofluorescence to quantify the presence of other key MK markers will be needed. Similarly
we would need to establish which portion of the population goes into platelet production
to better optimise this approach as a phenotypic screen. However the immunofluorescence
images generated thus far surpass those presented by other work demonstrating iPSC-MKs in
vitro thus far, setting a solid foundation for the application of this method for future research
in disease modelling.
Chapter 4
Post-translational modification of β-1
tubulin isoform
In previous chapters the development of CRISPR, single molecule imaging, and iPSC differ-
entiation methods have been discussed. The ultimate goal of this project is the application of
these techniques to the study of inherited thrombocytopenias. In this chapter these techniques
are applied to the study of TubB1 mutations identified in patients from the GAPP study.
4.1 Introduction: TubB1 and the tubulin code
Microtubules are a key component of the cytoskeleton, involved in an array of functions
including cell division, cargo transport, motility, and the development of specialist cell
morphologies and functions263, 264.
The building blocks of microtubules are heterodimers comprised of α- and β-tubulin
monomers, each with approximately 50% sequence homology at the amino acid level and with
a mass of approximately 50kDa 113. α- and β-tubulin subunits polymerise to create linear
arrays called protofilaments (Figure 4.1), 13 of which associate laterally to form cylindrical
pseudo-helical, hollow microtubules 25nm in diameter113.
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Figure 4.1: Microtubule structure. The building blocks of all microtubules are α- and
β-monomers which assemble to form heterodimers driving the polarity and orientation of
MTs. Each dimer is assembled into a linear array known as a protofilament, 13 of which
associate laterally to form a stagged, pseudo-helical, hollow cylinder known as a microtubule.
Each microtubule is 25 nm in diameter, and features a (-) and (+) end capped with an α-
and β subunit respectively.
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Polarity is key to microtubule function, with (-) and (+) ends terminating in α- and
β-subunits respectively. Microtubules elongate in both directions, but polymerise more
rapidly in the (+) direction. Polarity is a critical aspect of a vital property of microtubules
known as ’dynamic instability’ - namely the ability to polymerise and depolymerise extremely
rapidly to achieve growth and shrinkage263, 264.
When polymerising, tubulin dimers are GTP bound. While the GTP bound to α-tubulin
is stable, the β-tubulin bound GTP can be hydrolysed after assembly - the subsequently
formed GDP bound β-tubulin is susceptible to depolymerisation. Only GDP-bound β-
tubulin subunits at the exposed end of a microtubule can dissociate, thus achieving rapid
depolymerisation from the (+) end of the filament. Conversely, tubulin dimers assemble on to
GTP-bound subunits, and so regulation of the GTP/GDP state of the ends of microtubules
is key to their ability to rapidly grow and shrink263, 264.
Microtubules are nucleated and assembled at organising sites known as MTOCs (Mi-
crotubule Organising Centres) which are comprised of a distinctive γ-tubulin265. γ-tubulin
complexes with a host of accessory proteins to form a γ-tubulin ring complex (γ-TuRC)
which acts as an organising and initiating template for dimer polymerisation in the (+) end
away from the MTOC265.
4.1.1 Post-translational modification of microtubules
As ubiquitous cellular structures, the question of how microtubules are regulated to achieve
highly specialised functions and morphologies in specific cell types is a complex one. In recent
years this question has been addressed by ”the tubulin code”, a paradigm which describes
how MTs achieve unique roles through the differential expression of specific isoforms of α- and
β-tubulin, and the subsequent post-translational modifications of these isoforms to regulate
MT interactions with motor proteins, and other microtubule accessory and microtubule
interacting proteins (MAPs and MIPs respectively)113, 263, 264.
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The expression of specific tubulin isoforms is a key driver of specific functions and
morphologies113. Tubulin sequences are highly conserved across species, with abnormalities
poorly tolerated and with significant functional consequences266. As such, differences between
particular isoforms has significant consequences on microtubule dynamics, assembly, and
ultimately function113. Variations in flexible regions like the C-terminal tail result in a
mosaic of post-translational modifications which remain poorly understood. There are nine
mammalian isoforms for each tubulin monomer113. Disease modelling has been a significant
driver in understanding the effects of tubulin, and this is discussed in the context of post-
translational modifications in this section. A summary of PTMs and their known role in
human disease can be found in table 4.1.
Tyrosination and de-tyrosination refers to the alternating addition (ATP-dependent and
TTL (tubulin tyrosine ligase) mediated) or removal of C-terminal tyrosine residue from
α-tubulin (and the subsequent exposure of a terminal glutamate residue), with significant
consequences on the stability of MTs267. Following detyrosination further amino acids may be
removed to generate δ2-tubulin or δ3-tubulin, leaving the altered residue unable to undergo
further tyrosination or detyrosination268, 269.
Detyrosination of MTs is typical of stable microtubules, but is thought to be a consequence
of stability rather than a cause270. Detyrosinated microtubules are typically more stable
as certain kinesin motor proteins which mediate depolymerisation (e.g. MCAK (Mitotic
centromere-associated kinesin (MCAK) and kinesin family member 2A (KIF2a)) preferen-
tially target tyrosinated residues271. In contrast, KIF5 preferentially binds detyrosinated
microtubules in a manner thought to facilitate a specific cellular transport role272.
The interaction between detyrosinated microtubules and kinesin motors is vital to neuronal
development, with evidence suggesting that differential populations of tyrosinated and
detyrosinated MTs in axons drive specific MT dynamics and cargo transport in axons and
growth cones113, 263, 273 The loss of tyrosination evidenced by TTL knock out mice results in
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PTM Sub-types of MTs modified Reported defects and links with human
disease
Detyrosination Centrosomes, mitotic and mei-
otic spindles, axonemal MTs of
cilia and flagella, all neuronal
microtubules except the growth
cone, marginal band of platelets,
most myocyte microtubules
Dysfunction in tyrosination associated
with poor cancer prognosis (neuroblas-
toma and breast cancer in particular).
Loss of PTM results in neuronal ab-
normalities in mouse development. In
myocytes role for mechanotransduction,
and involved in cardiomyocyte contrac-
tion facilitates load bearing. Loss of the
regulation of this PTM can result in ar-
rythmia and muscle injury in Duchenne
Muscular Dystrophy.
Acetylation Mid-body and spindle micro-
tubules, enriched on axonemal
MTs of cilia and flagella, found in
all neuronal microtubules except
growth cone. Located on platelet
marginal band and found in pro-
platelet extensions of megakary-
ocytes.
Loss of this PTM causes subfertility in
mice, and defects in neurological de-
velopment. Loss of acetylation corre-
sponds with a loss of axonal develop-
ment in Charcot Marie Tooth disease.
Loss of acetylation causes thrombocy-
tosis in patients with myeloproliferative
neoplasms.
Polyglutamylation Spindle and mid-body micro-
tubules, enriched on centrioles.
Abundant in axonemal MTs
(cilia and flagella), enriched on
neuronal development.
Loss of polyglutamylation is linked to
loss of male fertility as a consequence of
poor spermatogenesis and sperm motil-
ity. Polyglutamylation is enriched in
photoreceptors, loss of this polymodifi-
cation has been linked to retinopathies
and other visual disorders. Affects res-
piratory cilia in mice. Loss of this PTM
causes extensive neurodegeneration in
mice.
Polyglycylation Enriched on primary cilia and
motile cilia. Poorly studied if
at all in other cell types.
Implicated in colon cancers, loss results
in retinal degeneration in mice.
Table 4.1: Summary of tubulin PTMS and their roles in human disease. While the
tubulin code remains a relatively recent field, the role of PTMs in healthy cell function and
development has been highlighted by human disease models. The mechanism by which many
of these PTMs regulate cell function remain unknown. Adapted from Magueira et al. 2018.
Found in myocytes though function remains unclear. While other tubulin PTMs have been
reported, they are not as strongly linked to human disease.
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significant defects in brain architecture and peri-natal death, likely due to defective neurite
outgrowth274.
Tyrosination also has a role in muscle cells, where detyrosination has been shown to affect
the function of MTs in cardiomyocyte contraction275. A loss of detyrosination results in
cardiac dysfunction by altering the stiffness of cardiomyocytes, while the converse upregulation
of detyrosination is found in patients with cardiomyopathy276.
Acetylation is a relatively well understood PTM which typically targets lysine 40 (K40) of
α-tubulin monomers, which lies within the lumen of MTs and is mediated by αTAT1, a tubulin
acetyle transferase277. Acetylation of K40 is reversed by either sirtuin2 (SIRT2) or histone
deacetylase 6 (HDAC6)278. Other acetylation sites have been more recently characterised,
however their function has yet to be understood279.
Neuronal MTs are heavily acetylated to mediate axon branching in development and the
migration of cortical neurons273. A recent report by Xu et al. shows that increased acetylation
results in an increased resistance to mechanical stress. Decreased tubulin acetylation has
other significant neurological consequences, for example decreased acetylation has been linked
to decreased axonal transportation in a range of diseases including Huntington’s Chorea,
Charcot-Marie-Tooth, and Parkinson’s disease280, 281, 282.
Polyglutamylation and glycylation are PTMs which target glutamate residues on both
tubulin monomers and result in the addition of glutamate or glycine residues respectively113, 263.
Interestingly polyglutamylation has been observed in microtubules in centrioles, axenomes,
neuronal outgrowths, and mitotic spindles113, 263.
Thus far polyglycylation has primarily been observed in axenomes, thus suggesting a role
for polyglycylation and polyglutamylation in regulating ciliary function - with important
consequences for ciliopathies113.
As these polymodifications target the same specific substrate - namely glutamate residues
in tubulin tails, there has been a level of competition observed between these PTMs. For
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example, glutamylation is evident on β-tubulin in post-natal development, but is found on
α-tubulin in younger neurons283. There is some debate as to whether these polymodifications
negatively regulate one another284, 285.
Ciliopathies result in a range of disorders which stem from aberrant functions in both
motile cilia and flagella, but also primary cilia286. The polyglutamaylation of C-terminal
tails has been shown to be an important regulator of ciliary beating273, with mutations in
the glutamylases and deglutamylases regulating this polymodification causing male infertility
through aberrant spermatogenesis and poor sperm motility287, 288, 289. Other motile cilia
include airway cilia , whose function is impaired on the loss of the polyglutamylase TTLL1
in mice290.
Primary (or non-motile) cilia are vital sensory organelles with important signalling roles.
In mice with a variant of the deglutamylase CCP1, an increase in polyglutamylation results
in the degeneration of photoreceptors in the retina291. A series of human mutations in the
deglutamylase CCP5 have been reported in patients with visual impairments292, 293.
A loss of glycylation has similarly been reported to affect ciliary function and length in
mice, and a loss of this PTM in photoreceptors results in ciliary shortening and subsequent
retinal degeneration in mouse models294, 295. A knock-out model of TTLL3 results in a loss
of glycylation and the development of tumours in the colon296.
Beyond ciliopathies glutamylation has significant roles in neuronal development and
function. Current research suggests a role for polyglutamylation in axonal transport (due to
the effects of this PTM on motor protein processivity) and synaptic function297.
Amongst the major modifications discussed above, there are a host of other PTMs
which have been discovered but remain poorly reported. These include phosphorylation,
polyamination, glycosylation, sumoylation, arginylation, ubiquitylation and methylation298.
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4.1.2 Motor proteins
Microtubule function is highly dependent on the recruitment and subsequent actions of
microtubule associated proteins (MAPs), of which motor proteins are a key component.
Referred to briefly in the section above, the microtubule motors are (-) end driven dynein
and (+) end driven kinesin299.
Dyneins are split into two broad categories, axonemal and cytoplasmic dyneins299. Axone-
mal dyneins are so named for their role in force generation in cilia, and this class of motor
protein is thought to drive microtubule sliding.
Cytoplasmic dyneins are further divided into two classes, cytoplasmic dynein-1 and
cytoplasmic dynein-2. Cytoplasmic dynein 1 is expressed ubiquitously in mammalian cells
and associated with various microtubule dependent processes, including vesicular transport,
cell migration, nucleokinesis, and nuclear envelope breakdown amongst a wealth of other
critical cell functions299. Cytoplasmic dynein 2 is involved in transport within specialised
structures like cilia and flagella, which are in turn facilitated in their unique mechanical
actions by a separate class of axonemal dyneins.
Kinesins are a primarily (+) end driven motor protein with key, ATP mediated, roles
in cell division and cargo transport300. Prominent examples include the role of of kinesin
sub-types in transporting neurotransmitters along the length of axons. Recently kinesin-1
has been reported as a player in platelet secretion300.
4.1.3 Microtubule accessory proteins
Microtubule accessory proteins, usually abbreviated to MAPs, are known to be regulators of
microtubule dynamics301. Tau proteins are MAPs with weights below 55-62 kDA and are
known to prevent depolymerisation and promote nucleation. In axons tau proteins have been
implicated in Alzheimers, with a role in stabilizing axonal MTs302.
There are four MAPs with molecular weights between 200-1000 kDa (creatively named
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MAP-1, MAP-2, MAP-3 and MAP-4). MAP-1 C is actually cytoplasmic Dynein, MAP-4 is
found in most mammalian cells, and MAP-2 is specific to the body of dendrites where they
mediate interactions with other cytoskeletal filaments301. Katanin, spastin, and figetin are
known as destabilisers of MTs (through microtubule severing) and therefore regulate tubule
length301.
Plus end tracking proteins are MAPs which find to growing MTs and are involved in
MT interactions with chromsomes. TIPs include End Binding proteins (EB-1, EB2, EB3),
Dynamitin, Lis1, and CLASP1 and 2301.
4.1.4 Microtubules in platelets and inherited thrombocytopenia
Critical to achieving these functions is the expression of TubB1, the platelet and megakaryocyte
specific isoform of β-tubulin. As detailed in section 4.1, microtubules play a critical role in
proplatelet formation, and hence platelet production. Knock-out mouse models and a series
of studies highlight the importance of TubB1 in achieving the unique cytoskeletal changes
needed for MKs to produce platelets.
TubB1 is located on chromosome 20 and is 7,401 base pairs in length303. The resulting
protein, tubulin β-1 is 451 amino acids in length, with a mass of approximately 50kDa303.
Interestingly tubulin β-1 is the most divergent at the sequence level of the many mammalian
tubulin isoforms, and features the longst C-terminal tail.
Platelets rely on microtubules to maintain a marginal band when quiescent, resulting in
the classic flat discoid shape of circulating resting platelets304, 305. While other haematopoeitic
cell types assemble marginal bands, platelets are the only known mature cell in humans which
require a circumferential marginal band306. The MB is comprised of 7-12 rings of mixed
polarities actively assembled during both resting and activation307
The activation of platelets involves a tightly regulated rearrangement of the cytoskeleton
which results in a series of shape changes. Antagonistic motor proteins maintain the resting
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state of the marginal band, and during platelet activation a motor protein dependent
mechanism results in sliding which extends the marginal band and causes the transition to a
spherical shape 305. This change can either be transient and reversible or, in the presence of
a sufficiently strong stimulus, become irreversible through actomyosin contraction and the
subsequent concentration of granules to the centre of the platelets308. The disc-to-sphere
transition is a critical part of platelet activation, which also involves the secretion of granules
as a terminal step in platelet activation.
In humans, TubB1 mutations have been shown to result in impaired platelet production,
with a resulting macrothrombocytopenia (a list of reported rare variants and their phenotypes
is found in table 4.2) An early report of a TubB1 mutation resulting in a familial congenital
macrothrombocytopia by Kunisima et al. described low platelet counts (40-60 x 109/L) in
Variant Protein AF Phenotype Ref
c.35delG p.Cys12Leufs*12 0.0025 Macrothrombocytopenia Bastida et al. 2017
c.319A>C p.Thr107Pro 0.0016 Macrothrombocytopenia Bastida et al. 2017
c.326G>A p.Gly109Glu 0.0873 Macrothrombocytopenia Auer et al. 2014,
Astle et al. 2016
c.721C>T p.Arg241Trp 0.0107 Thrombocytopenia
(Platelet size n/a)
Johnson et al. 2016
c.726C>G p.Arg242Leu - Thrombocytopenia
(Platelet size n/a)
Johnson et al. 2016
c.779T>C p.Phe260Ser - Macrothrombocytopenia Kunishima et al.
2014
c.860C>T p.Ala287Val 0.0058 Increase in platelet distri-
bution width (GWAS)
Astle et al. 2016
c.952C>T p.Arg318Trp 0.0041 Macrothrombocytopenia Kunishima et al.
2009
c.1075C>T p.Arg359Trp 0.6233 Macrothrombocytopenia Bastida et al. 2017
c.1080insG p.Leu361Alafs*19 - Thrombocytopenia
(Platelet size n/a)
Johnson et al. 2016
c.1267C>T p.Gln423* 0.0017 Macrothrombocytopenia Bastida et al. 2017,
Fiore et al. 2017
Table 4.2: Summary of reported TubB1 mutations. A summary of reported rare
TubB1 variants. A range of mutations across the length of the protein typically result in
macrothrombocytopenia. Table adapted from Burley et al. 2017.
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a 7 year old patient initially diagnosed with idiopathic thrombocytopenia purpurra. This
novel p.R318W mutation resulted in abnormally large platelets, however platelet aggregation,
megakaryocyte number and function also appeared normal. The same group followed up with
a separate report in 2014 of a p.F260S mutation with a similar phenotype 309. More recently,
a C-terminal truncation of β-tubulin 1 has been shown to cause a macrothrombocytopenia,
suggesting that C-terminal modifications may be drivers of protein function and causative of
the disease phenotype observed 310.
Genome wide association studies (GWAS) have shown that TubB1 variants can be
broadly linked with changes in mean platelet volume and distribution width correlating with
macrothrombocytopenias reported in the GAPP cohort and other studies311, 312. Interestingly
the majority of GWAS TubB1 variants can be found in non-coding regulatory elements.
While the link between TubB1 variants and macrothrombocytopenia has been established,
the question of how the loss of protein function results in defective proplatelet formation
has yet to be addressed. Similarly the question of whether or not there is a functional effect
on platelet function has not been fully addressed. Fiore et al. show that the C-terminal is
likely to be a vital facilitator of MT function in platelet production, but like the majority of
studies investigating TubB1 variants the limited availability of patient sample and expression
of mutated protein through over-expression in cell lines severely restricts any mechanistic
interrogation of interesting variants310.
4.1.5 Aims and Hypotheses
In the context of the tubulin code, TubB1 is an archetypal example of a lineage restricted
isoform, the expression of which results in unique morphologies and functions executed by
motor proteins. Despite this, and a strong link to human disease, the nature of TubB1 specific
PTMs remains unknown, and while some elegant work has been performed to highlight the
role of motors in executing both platelet production and function on activation, the link
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between TubB1 and these consequences remains relatively poorly understood.
Therefore the aim of this chapter is to apply methodologies developed thus far over the
course of this studentship to establish the role of C-terminal PTMs in proplatelet production
and subsequently in the activation and spreading of platelets. Thus far the only reported
PTMs in platelet MTs are acetylation and tyrosination, neither of which are specific to TubB1
and are therefore, while undeniably important, unlikely to be effectors of MT function in
these cells.
Using patient mutations as a model, we aim to interrogate likely TubB1 specific modifica-
tions at both the proplatelet and platelet spreading stage. The C-terminus of β-tubulin is
rich in glutamate residues (figure 4.2), and therefore is a likely site for polyglutamylation
and glycylation - neither of which have been reported in platelet or megakaryocyte PTMs.
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Figure 4.2: Sequence of the β-tubulin 1 C-terminus. The unique C-terminus of TubB1
is rich in glutamates making it a likely site for glutamylation and glycylation, neither of
which have been reported in megakaryocytes or platelets. We reason that these modifications
are likely to be important to both platelet production and function by co-ordinating motor
proteins and their associated sliding and cargo transport roles.
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4.2 Materials and Methods
4.2.1 Platelet preparation
Whole blood was obtained for each experiment from healthy volunteers under the University
of Birmingham’s ERN 11-0175 license ’The regulation of activation of platelets’. Volumes
of 25 mL were drawn from volunteers into sodium citrate. PRP (platelet-rich plasma) was
generated by centrifugation of samples for 20 minutes at 200g. PRP was further spun to
isolate platelets by centrifugation at 1,000g for 10 minutes with prostacyclin (0.1 µg/mL) and
ACD. The resulting pellet was suspended in Tyrode’s buffer prepared fresh, and pre-warmed
at 370C (5mM glucose, 1mM MgCl2, 20mM HEPES, 12mM NaHCO3, 2.9 mM KCL, 0.34mM
Na2HpO4, 129mM NaCL to a pH of 7.3). This suspension was spun again at 1,000g with
prostacyclin at the same concentration before re-suspended to a final concentration of 2 x 108.
Platelets were left to rest for 30 minutes at room temperature before any further processing
or treatment.
The UK-GAPP study is included in the National Institute of Health Research Non-
Malignant Haematology Study Portfolio (ID-9858) and was approved by the National Research
Ethics Service Committee of West Midlands (Edgbaston REC reference: 06/MRE07/36).
Participants gave written informed consent in accordance with the Declaration of Helsinki.
The study was registered at www.isrctn.org as ISRCTN 77951167.
4.2.2 Platelet spreading
Resting platelets were fixed by preparing platelets at a concentration of 4 x 107 and mixing
with equal volumes of 10% neutral buffered Formalin in a 15mL falcon tube. This mixture
was inverted gently to mix the sample, and left to incubate for 5 minutes before subsequently
adding 300µL of the resulting fixed, resting platelets to coverslips coated in Poly-L-Lysine
(Sigma). Cells were then spun down at 200g for 10 minutes.
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Spreading was performed on human fibrinogen (Plasminogen, von Willebrand Factor
and Fibronectin depleted - Enzyme Research Laboratories) and Horm collagen (Takeda).
Coverslips were coated overnight at a concentration of 100 µg and 10µg/mL (fibrinogen
and collagen) respectively, before blocking for 1 hour in denatured fatty acid free 1% BSA
(Life Technologies). Finally coverslips were washed once with PBS before the addition of
platelets. Unless otherwise stated (as in the time course experiment), platelets were spread
for 45 minutes at 370C. Fixation for spread platelets was performed in formalin as for resting
platelets for 10 minutes.
4.2.3 Immunofluorescence
After fixation platelets were washed twice with PBS before incubation in 0.1% Triton X-100
for 5 minutes. The subsequently permeabilised cells were washed twice with PBS before
blocking in 2% Goat serum (Life Technologies) and 1% BSA (Sigma).
Fixed, permeablised, and blocked cells were then incubated with primary antibodies
at a concentration of 1:500 unless otherwise stated. The following antibodies were used
for experiments in this chapter: polyglutamylated tubulin (mouse monoclonal antibody,
clone B3 T9822, Sigma), pan-polyglycylated antibody (mouse monoclonal antibody, AXO49,
MABS276 Millipore), monoglycylated antibody (AXO 962 mouse monoclonal MABS277,
EMD Millipore), kinesin-1 (rabbit monoclonal to KIF1B ab 167429, abcam), axonemal
dynein, β-tubulin (Rabbit polyclonal PA5-16863 tyrosinated tubulin (rabbit monoclonal
antibody, clone YL1/2, MAB1864, EMD Millipore), acetylated tubulin (Lys40, 6-11B-1,
mouse monoclonal antibody, Cell Signalling Technology). DNAL1 antibody (PA5-30643
Invitrogen).
After a 1 hour incubation in the relevant mix of primary antibodies. Cells were washed
with PBS 2x before incubation in secondary antibodies (Alexa568-phalloidin, anti-rabbit
Alexa-647, anti-mouse Alexa-588) for one hour at a dilution of 1:300 in PBS.
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4.2.4 Image and statistical analysis
Statistical analysis was performed using GraphPad PRISM 7. Image analysis was performed
using a custom segmentation algorithm developed by Jeremy Pike. Briefly, the actin channel
from resting and spread platelet images was used to train Ilastik classifiers (approximately 6
images per condition) for segmentation based on this channel. This was incorporated into
a Knime workflow which would run images through the classifier to generated segmented
binaries in which co-localisation and fluorescence intensity statistics were calculated. For the
data presented in this chapter, M1 (a corrected Mander’s co-efficient to channel 1) was used
to determine the co-localisation of PTMs to tubulin, and an M2 value (corrected Mander’s
co-efficient to channel 2) was used to calculate the co-localisation of motor proteins to PTMs
of interest.
4.2.5 Cloning
Donor vectors were generated as described in chapter 2. Briefly, homology arms and inserts
were designed with 20 base pair overlaps and ordered as gBlocks from IDT. On arrival,
gBlocks were resuspended and added at equimolar ratios to an empty pGem-T-Easy backbone
for a 4 fragment gibson assembly (Hi-Fi kit, NEB). Clones were first validated by EcoRI
digest before Sanger sequencing (UoB Genomics) to validate the correct assembly of each
fragment.
Mutants of the TubB1 overexpression plasmid were generated through the use of a Q5 site
directed mutagenesis kit (NEB). For each reaction, five colonies were picked for validation by
Sanger sequencing. All sequences for primers and homology arms for CRISPR experiments
are described in 6.2.
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4.2.6 iPSC MK generation
iPSC-MKs were generated as described in chapter 3. Immunofluorescence of iPSC MK
samples was performed identically to platelet experiments.
Chapter 4. Post-translational modification of β-1 tubulin isoform 153
4.3 Results
4.3.1 Identifying and modelling candidate TubB1 mutations
Two C-terminal TubB1 mutations were identified from the GAPP cohort, each of which
belong to unrelated families presenting with macrothrombocytopenia (Figure 4.3). Family
A patients were found to be heterozygous for a C to T missense mutation resulting in an
arginine to tryptophan change (c.C1075T, p.R359W) in TubB1. Individuals in this family
also carry a GFI1B mutation (p.Cys168Phe), however only individuals A:1 and A:3, both of
whom carry both mutations, present with a macrothrombocytopenia (107 and 85 x 109/L).
Individual A:2 has the GFI1B mutation but does not carry the TubB1 variant and presents
with a normal platelet count (221 x 109/L). Interestingly, individuals A:1 and A:3 also present
with significantly higher immature platelet fractions and mean platelet volumes than their
TubB1 WT relative (53.5% and 55.1% compared to 25.5%, MPV for A:1 and A:3 too large
for measurement). This variation in count and phenotype suggest that TubB1 is causative of
the macrothrombocytopenia in this instance.
Family/patient B was an elderly gentleman (now deceased) with a G insertion and
subsequent frameshift truncation of the protein 19 amino acids from the site of insertion (c.
1080insG, p.:361Afs*19). This patient had a severe macrothrombocytopenia with a count
of 11 x 109/L and MPV of 13.4 (Table 4.3). At the time of study, IPF measurement was
unavailable.
Both mutations are positioned in the C-terminal region of the β − 1 isoform encoded
by TubB1 as indicated in figure 4.3B. This region is positioned away from the dimer:dimer
interface, and is a likely site for post-translational modification. Both affected nucleotides
are highly conserved in mammals (Figure 4.3C). We predict that the R359W missense is
likely to alter the fold of the C-terminal tail, potentially affecting PTM or interactions with
critical MAPs (Figure 4.3 D). Similarly the G insertion and subsequent frameshift are likely
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Figure 4.3: Candidate TubB1 mutations and their hypothesised effect on the C-
terminus of β-tubulin. (A) Two unrelated families were identified as carrying mutations
in the TubB1 gene within 6 base pairs of one another. The first, family A, is comprised of 3
individuals, two of whom carry an Arginine to Tryptophan (p.R359W) coding mutation.
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Figure 4.3: Cont. Interestingly, all 3 individuals in family A harbour a GFI1B mutation.
However, the individuals with the reported TubB1 mutation (A:1 and A:3) present with
a macrothrombocytopenia and high IPF, while the patient without the R359W TubB1
mutation presented with a normal platelet count. The second family is comprised of a single
individual, recently deceased, with a frameshift mutation 6 base pairs from the missense
reported in family A. In this individual’s case, the insertion of a guanine nucleotide results in
a frameshift with a premature stop codon 19 amino acids from the leucine to alanine change.
(B) The C-terminal tail is downstream of both mutations in these families, and projects away
from the dimer/dimer interface. (C) The arginine residue mutated in family A is highly
conserved across species, as are sequences adjacent to the frameshift in patient B. (D) Based
on homology modelling of TubB1, we predict that the missense mutation reported in family
A is likely to affect the fold of the C-terminal tail, while the frameshift causes a truncation of
the C-terminal tail.
to truncate the C-terminal region if the stability of the protein is not undermined by such a
significant deletion.
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Patient Age TubB1 mut. Plat. Ct. (109) MPV(fL) IPF (%) Secondary Defect
A:1 (M) 66 p.R359W 107 large 53.5% Yes (Secretion)
A:2 (F) 41 - 221 13.9 24.5% Yes (Secretion)
A:3 (M) 29 p.R359W 85 large 55.1% Yes (Secretion)
B:1 (M) dec. p.L361Afs*19 11 13.4 N/A Yes (Secretion, Gi)
Table 4.3: Summary of Patient Data. Family A is comprised of 2 affected individuals
with the TubB1 p.R359W mutation with macrothrombocytopenia (note an MPV of large
refers to platelets too large to be accurately measured) and one unaffected individual with a
normal platelet count. All individuals in this family were positive for a predicted non-disease
causing GFI1B mutation (p.C168F). Interestingly the two affected individuals also have a
much higher IPF than the unaffected individual in this family. Family B is comprised of
a single individual recently deceased, with a severe macrothrombocytopenia, and both a
secondary secretion and Gi defect.
The GAPP project includes FACS data as part of the initial phenotyping process, which
provides an interesting functional insight into the effects of both mutations on the recruited
patients. Interestingly, patient B shows a significant reduction in surface P-selectin and
Fibrinogen uptake in response to all agonists (Figure 4.4). Family A shows no change in
surface receptor expression, but show a weak P-selectin and fibrinogen response to low dose
ADP, CRP, and PAR-1, suggesting a mild secretion defect (Figure 4.4 C,D).
To determine whether these mutations alter the fold of β-1 we first cloned the TubB1
sequence into an mApple over-expression vector (Figure 4.5). After validation and sequencing,
this vector was further mutated using a Q5 site directed mutageneis kit to incorporate a
thrombin site (for cleavage on protein purification) and each individual patient mutation.
Work to establish the CD of these proteins versus wild type is currently underway, and will
establish whether the patient phenotype observed is an effect restricted to the C-terminal
tail, or a consequence of a catastrophic misfold of the protein.
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Figure 4.4: Patient flow cytometry data reveals secondary defects. The GAPP
project collects phenotypic data on patient recruitment, allowing for the assessment of
secondary defects through FACS screening.
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Figure 4.4: Cont. (A) Patient B shows a marked reduction in P-selectin surface expression
and (B) fibrinogen uptake compared to controls. (C) Individuals from family A show a
reduction in P-selectin at both doses of CRP, low dose CRP, and low dose PAR-1. (D)
Patients similarly show a reduction in fibrinogen uptake compared to controls, but show no
difference in (E) surface marker expression. Note that this data was procured by Ben Johnson
and Dr. Gillian Lowe through the GAPP study. Control counts were normalised for patient
B due to the patient’s severely low platelet count.
Figure 4.5: Cloning of a fluorescently labelled β-1 tubulin over-expression vector.
(A) An N-terminally mApple tagged β-1 tubulin over-expression construct was designed to
generate the protein for stability studies and for future transfection and analysis. The TubB1
sequence was cloned into an C-terminal mApple empty vector generously provided by the
Davidson lab. Upon gibson assembly, transformation, and the harvesting of individual clones,
vectors were mini-prepped and analysed by EcoRI restriction digest. Clone 6 was verified
has having correct cleavages at the predicted sites, and was sequenced to confirm a correct
assembly. (B) The plasmid was then transfected and co-stained with a β-tubulin antibody to
confirm its function. 10µm scale bar.
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4.3.2 Investigating candidate C-terminal PTMs on WT platelets
As we hypothesise that the C-terminal tail of TubB1 is rich in glutamate residues ripe for
polymodification, we first performed immunofluorescence assays on wild type platelets from
healthy donors to establish whether glutamylation or glycylation are evident. To date, no
evidence showing either of these polymodifications has been presented to our knowledge.
Platelets spread on fibrinogen and collagen were compared to resting platelets fixed and
spun down to poly-L-lysine. Platelets in each condition were co-stained with Phalloidin-568,
an antibody to β − tubulin, and an antibody to either polyglutamylated, monoglycylated, or
polyglycylated tubulin (Figure 4.6).
Interestingly while resting platelets demonstrate low levels of each of these polymodi-
fications, their distribution and intensity is dramatically altered on spreading (and hence,
activation) (Figure 4.6). Microtubules on fibrinogen and collagen spread platelets appear to
be heavily polyglutamylated, particularly at the marginal band of partially spread cells (Fig-
ure 4.6A). Monoglycylated and polyglycylated residues alter their distribution dramatically,
becoming punctage and diffuse throughout the cell (Figure 4.6 B,C).
To quantify whether these polymodified residues, which do not appear to be part of the
marginal band in resting platelets, are incorporated into β-tubulin on spreading activation
quantification of a Mander’s coefficient was performed across all three conditions. Unsur-
prisingly, low co-localisation is observed between each polymodification and β-tubulin in the
resting state, and this significantly increases on platelet spreading for polyglutamylated (****
p < 0.0001, *** p = 0.003 between fibrinogen and collagen spread cells respectively) and
monoglycylated residues (** p = 0.0037 in fibrinogen spread cells).
Interestingly this corresponds to a significant increase in intensity on spreading in polyglu-
tamylated tubulin (** p = 0.0070, * p = 0.0415 fibrinogen and collagen spread respectively),
consistent with the qualitative observation of extensive polyglutamylation of the marginal
band and β-tubulin on spreading (Figure 4.6E). Interestingly the intensity of monoglycylated
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Figure 4.6: Platelet spreading results in extensive post-translational modification.
(A) Resting platelets do not demonstrate a significant degree of polyglutamylation, particularly
on the marginal band (yellow arrows).
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Figure 4.6: Cont. On activation and spreading on fibrinogen and collagen, extensive polyglu-
tamylation of the marginal band can be observed. (B,C) Both mono- and polyglycylated
residues demonstrate a markedly different distribution on activation. (D) Quantification of
the co-localisation of post-translationally modified residues and β-tubulin in both resting
and spread platelets shows a statistically significant change across both post-translational
modifications and conditions (** p = 0.0029 and **** p ¡ 0.0001 respectively). There is
a significant increase in the co-localisation of polyglutamylated residues between resting
and both fibrinogen and collagen spread cells (**** p ¡ 0.0001, *** p 0.003). A significant
increase in the co-localisation of monoglycylated residues is also observed between resting
and fibrinogen spread platelets (** p = 0.0037). (E) A significant increase in signal intensity
per platelet is observed for fibrinogen and collagen spread cells versus resting control (** p =
0.0070 and * p =0.0415). No significant increase in monoglycylation is observed on platelet
spreading, however interestingly a significant increase in polyglycylation is observed in both
fibrinogen and collagen spread cells (* p = 0.0349 and * p = 0.0338). Two-way ANOVA with
uncorrected multiple comparisons performed, line of each plot represents mean and min/max
values. One-way ANOVA performed for polyglutamylated intensity measurements (S.D.) n
= 3. 10µm scale bar.
tubulin remains consistent on spreading despite an increase in colocalisation, while the extent
of polyglycylation increases despite no significant change in co-localisation (* p = 0.0349 and
* p = 0.0388 on fibrinogen and collagen spread cells respectively).
This data suggests that polyglutamylation, particularly of the marginal band, is a
significant factor in the initial destabilisation of the tubulin ring required for rapid shape
change on platelet activation. Interestingly we see an altered distribution of glycylated
residues, and an increase in polyglycylation despite poor colocalisation to β-tubulin within
the cell, suggesting that platelet spreading involves the extension of glycine chains on
monoglycylated residues to potentially mediate MAPs.
To determine whether polyglutamylation precedes or eclipses other PTMs previously
reported in platelets (namely acetylation and tyrosination), a time course was performed on
fibrinogen to establish the temporal relationships between these modifications. Acetylation
has been shown to decrease on platelet activation and spreading by Sadoul et al.. A
rapid polyglutamylation of the marginal band and subsequent β-tubulin is evidence at
every time point (Figure 4.7A), while a change in acetylation is more evident at later
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time points (indicated by yellow arrows on the figure panel). Similarly no significant
variation in tyrosination is observed. This trend is confirmed by the quantification of sum
intensity per platelet across three replicates (p < 0.0001). This data suggests that extensive
polyglutamylation of β-tubulin is indeed the driving PTM on platelet spreading.
The literature suggests that changes in motor protein function are likely drivers of
marginal band deformation on platelet activation. To that end we investigated the effects
of polyglutamylation on co-localisation with dynein, a motor known to be involved in both
platelet production and function. As shown in Figures 4.7C and D, the polyglutamylation of
tubulin coincides with a sharp decrease in co-localisation between dynein and polyglutamylated
residues. This is consistent with evidence suggesting that hyperglutamylation has a significant
effect on motor protein processivity.
Interestingly we note that dynein is present in leading edges as platelets spread, with
this particular motor found at the periphery of fully spread cells as indicated by the yellow
arrow in figure 4.7C. This distribution suggests that this (-) end driven protein is involved in
driving the expansion of platelets on spreading.
Further co-localisation analysis was performed to determine the spatial relationship
between dynein and other polymodified residues (Figure 4.8). On platelet spreading on
fibrinogen and collagen, the same pattern of reduced co-localisation is observed in cells stained
for polyglutamylated tubulin (** p = 0.0082 and *** 0.0004 in fibrinogen and collagen spread
cells respectively). Surprisingly we do not observe this trend in glycylated residues, with a
significant increase in co-localisation evident on fibrinogen spread platelets (* p = 0.0251).
Polyglycylated residues do not show any change in co-localisation with dynein.
Kinesin is the second MT motor protein with critical roles in cargo transport. The
reorganisation and subsequent secretion of platelet granules is a key aspect of platelet
activation. Having observed a dramatic effect on the association of polyglutamylated residues
with dynein, co-localisation studies were performed to investigate the spatial association
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Figure 4.7: Platelet activation results in hyperglutamylation of the marginal band
and a subsequent mobilisation of dynein. A time course was performed to investigate
the rate at which polyglutamylation of the marginal band occurs, and to compare this post-
translational modification with acetylation and tyrosination, two modifications previously
thought to influence marginal band stability at the resting state (and upon subsequent
activation).
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Figure 4.7: Cont. (A) A comparison of the polyglutamylation, acetylation, and tyrosination
of platelets shows a rapid increase in polyglutamylation in as little as 10 minutes of spreading
on fibrinogen. Interestingly this increase in polyglutamylation is significantly larger than
fold changes in the intensity of acetylated and tyrosinated tubulin (**** p ¡ 0.001), with
acetylation of the marginal band only becoming evident at later time courses (20 minutes
and on wards as indicated by the yellow arrow in the 30 min image). (B) Quantification
of the co-localisation of dynein with polyglutamylated tubulin shows a marked decrease in
co-localisation on platelet activation.. One-way ANOVA , S.D. n = 3. 10µm scale bar.
of polymodifications with kinesin-1. Kinesin-1 has been recently reported by Adam et al.
as a player in platelet secretion123. Interestingly a significant reduction in co-localisation
with polyglutamylated, monoglycylated, and polyglycylated residues is observed (Figure 4.9).
This data suggests an effect on kinesin-1 processivity as a consequence of glutamylation and
glycylation.
Unfortunately family A repeatedly declined invitations to provide further samples for
analysis. In the absence of patient samples carrying the suspected C-terminal defect, it
becomes very difficult to establish whether the loss of these PTMs is driving abnormal platelet
production and behaviour. To that end, efforts to reproduce patient mutations in iPSC
derived MKs are important, particularly as transfection into cell lines, which will carry a
different landscape of modifying enzymes, is unlikely to faithfully recapitulate the highly
specific system in platelets and MKs.
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Figure 4.8: Platelet activation results in a loss of dynein co-localisation with
polyglutamylated tubulin, but not with gylycylated residues. (A) Extensive polyg-
lutamylation of the marginal band is observed in spread cells. In fully spread cells, dynein
can be seen to collect on the periphery of the cell, implying that this - end driven motor
protein facilitates platelet expansion by mobilising outwards. (B,C) Mono- and polyglycylated
residues change distribution on platelet spreading. (D) Quantification of the co-localisation of
dynein with each of the three PTMs studied reveals dramatically different relationships (** p
= 0.0096). Dynein co-localisation with polyglutamylated residues decreases dramatically on
platelet spreading in both fibrinogen and collagen (** p = 0.0082 and *** 0.0004 respectively).
Conversely there is a significant increase in the co-localisation of dynein with monoglycylated
residues in fibrinogen spread (* p = 0.0251) but not in collagen spread platelets. No significant
change in co-localisation with polyglycylated residues is observed. Two-way ANOVA with
uncorrected multiple comparisons performed, line of each plot represents mean and min/max
values. n = 3. 10µm scale bar.
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Figure 4.9: Platelet spreading results in a significant decrease in kinesin localisa-
tion with post-translationally modified residues. (A, B, C) On platelet spreading on
fibrinogen and collagen kinesin can be found distributed across the cell, with no substan-
tial co-localisation with polyglutamylated, monoglycylated, or polyglycylated tubulin. (D)
The quantification of this co-localisation supports this, showing a significant decrease in
co-localisation on both fibrinogen and collagen between kinesin and polyglutamylated (**
p = 0.0017, **** p ¡ 0.0001), monoglycylated (** p = 0.0094, *** p = 0.0009) residues. A
significant decrease with polyglycylated residues was only observed in fully spread collagen
cells (** p = 0.0017). Two-way ANOVA with uncorrected multiple comparisons performed,
line of each plot represents mean and min/max values. n = 3. 10µm scale bar.
Chapter 4. Post-translational modification of β-1 tubulin isoform 167
4.3.3 Designing TubB1 targeting CRISPRs
One of the goals of this studentship has been adapting genome editing to the targeting of
iPSC, and the subsequent generation of MKs from these edited populations. The difficulty in
recruiting patients after their initial appointment highlights the importance of being able to
produce patient mutations in vitro for further mechanistic analysis and study.
To this end, two lines of CRISPR editing were pursued for the study of polymodifications
in TubB1. The first would be the generation of an mEGFP or mEos 4b CO tagged TubB1
line. This would offer a means by which to visualise polymodifications in the context of
TubB1 expression, would be a potent tool in studying how specific polyglutamylation and
polyglycylation are to the expression of this specific isoform.
A strategy similar to the one pursued for the labelling of TubA1B was pursued. As shown
in figure 4.10, a donor sequence carrying the insert of choice (mEGFP or mEos 4b CO in
this instance) with a linker and flanking homology arms was designed to the N-terminus of
TubB1. The protein coding region of the first exon of these gene is 57 base pairs long, and is
flanked by a 5’ UTR and an intron in the 3’ direction (Figure 4.10A).
The homology arms and insert sequences were ordered as gBlocks with overhanging arms
for gibson assembly, and cloned into an empty, linearised pGem-T-Easy vector as in chapter
2. Upon transformation, clonal isolation, and DNA preparation, clones were verified through
an EcoRI digest of the relevant plasmid (Figure 4.10B,C). Control clones were linearised
and ran at 3000 base pairs, while successfully assembled plasmids carried an insert which
presented as a second band running at approximately 1500-2000 base pairs.
With donor plasmids in hand, guide sequences targeting exon 1 of the TubB1 gene were
generated (Figure 4.11A). Each of the 4 guides was transfected using the Alt-R®method,
and as the gene is not expressed, editing efficiency was evaluated through PCR and a T7EI
assay.
The T7EI assay generates heteroduplexes of wild type and cleaved DNA which are
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Figure 4.10: Design and assembly of TubB1 HDR donors. A CRISPR mediated HDR
knock-in strategy was adapted from previous work to tag the N-terminus of the TubB1
protein. (A) Homology arms were designed to flank each tag and targeted to the first exon
of TubB1 and sit prior to the 57bp coding region in this exon.
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Figure 4.10: Cont. (B) An mEGFP carrying donor was generated through gibson assembly
into a pGem-T-Easy backbone, colonies were picked and verified with an EcoRI digest before
sequencing to confirm a correct assembly. (C) A similar strategy was employed using an
mEos 4CO gBlock to generate a TubB1 HDR donor carrying this photoswitchable reporter.
Clones were validated through restriction digest before sequencing.
recognised and cleaved by the T7-Endonuclease. In the presence of edited DNA which is
successfully cleaved, a pair of cleavage products can be observed beneath the PCR product
in question. As shown in figure 4.11B, a positive control shows two distinctive bands on
cleavage. In contrast, untreated iPSC and those transfected with either donor plasmid only
or purified Cas9 protein (no guides) show no evidence of cleavage, and so no evidence of
heteroduplex formation and thus gene editing.
Cells transfected with each of the guides show some evidence of cleavage, however guide
A shows the most substantial level of cleavage, making it the most efficient of the guides
tested. As we co-transfect with a donor template, there is evidence of a second band at the
predicted molecular weight of an mEGFP-tagged TubB1. While there is a faint band at this
weight in the donor only control, the increased intensity in the guide treated lane suggests
there is some integration of the tag in this population.
Unfortunately on limiting dilution and clonal expansion, none of the 18 screened clones
showed any evidence of a tagged TubB1 gene (Figure 4.11C). This suggests that the amplifi-
cation of the tagged band in figure 4.11B is an artefact and a consequence of the amplification
of the donor template.
Work to generate the tag is ongoing, with experiments testing small molecule inhibitors as
discussed in chapter 2 offering the potential for increased integration. Currently a CRISPY
treated population is being expanded for validation, as demonstrated in figure 4.11D, this
includes testing dsDNA donor templates and the nickase/CRISPY format of this experiment.
Primers have been designed to span the region outside of the plasmid sequence to better
determine the presence of an insert in these samples.
CRISPR experiments aiming to introduce the two patient SNPs discussed in this work
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Figure 4.11: CRISPR mediated labelling of TubB1 with mEGFP. Guides targeting
exon 1 of TubB1 were generated and transfected using the Alt-R®system described in
chapter 2 into iPSC. (A) Four guides were generated, two of which targeted the forward
strand (gA, gB) and reverse strand (gC,gD). (B) Transfected cells were detached 48 hours
after transfection and pelleted for DNA extraction. This DNA was then amplified using
primers flanking the insert site for analysis through a T7EI assay.
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Figure 4.11: Cont. The positive control (mismatched DNA duplexes from a Gibco kit)
undergo cleavage upon T7EI treatment, resulting in two cleaved bands beneath the 500bp
amplicon. Negative, lipofectamine, and Cas9 only treated controls do not appear to have
two bands beneath the designed amplicons. Conversely cells treated with guides and Cas9s
both demonstrate cleavage bands and an additional heavier band at approximately 1300bp,
consistent with a successful integration of the donor mEGFP sequence. Of the guides tested,
guide A appeared to cause the most significant cleavage and integration, suggesting this guide
is best suited for targeting the TubB1 locus. (C) Guide A targeted cells were then subject
to a limiting dilution before individual clones were expanded and analysed for an mEGFP
insertion at this locus. Unfortunately none of the 18 clones carried an mEGFP tagged TubB1
gene. (D) Current efforts are focussing on increasing the efficiency of insertion to better
isolate mEGFP tagged cells.
are ongoing. Two oligonucleotide donors were designed to the target region, one carrying
the C>T mutation and the other harbouring the G insert (Figure 4.12). Each of these has
been transfected into iPSC with either a wild type Cas9 with a validated guide, or a Cas9
D10A nickase with two guides flanking the target site. T7EI analysis of transfected cells
reveal cleavage in each of the samples. Unfortunately the assay is not sensitive enough to
detect SNPs, and so clonal isolation will be necessary to determine whether there has been a
successful insertion of the donor sequence. Interestingly however, more cleavage is evident
in the Gins donor treated sample, which would be consistent with the introduction of a
frameshift.
4.3.4 iPSC MKs and polymodifications
Developing iPSC MKs carrying patient mutations is a critical part of determining the effects
of our polymodifications of interest, however as these cells are currently being generated,
some preliminary work has been performed to investigate whether proplatelet iPSC MKs are
positive for the polymodifications observed thus far in wild type platelets.
In iPSC differentiated MKs forming proplatelets, polyglutamylation, monoglycylation, and
polyglycylation are observed as shown in figure 4.13. The presence of mono- and polyglycylated
residues to this extent is particular interesting, as staining with these antibodies in platelets
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Figure 4.12: Targeting TubB1 to introduce patient SNPs in iPSC. Introducing
candidate patient SNPs will be critical to this project and future attempts at disease
modelling. (A) Anti-sense oligonucleotides carrying either the C¿T mutation or a G insertion
were designed with 45 base pair homology arms. (B) Cells were transfected with guides
targeting the SNP region and subject to a T7EI assay after DNA extraction. Untreated, Cas9,
and Lipofectamine treated cells do not demonstrate cleavage products after T7EI treatment.
Conversely cells treated with either wild type DNA and a previously verified guide D and a
Cas9 nickase with two separate guides both demonstrate efficient cleavage after treatment.
Transfected cells also carried an RW or G insert donor to facilitate HDR and the introduction
of patient SNPs at these loci.
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produces markedly different signals and distributions. Notably, CD42 negative cells in these
images do not show any evidence of these polymodification, suggesting that they are specific
to mature MKs which are likely to express TubB1.
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Figure 4.13: Proplatelet forming human iPSC megakaryocytes demonstrate signif-
icant polymodifications specific to MKs and proplatelet forming cells. Proplatelet
forming iPSC MKs show extensive polyglutamylation, mono-, and polyglycylation which
appears specific to CD42 positive cells. As indicated by yellow arrows, CD42 negative cells
(which are detectable by DAPI staining) are negative for these polymodifications 50µm scale
bar.
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4.4 Discussion and Conclusions
The work reported in this chapter represents efforts to translate methodologies developed
over the course of this studentship to investigate the mechanistic causes of thrombocytopenia
in a particular patient cohort from the GAPP project. At the heart of this is an attempt to
improve our understanding of the role of TubB1 in platelet production and function in the
context of the tubulin code.
While the vital role of TubB1 in platelet production has been shown in both mouse models
and human disease case studies, the capacity of this particular isoform to achieve the unique
function of both MKs and platelets remains unclear. While the acetylation and tyrosination
of the marginal band has been reported in platelets, neither modification has been tied to
proplatelet formation or platelet function. Perhaps more importantly, both modifications are
ubiquitous and no clear link to TubB1 has been established.
Of the handful of patient mutations published, the most interesting has been Fiore et
al.’s report of a C-terminal truncation which exhibits all the hallmarks of a TubB1 related
macrothrombocytopenia310. In the context of the tubulin code, this is a very interesting
finding as it suggests that post-translational modifications of the β-1 protein are likely to
drive its function.
As the C-terminal tail of TubB1 is rich in glutamate residues, we reasoned that polymod-
ification of these residues is a likely driver of MK and platelet function113, 264, 273. This would
be consistent with extensive studies in neuronal and ciliated cells which demonstrate critical
roles for both glutamylation and glycylation in healthy cell development and function. While
not directly comparable to axons or axonemes, there is none the less a parallel between MKs
and neurons as demonstrated by Bender et al. who show that the dynein driven sliding of
MTs first observed in nervous cells is a driver of proplatelet formation.
Our data thus far firstly reports the presence of polyglutamylated and mono/polyglycylated
residues in human platelets and megakaryocytes. To our knowledge, this is the first report of
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these modifications in this cell lineage.
Secondly we show a critical role for polyglutamylation on platelet activation through
spreading on fibrinogen and collagen. Our data shows a significant increase in polyglutamyla-
tion on platelet activation which is present across a range of spreading times, and clearly
localises to the marginal band on spreading platelets. In resting platelets, there is no evidence
of polyglutamylation of this MT ring. We subsequently report a rapid decrease in dynein and
kinesin-1 localisation to these polyglutamylated residues, implying that hyperglutamylation
of the marginal band is responsible for the mobilisation of motor proteins required for shape
change on platelet activation as reported by Diagoura et al..
Evidence of significant polyglutamylation in proplatelet producing MKs suggests that
this modification is a likely driver of the dynein driven sliding of MTs required for proplatelet
formation. While this data is preliminary, further investigation and the use of iPSC-MKs
carrying patient specific mutations is likely to provide invaluable insights into the specificity
of these polymodifications to TubB1, and the effect of patient impairments on these PTMs.
The role of polyglutamylation in mobilising motor proteins has been previously reported
in neuronal cells, and recent work in retinal cells highlights the importance of a ratio
between glutamylated and glycylated residues. In excellent work by Sirajuddin et al.,
polyglutamylation is shown to increase kinesin-1 motility on neuronal β-tubulin in an in
vitro assay of motor processivity on specific β-tubulin isoforms313. In our data, the effects
of polyglutamylation include a decrease in the co-localisation of both dynein and kinesin,
suggesting that hyperglutamylation increases processivity on platelet activation.
Interestingly our data shows the presence and mobilisation of axonemal dynein in platelets
in response to polyglutamylation. To our knowledge, no previous reports have detailed the
presence or function of axonemal dynein in non-ciliated cells. That being said, considering
that platelets are produced by long processes analogous to cilia in some ways, it is not
surprising that axonemal dynein is present and is affected by polyglutamylation of MTs
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on activation. The distribution of this dynein subtype on the edge of the cell on platelet
spreading strongly suggests that the movement of this motor towards the periphery cell is a
driver of cell spreading in this instance.
Interestingly proplatelet forming iPSC MKs also demonstrate extensive glycylation in
contrast with platelets stained with these antibodies. In proplatelet forming and mature
MKs, these polymodifications are likely to play a markedly different role when compared to
platelets. Polyglycylation has not been previously reported in platelets or MKs, in fact work
by Rogowski et al. suggests an evolutionary redundancy of polyglycylation in humans285.
While Ikegami et al. show that the polyglycylase TTLL10 is functional in its elongase capacity
if co-expressed with an appropriate initiase (TTLL8)314. This highlights the importance of
using a human model for the study of PTMs as the palette of modifying enzymes is species
and cell type specific.
Our data shows an increase in polyglycylation, though it is unclear what role this may
play in platelet spreading. Surprisingly kinesin-1 poorly colocalises with polyglycylated
residues, while dynein shows a significant increase in dynein co-localisation, suggesting that
these PTMs may be involved in regulating the motility of this particular motor.
One possible explanation is that glycylated residues act to limit the mobility of dynein,
and that while in iPSC Mks this is needed to regulate the extension, twisting, budding and
eventual severing of platelets, it is likely that this ’stopping’ action is not needed in platelets,
where hyperglutamylation of the marginal band is needed to rapidly induce instability and
hypermobilisation of dynein.
While the development of fluorescently labelled TubB1 iPSC lines, and cells carrying
patient SNPs is still under way, these measures should provide a substantial insight into the
role of these PTMs in the disease state. In the absence of effective inhibitors to TTLLs, these




In this chapter the results presented in this thesis are discussed in the broader context of
the literature, with an emphasis on future directions. The key goal of this project was the
generation of protocols for CRISPR mediated HDR, and the development of protocols which
allow for the differentiation of iPSCs into mature, proplatelet forming MKs. Ultimately the
aim is to apply these methods to interrogate the role of novel mutations in causing inherited
thrombocytopenias in the GAPP patient cohort.
5.1 Development of CRISPR-PALM
The second chapter of this thesis presented the development of a novel means of single
molecule imaging through the knock-in of photoswitchable tags. This method, dubbed
CRISPR-PALM, has since been published in Scientific Reports 315.
Interestingly we found a sequence and cell line dependent effect on expression of tagged
alleles. While mEGFP was consistently well expressed, mEos 3.2 insertions were substantially
down regulated in all three cell lines studies. To our knowledge, no such effect on endogenous
expression has been reported. We were also unable to generate homozygous knock-ins at the
TubA1B locus in any of the cell lines targeted. These findings together suggested, to our
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surprise, that endogenous expression of tagged genes is down regulated where the insertion
of a tag affects protein function. mEGFP, which is the most monomeric and codon optimised
of the many existing fluorescent proteins, is well tolerated, while mEos 3.2, a substantially
less monomeric protein is consistently downregulated.
To test the hypothesis that fundamental properties of the fluorophore drive this downreg-
ulation, we codon optimised mEos 3.2 and tested a more monomeric variant known as mEos
4b (which we also codon optimised). A comparison of these fluorophores both in their codon
optimised and original sequence state reveals that mEos 4b CO is far better expressed than
its counterparts, while still not as highly expressed as mEGFP. The improved expression of
mEos 4b CO naturally results in more detections, and there improves the quality of single
molecule imaging performed through the CRISPR PALM system.
The finding that insertions can so significantly affect allele expression is an extremely
important one, with serious implications for knock-in work currently performed. At present
little functional validation is performed on knock-in cells, in most published work attention
is paid to correctly identifying the genomic change produced by CRISPR experiments. We
believe that all insertions should be carefully assessed for downregulation at the protein level,
as this is likely to have significant functional consequences. With a wide range of fluorescent
proteins available, characterising which tags are best suited to endogenous expression will be
critical to achieving the potential of imaging experiments utilising knock-in cells.
From a single molecule perspective a significant finding is that where expression of
endogenous mEos 3.2 is high, sufficient labelling is achieved to demonstrate high quality
SMLM which is comparable by a number of metrics to dSTORM. Achieving such high level
spatial resolution through endogenous expression is a significant finding, particularly for a
complex structure like tubulin which demands stringent labelling to achieve high quality
SMLM. This data suggests that where the down-regulation of an inserted fluorophore can be
limited, endogenous expression is a viable method of single molecule imaging.
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Further work must be performed to establish whether these effects are consistent across
multiple genes. Currently cell lines carrying these inserts in the Vimentin and CXCR4 genes
are being developed and assessed for their expression level and performance in single molecule
imaging. Vimentin has been previously reported as a heterozygous knock-in of rsEGFP
in U2OS cells by Ratz et al., the authors apply RESOLFT to image these cells and show
a marginal improvement in resolution compared to confocal microscopy206. Reproducing
these results and validating whether mEos 4b CO is better expressed in a separate gene will
help confirm our conclusion that tag specific properties are important to the expression of
CRISPR edited genes.
Similarly CXCR4 offers an ideal target for testing the potential of CRISPR-PALM in
quantifying receptor clustering and distribution on the single molecule level. Single molecule
quantification remains a challenging and contentious subject, however the introduction of a
system which involves the endogenous expression of a fusion tag may resolve many of the
classic issues in this field.
Approaches for both the acquisition of single molecule data and its processing have
advanced significantly in the 3 years of this project. High throughput single molecule
imaging and automated analysis modalities have substantially advanced the application of
these techniques to answering biological questions316. The use of lightsheet imaging has
further allowed for SMLM in complete volumes with remarkable resolution196, 180. The onus
is therefore on developing biological samples which can be best used in these modalities.
Over-expression results in artifacts and significant cell to cell variation, particularly on the
nano-scale. Similarly antibody staining for dSTORM features a number of confounding
factors which can influence the quality of results. Developing cell lines with consistent cell to
cell expression and with reporters demonstrating defined switching kinetics will be vital to
establishing robust, high throughput single molecule imaging.
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5.2 Adapting and developing methods of iPSC trans-
fection, CRISPR editing, and differentiation
Developing CRISPR methods for iPSC proved to be significantly more challenging than we
had originally thought, particularly in light of our success with HDR in cell lines. While
the literature makes it clear that integration efficiencies are substantially lower in stem cells
than cell lines, our inability to yield higher rates of insertion, even through the use of small
molecules is concerning.
Fortunately independent work by Roberts et al. published in late 2017 also reported
extremely low targeting of this gene (0.1%) in iPSC 219. There is a likelihood that targeting
this specific allele in iPSC is problematic, and so current work targeting TubB1 in iPSC is
likely to shed further light on the effect of small molecule inhibition on HDR efficiency.
Similarly there remain a number of conditions which have been reported to improve tag
insertion in iPSC which we have yet to trial. These include using single stranded donor DNA
templates, and altering the design of paired nickase guides to optimally introduce staggered
cuts. Unfortunately there is a never ending stream of research on improved HDR in difficult
cell types, discerning which approach is likely to suit our needs is an unfortunately tedious
approach of trial and error.
The development of a protocol for iPSC differentiation was, fortunately, significantly more
successful. Despite early difficulties in determining which media and basement membrane
would be best suited to directed differentiation, the resulting protocol efficiently generates
populations of mature iPSC MK positive for archetypal markers. More importantly, these cells
produce proplatelets in vitro, rendering them useful for phenotypically screening knock-ins.
The study of MK and platelet specific genes has suffered due to the absence of human
cell lines capable of reproducing this a proplatelet phenotype in vitro. As a result, there has
been a significant emphasis on mouse models and primary murine megakaryocytes in the
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study of platelet and MK defects. The generation of a mouse model is significantly more
time consuming and costly than purely in vitro work, and has thus limited the throughput
and pace of study in this field.
Similarly functional differences between mice and humans are critical when interpreting
mouse data in the context of human platelet biology. This is particularly significant when
studying the tubulin code, where a cell and species specific landscape of modifying enzymes
drives PTMs and their effects.
The current focus of our work is refining the terminal stage of the differentiation protocol
in a robust proplatelet assay. The introduction of patient SNPs is a priority, as in the absence
of patient material the effects of our candidate mutations can be effectively studied using
these differentiation protocols.
5.3 Dissecting the role of novel TubB1 PTMs in the
function of platelets and MKs in the context of
inherited thrombocytopenia
The data discussed thus far in chapter 4 reveals a complex co-ordination of motor protein
function through post-translational modifications. These findings describe a role for a
series of novel PTMs which, to our knowledge, have not yet been reported in platelets and
MKs. Polyglutamylation in particular appeaks to play a significant role in destabilising the
marginal band by hypermobilising dynein and kinesin on activation, supporting broader work
implicating these motors in driving shape change in platelet activation.
The role of glycylation is less obvious, but equally interesting. Monoglycylation is
consistent regardless of the activation state of our platelets, however we observe a significant
increase in polyglycylation on activation and spreading, suggesting a role for these cells in
this process. Interestingly there is an increase in dynein co-localisation with polyglycylated
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residues, suggesting that these modifications could alter processivity to regulate motor protein
function on spreading. This would be particularly interesting in the context of thrombi,
where uncontrolled platelet spreading could be potentially detrimental.
Preliminary evidence shows the presence of polyglutamylation, monoglycylation, and
polyglycylation on proplatelet forming cells. In the context of our platelet data and the
broader literature, the role of these PTMs on proplatelets is likely to be in the process of
microtubule sliding to drive proplatelet extension. However the markedly different distribution
of glycylated residues in platelets when compared to their progenitor cells implies a complex
role for the regulation of these PTMs in fine tuning the processivity of motor proteins along
these extensions.
Unfortunately there is limited data discussing the role of glycylation in microtubule
function, particularly in the context of work by Rogowski et al. disputing the presence of
these polymodifications in humans 285 . A significant flaw in this work is the use of a bone
osteosarcoma cell line to determine the effects of candidate tubulin ligases. As Ikegami et al.
314 later show, TTLL10 function is specifically as an elongase, and is restored in human cells
on co-expression of an initiase (TTLL8). The controversy of these works highlights the need
for a species and lineage specific model for the study of polymodifications, as there is likely
to be an MK and platelet specific mix of tubulin modifying enzymes working in concert to
first extensively polyglutamylate and glycylate proplatelet processes, before removing these
modifications in the resting platelet, and finally polyglutamylating the marginal band on
platelet activation. As none of the polymodifications rich in iPSC-MKs forming proplatelets
are evident in the marginal band of resting platelets, there is likely a critical role for enzymes
in reversing these polymodifications in mature, circulating platelets.
As discussed above, the generation of patient specific mutants will be key to linking these
observations with the TubB1 C-terminal tail. Establishing changes in these polymodifications
in a diseased stem cell model, and any subsequent functional defects, will be a very exciting
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TubA1B Guide A Top Oligo CACCGCCTCGACTCTTAGCTTGTCG
TubA1B Guide A Bottom Oligo AAACCGACAAGCTAAGAGTCGAGGC
TubA1B Guide B Top Oligo CACCGCCCCGACAAGCTAAGAGTCG
TubA1B Guide B Bottom Oligo AAACCGACTCTTAGCTTGTCGGGGC
TubA1B Guide C Top Oligo CACCGACCTCGACTCTTAGCTTGTC
TubA1B Guide C Bottom Oligo AAACGACAAGCTAAGAGTCGAGGTC
TubA1B Guide D Top Oligo CACCGATTAGGAGGCGAAGGCGAC
TubA1B Guide D Bottom Oligo AAACGTCGCCTTCGCCTCCTAATC
TubA1B jPCR Fwd Primer TAATCTTGCACTCACTCTCTAGGAA
TubA1B jPCR Rev Primer AGGCATTGTCTGATATTTAGCAAGT
OS280 Primer CAGGGTTATTGTCTCATGAGCGG
Table 6.1: Table of TubA1B Primer Sequences.
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Name Sequence
TubB1 SNP Region Primer Fwd AGACCAGGAACAGCAGCT
TubB1 SNP Region Primer Rev GGATGGCCGTGTTGTTGC
TubB1 N-Terminal Insertion Fwd TAATCTTGCACTCACTCTCTAGGAA
TubB1 N-Terminal Insertion Rev AGGCATTGTCTGATATTTAGCAAGT
TubB1 Sense Donor 1 Gins Fwd CAACGTCAAGGTCGCTGTCTGCGACATCC
CGCCCCGGGGCGCTGAGCATGGCCGCCAC-
CTTCATTGGCAACAACACGGCCA
Table 6.2: Table of TubB1 Primer Sequences.
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Sequences for homology arms and inserts:
















































































































TubB1 Left Homology Arm
Gcaggacactgcagagtaacttgcatacagggcgagagagggcatgtgggggagggcgggcagacagtgcctgatgcaggccatcc
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